




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/54, 15/62, 9/12, C07K 16/40, C12Q 1/68, 1/70, G01N 33/571, A61K 31/70		A1	(11) International Publication Number: WO 97/04105 (43) International Publication Date: 6 February 1997 (06.02.97)
(21) International Application Number: PCT/US96/11688 (22) International Filing Date: 12 July 1996 (12.07.96) (30) Priority Data: 60/001,148 14 July 1995 (14.07.95) US Not furnished 11 July 1996 (11.07.96) US (60) Parent Applications or Grants (63) Related by Continuation US 60/001,148 (CIP) Filed on 14 July 1995 (14.07.95) US Not furnished (CIP) Filed on 11 July 1996 (11.07.96) (71) Applicant (for all designated States except US): UNIVERSITY OF WASHINGTON [US/US]; Office of Technology Trans- fer, Suite 200, 1107 N.E. 45th Street, Seattle, WA 98105 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ROSE, Timothy, M. [US/US]; 5045 N.E. 70th Street, Seattle, WA 98115 (US). BOSCH, Mamix, L. [NL/US]; 2601 78th Avenue N.E.,		Bellevue, WA 98004 (US). STRAND, Kurt [US/US]; 22101 S.E. 32nd Street, Issaquah, WA 98027 (US). TODARO, George, J. [US/US]; 1940 15th Avenue East, Seattle, WA 98112 (US). (74) Agents: SCHIFF, J., Michael et al.; Morrison & Foerster L.L.P., 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: DNA POLYMERASE OF GAMMA HERPES VIRUSES ASSOCIATED WITH KAPOSI'S SARCOMA AND RETROPERITONEAL FIBROMATOSIS



(57) Abstract

This invention provides isolated polynucleotides encoding DNA polymerases of three members of a subfamily of gamma herpes viruses. Two were obtained from macaque monkeys affected with retroperitoneal fibromatosis, the other from human AIDS patients affected with Kaposi's sarcoma. A 454-base pair fragment encoding a region near the active site of the DNA polymerase is 69-83 % identical amongst the three viruses, but only 54-68 % identical with other known gamma herpes sequences and < 55 % identical with alpha and beta herpes sequences. Also provided are polynucleotides encoding DNA polymerase from related viruses in the RFHV/KSHV subfamily. Polynucleotides prepared according to the sequence data can be used as reagents to detect and characterize related sequences. Such reagents may be used to detect members of the RFHV/KSHV subfamily, including but not limited to RFHV, RFHV2, and KSHV. Corresponding polypeptides and peptide fragments may be obtained by expressing the polynucleotide or by chemical synthesis. They may be used for detecting specific antibody potentially present in the serum of infected subjects. They may also be used for designing or screening pharmaceutical compounds that limit viral replication by inhibiting DNA polymerase activity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**DNA POLYMERASE OF GAMMA HERPES VIRUSES ASSOCIATED WITH KAPOSI'S
SARCOMA AND RETROPERITONEAL FIBROMATOSIS**

5

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. provisional patent application Serial No. 60/001,148, filed July 14, 1995, and pending U.S. patent application Serial No. [pending, attorney docket 29938-20001.00], filed July 11, 1996, which are hereby incorporated herein by reference in their entirety.

10

**STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER
FEDERALLY SPONSORED RESEARCH**

This invention was made in part during work supported by a grant from the National Institutes of Health (RR00166-34). The Government has certain rights in the invention.

15

TECHNICAL FIELD

The present invention relates generally to the field of virology, particularly viruses of the herpes family. More specifically, it relates to the identification and characterization of DNA polymerase in a virus subfamily, members of which are associated with fibroproliferative and neoplastic conditions in primates, including humans.

20

BACKGROUND ART

25

Kaposi's Sarcoma is a disfiguring and potentially fatal form of hemorrhagic sarcoma. It is characterized by multiple vascular tumors that appear on the skin as darkly colored plaques or nodules. At the histological level, it is characterized by proliferation of relatively uniform spindle-shaped cells, forming fascicles and vascular slits. There is often evidence of plasma cells, T cells and monocytes in the inflammatory infiltrate. Death may ultimately ensue due to bleeding from gastrointestinal lesions or from an associated lymphoma. (See generally Martin et al., Finesmith et al.)

30

Once a relatively obscure disease, it has leapt to public attention due to its association with AIDS. As many as 20% of certain AIDS-affected populations acquire Kaposi's during the course of the disease. Kaposi's Sarcoma occurs in other conditions associated with immunodeficiency, including kidney dialysis and therapeutic immunosuppression. However, the epidemiology of the disease has suggested that immunodeficiency is not the only causative factor. In particular, the high degree of association of Kaposi's with certain sexual practices suggests the involvement of an etiologic agent which is not the human immunodeficiency virus (Berel et al.).

35

A herpes-virus-like DNA sequence has been identified in tissue samples from Kaposi's lesions obtained from AIDS patients (Chang et al., confirmed by Ambroziuk et al.). The sequence was obtained by representational difference analysis (Lisitsyn et al.), in which DNA from affected and unaffected tissue were amplified using unrelated priming oligonucleotides, and then hybridized together to highlight

40

differences between the cells. The sequence was partly identical to known sequences of the Epstein Barr Virus and herpesvirus saimiri. It coded for capsid and tegument proteins, two structural components. In a survey of tissues from various sources, the sequence was found in 95% of Kaposi's sarcoma lesions, regardless of the patients' HIV status (Moore et al.). 21% of uninvolved tissue from the same patients was positive, while 5% of samples from a control population was positive. There was approximately 0.5% sequence variation between samples. The sequence was also detected at a higher copy number in body cavity lymphoma, a lymphomatous effusion with a B-cell genotype occurring uniquely in AIDS patients (Cesarman et al.). Other AIDS-associated lymphomas were negative.

The herpes virus family comprises a number of multi-enveloped viruses about 100 nm in size, and capable of infecting vertebrates. (For general reviews, see, e.g., Emery et al., Fields et al.). The double-stranded DNA genome is unusually large – from about 88 to about 229 kilobases in length. It may produce over 50 different transcripts at various stages in the life cycle of the virus. In one of the stages, a number of nucleotide and polynucleotide processing enzymes are produced that are required for viral replication, including DNA polymerase, DNase, dUTPase, ribonucleotide reductase, uracil-DNA glycosylase, and thymidine kinase. These functional proteins tend to be relatively well conserved between species, compared with external viral components (Karlin et al.).

The herpes virus family has been divided into several subfamilies. Assignments to each of the categories were originally based on the basis of biologic properties, and are being refined as genomic sequence data emerges. The alpha subfamily comprises viruses that have a broad host range, a short replicative cycle, and an affinity for the sensory ganglia. They include the human simplex virus and the Varicella-zoster virus. The beta subfamily comprises viruses that have a restricted host range, and include Cytomegalovirus and human Herpes Virus 6. The gamma subfamily comprises viruses that are generally lymphotropic. The DNA is marked by a segment of about 110 kilobases with a low GC content, flanked by multiple tandem repeats of high GC content. The subfamily includes Epstein Barr Virus (EBV), herpes virus saimiri, equine Herpes Virus 2 and 5, and bovine Herpes Virus 4.

Herpes viruses are associated with conditions that have a complex clinical course. A feature of many herpes viruses is the ability to go into a latent state within the host for an extended period of time. Viruses of the alpha subfamily maintain latent forms in the sensory and autonomic ganglia, whereas those of the gamma subfamily maintain latent forms, for example, in cells of the lymphocyte lineage. Latency is associated with the transcription of certain viral genes, and may persist for decades until conditions are optimal for the virus to resume active replication. Such conditions may include an immunodeficiency. In addition, some herpes viruses of the gamma subfamily have the ability to genetically transform the cells they infect. For example, EBV is associated with B cell lymphomas, oral hairy leukoplakia, lymphoid interstitial pneumonitis, and nasopharyngeal carcinoma.

A number of other conditions occur in humans and other vertebrates that involve fibroproliferation and the generation of pre-neoplastic cells. Examples occurring in humans are retroperitoneal fibrosis, nodular fibromatosis, pseudosarcomatous fibromatosis, and sclerosing mesenteritis. Another condition known as Enzootic Retroperitoneal Fibromatosis (RF) has been observed in a colony of macaque monkeys at the University of Washington Regional Primate Research Center (Giddens et al.). Late stages of the disease are characterized by proliferating fibrous tissue around the mesentery and the dorsal part of the peritoneal

cavity, with extension into the inguinal canal, through the diaphragm, and into the abdominal wall. Once clinically apparent, the disease is invariably fatal within 1-2 months. The condition has been associated with simian immunodeficiency (SAIDS) due to a type D simian retrovirus, SRV-2 (Tsai et al.). However, other colonies do not show the same frequency of RF amongst monkeys affected with SAIDS, and the frequency of RF at Washington has been declining in recent years.

The study of such conditions in non-human primates is important not only as a model for human conditions, but also because one primate species may act as a reservoir of viruses that affect another species. For example, the herpes virus saimiri appears to cause no disease in its natural host, the squirrel monkey (*Saimiri sciureus*), but it causes polyclonal T-cell lymphomas and acute leukemias in other primates, particularly owl monkeys.

There is a need to develop reagents and methods for use in the detection and treatment of herpes virus infections.

For example, there is a need to develop reagents and methods which can be used in the diagnosis and assessment of Kaposi's sarcoma, and similar conditions. Being able to detect the etiologic agent in a new patient may assist in differential diagnosis; being able to assess the level of the agent in an ongoing condition may assist in clinical management. The tegument encoding polynucleotide of Chang et al. may have limited applicability in this regard. It is desirable to obtain a marker capable of distinguishing active from latent infection. It is also desirable to obtain a marker that is immunogenic, and can be used to assess immunological exposure to the agent as manifest in the antibody response.

Second, there is a need to develop reagents and methods which can be used in the development of new pharmaceuticals for Kaposi's sarcoma, and similar conditions. The current treatment for Kaposi's is radiation in combination with traditional chemotherapy, such as vincristine (Northfelt, Mitsuyasu). While lesions respond to these modalities, the response is temporary, and the downward clinical course generally resumes. Even experimental therapies, such as treatment with cytokines, are directed at the symptoms of the disease rather than the cause. Drug screening and rational drug design based upon the etiologic agent can be directed towards the long-felt need for a clinical regimen with long-term efficacy.

Third, there is a need to develop reagents and methods which can be used to identify viral agents that may be associated with other fibroproliferative conditions. The representational difference analysis technique used by Chang et al. is arduously complex, and probably not appropriate as a general screening test. More desirable are a set of primers or probes to be used as reagents in more routine assays for surveying a variety of tissue samples suspected of containing a related etiologic agent. Preferably, the reagents are sufficiently cross-reactive to identify previously undescribed viral compounds, but sufficiently specific to avoid identifying unwanted viruses or endogenous components of the host.

DISCLOSURE OF THE INVENTION

It is an objective of this invention to provide isolated polynucleotides, polypeptides, and antibodies derived from or reactive with the products of novel DNA polymerase genes. The genes are present in herpes viruses associated with fibroproliferative conditions and neoplasms, especially those that occur in humans and non-human primates. Another objective of this invention is to provide polynucleotide primers and probes for detecting and characterizing DNA polymerase genes in any member of the herpes virus

family, especially the gamma herpes subfamily. Another object of this invention is to provide materials and methods based on these polynucleotides, polypeptides, and antibodies for use in the diagnosis and treatment of gamma herpes virus infection in primates, particularly humans.

Embodiments of the invention include the following:

- 5 • An isolated polynucleotide with a region encoding a DNA polymerase of a herpes virus, the polynucleotide comprising a sequence (preferably 475 nucleotides long) that is at least 69% identical to nucleotides 27 to 501 of a sequence selected from the group consisting of SEQ. ID NO:1 and SEQ. ID NO:3.
- 10 • An isolated polynucleotide comprising a fragment of at least 18, more preferably at least about 35, still more preferably at least about 50 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of the previous embodiment, wherein the sequence of said fragment is not contained in SEQ. ID NOS:110 or 111. Preferred examples are isolated polynucleotides comprising a fragment of at least 18 consecutive nucleotides contained in SEQ. ID NOS:1, 3, 116, or 118.
- 15 • An isolated polynucleotide with a region encoding a DNA polymerase of a herpes virus, the polynucleotide comprising a sequence of 26 nucleotides at least 80% identical to oligonucleotide LSGGA (SEQ. ID NO:107).
- An isolated polynucleotide with a region encoding a DNA polymerase of a herpes virus, the polynucleotide comprising a sequence of 29 nucleotides at least 69% identical to oligonucleotide CTDPA (SEQ. ID NO:108).
- 20 • An isolated polynucleotide with a region encoding a DNA polymerase of a herpes virus, the polynucleotide comprising a sequence of 32 nucleotides at least 80% identical to oligonucleotide KMLEA (SEQ. ID NO:22).
- An isolated polynucleotide with a region encoding a DNA polymerase of a herpes virus, the polynucleotide comprising a sequence of 29 nucleotides at least 69% identical to oligonucleotide GISPA (SEQ. ID NO:109).
- 25 • An isolated polynucleotide comprising a fragment of at least 18, more preferably at least about 35, more preferably at least about 50 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of the previous embodiments, wherein the sequence of said fragment is not contained in SEQ. ID NOS:110 or 111.
- 30 • The polynucleotide of any of the previous embodiments, wherein said herpes virus is capable of infecting primates. Preferred examples are RFHV, KSHV, and RFHV2.
- An isolated polynucleotide comprising a linear sequence of at least 18 nucleotides identical to a linear sequence between nucleotides 27 to 501 inclusive of SEQ. ID NO:1, or between nucleotides 27 to 501 inclusive of SEQ. ID NO:3, or between nucleotides 36 to 2499 inclusive of SEQ. ID NO:116, or between nucleotides 1 to 454 inclusive of SEQ. ID NO:118, but not to a linear sequence within either SEQ. ID NO:110 or SEQ. ID NO:111. The isolated polynucleotide preferably comprises a linear sequence essentially identical to nucleotides 27 to 501 of SEQ. ID NO:1, or to nucleotides 27 to 501 of SEQ. ID NO:3, or to nucleotides 36 to 2499 of SEQ. ID NO:116, or to nucleotides 1 to 454 of SEQ. ID NO:118.
- 35
- 40 • An isolated polypeptide encoded by any of the polynucleotides embodied in this invention.

- An isolated polypeptide, comprising a linear sequence of at least 11, preferably 12, and more preferably 15 amino acids essentially identical to a sequence between amino acids 10 to 167 inclusive of SEQ. ID NO:2 or between amino acids 10 to 167 inclusive of SEQ. ID NO:4 or between amino acids 13 to 833 inclusive of SEQ. ID NO:117, or in any of SEQ. ID NOS:119-123, but which is not contained in SEQ. ID NOS:112 or in SEQ. ID NO:113.
- A fusion polypeptide comprising the amino acid sequence of an isolated peptide of the previous embodiment, joined to a second amino acid sequence.
- The isolated polypeptide of the previous embodiment, which has nucleic acid binding activity, nucleotide binding activity, or DNA polymerase activity.
- An isolated polypeptide, comprising a linear sequence of amino acids identical to a sequence selected from the group consisting of SEQ. ID NOS:80, 82, 84, 86, 88, and 90 to 103.
- An isolated polynucleotide encoding a polypeptide embodied in this invention.
- A non-naturally occurring polynucleotide encoding a polypeptide embodied in this invention.
- A polynucleotide encoding a fusion polypeptide, comprising the polynucleotide embodied in this invention joined directly to a second polynucleotide encoding a polypeptide.
- A recombinant cloning vector comprising a polynucleotide sequence encoding a polypeptide of at least 11, preferably at least 12, more preferably at least 15 consecutive amino acids between amino acids 10-167 inclusive of SEQ. ID NO:2, or between amino acids 10-167 inclusive of SEQ. ID NO:4, or between amino acids 13-833 inclusive of SEQ. ID NO:117, or in any of SEQ. ID NOS:119-123, but not contained in SEQ. ID NO:112 or SEQ. ID NO:113.
- A recombinant expression vector comprising a polynucleotide sequence encoding a polypeptide of at least 1, preferably at least 12, more preferably at least 15 consecutive amino acids between amino acids 10-167 inclusive of SEQ. ID NO:2, or between amino acids 10-167 inclusive of SEQ. ID NO:4, or between amino acids 13-833 inclusive of SEQ. ID NO:117, or in any of SEQ. ID NOS:119-123, but not contained in SEQ. ID NO:112 or SEQ. ID NO:113, operatively linked to a control polynucleotide sequence.
- A recombinant cloning vector comprising a linear sequence of at least 18 nucleotides identical to a linear sequence within SEQ. ID NOS:1, 3, 116, or 118, but not in SEQ. ID NOS:110 or 111.
- A host cell genetically altered by any of the polynucleotides, cloning vectors, or expression vectors of this invention.
- A monoclonal or isolated polyclonal antibody specific for a DNA polymerase encoded in said encoding region of a polynucleotide of this invention.
- A monoclonal or isolated polyclonal antibody specific for a peptide of this invention.
- An oligonucleotide essentially identical to an oligonucleotide selected from the group consisting of SEQ. ID NOS:5 to 16, 21, 22, 104-109, and 124-152.
- A method of obtaining an amplified copy of a polynucleotide encoding a DNA polymerase, comprising the steps of contacting the polynucleotide with an oligonucleotide of this invention, which may be a Type 1, Type 2, or Type 3 oligonucleotide, and elongating oligonucleotide that has formed a duplex with the polynucleotide. Preferably, the amplification reaction is a polymerase chain reaction (PCR).

The PCR preferably comprises repeated cycles of annealing and elongating, and the annealing is conducted at a temperature of at least 60°C.

- The PCR is preferably conducted in a buffer containing 10-30 mM $(\text{NH}_4)_2\text{SO}_4$ and 1-10 mM MgCl_2 , such as WB4 buffer.
- 5 • A method of obtaining an amplified copy of a polynucleotide encoding a DNA polymerase, wherein the polynucleotide which is amplified is first obtained from a biological sample taken from an individual affected with a disease featuring fibroblast proliferation and collagen deposition.
- A method of obtaining an amplified copy of a polynucleotide encoding a DNA polymerase, wherein the polynucleotide which is amplified is first obtained from a biological sample taken from an individual affected with a malignancy of the lymphocyte lineage. Also included is a method wherein the polynucleotide which is amplified is first obtained from a biological sample taken from an individual affected with a condition selected from the group consisting of retroperitoneal fibrosis, nodular fibromatosis, pseudosarcomatous fibromatosis, fibrosarcoma, sclerosing mesenteritis, acute respiratory disease syndrome, idiopathic pulmonary fibrosis, diffuse proliferative glomerulonephritis, glioma, glioblastomas, gliosis, leukemia and lymphoma.
- 10 15
- A method of detecting viral DNA or RNA in a sample of primate origin, comprising the steps of: contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of this invention, under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:24 to 29; and detecting the presence of said stable duplex formed in step a), if any. The conditions referred to are a single set of reaction parameters, such as incubation time, temperature, solute concentrations, and washing steps, that fulfills all the criteria listed. Under these conditions, the polynucleotide would be capable of forming a stable duplex if contacted with a polynucleotide having SEQ. ID NO:1. It would also be capable of forming a stable duplex if contacted with a polynucleotide having SEQ. ID NO:3. It would not be capable of forming a stable duplex if contacted with a polynucleotide having a sequence of any of SEQ ID NO:24 to SEQ. ID NO:29. The reaction conditions may optionally be tested by contacting with the polynucleotides consisting only of the sequences indicated, or by contacting with polynucleotides with the sequences indicated linked to additional nucleotides, so long as formation of a stable duplex under the test conditions relies on the sequence indicated. Also included are similar methods using other polynucleotides of this invention. This includes conducting an amplification reaction on the DNA or RNA of the sample prior to being contacted with the probe. The amplification reaction may be conducted using an oligonucleotide primer of this invention.
- 20 25 30
- A method of detecting viral DNA or RNA in a sample of primate origin, comprising the steps of: contacting the DNA or RNA in the sample with an oligonucleotide probe comprising a sequence shown in SEQ. ID NOS: 21, 22, 107, 108, or 109, under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:24 to 29; and detecting the presence of said stable duplex formed, if any.
- 35 40

- 5 • A method of detecting viral DNA or RNA in a sample, comprising the steps of: contacting the DNA or RNA in the sample with an oligonucleotide probe comprising a sequence shown in SEQ. ID NOS:22, 107, 108 or 109 under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:23 to 29; and detecting the presence of said stable duplex formed if any.
- 10 • A method of detecting viral DNA or RNA in a sample, comprising the steps of: conducting an amplification reaction on a polynucleotide in the sample using the oligonucleotide of this invention as a primer in the reaction; and detecting the presence of amplified copies of the polynucleotide, if any.
- 15 • An isolated polynucleotide capable of forming a stable duplex with an oligonucleotide comprising a sequence selected from the group consisting of SEQ. ID NO:107, SEQ. ID NO:108, and their respective complementary sequences, under conditions wherein the oligonucleotide is capable of forming a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:23 to 29. An isolated polypeptide comprising a linear sequence of at least 11 amino acids, preferably at least 12 amino acids, more preferably at least 15 amino acids encoded within the polynucleotide of the preceding embodiment.
- 20 • A method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of embodied in this invention. Also included is a method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of: a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of this invention under conditions that would permit the probe to form a stable duplex with a polynucleotide having at least one sequence selected from the group consisting of SEQ. ID NOS:1, 3, 116, or 118, but not with polynucleotides having a sequence of any of SEQ. ID NOS:24 to 29; and b) detecting the presence of said stable duplex formed in step a), if any. Also included is a method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of: a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of this invention under conditions that would permit the probe to form a stable duplex with a polynucleotide having a sequence shown in SEQ. ID NO:116, but not with polynucleotides having a sequence of any of SEQ. ID NOS:24 to 29; and b) detecting the presence of said stable duplex formed in step a), if any.
- 25 • A diagnostic kit for detecting a herpes virus polynucleotide in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises a polynucleotide of this invention
- 30 • A diagnostic kit for detecting a herpes virus polynucleotide in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the oligonucleotide of this invention.
- 35 • A method of detecting infection of an individual by a herpes virus, comprising the steps of: contacting antibody from a sample obtained from the individual with the polypeptide of this invention under

- conditions that permit the formation of a stable antigen-antibody complex; and detecting said stable complexes formed, if any.
- A diagnostic kit for detecting an anti-herpesvirus antibody present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises a polypeptide of this invention.
 - 5 • A method of detecting infection of an individual by a herpes virus, comprising the steps of: contacting antibody from a sample obtained from the individual with a polypeptide of this invention under conditions that permit the formation of a stable antigen-antibody complex; and detecting said stable complexes formed, if any.
 - 10 • A diagnostic kit for detecting an anti-herpesvirus antibody present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises a polypeptide of this invention.
 - A method of detecting infection of an individual by a herpes virus, comprising the steps of: contacting a polypeptide from a sample obtained from the individual with the antibody of this invention under conditions that permit the formation of a stable antigen-antibody complex; and detecting said stable complexes formed, if any.
 - 15 • A diagnostic kit for detecting a herpes virus polypeptide present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises an antibody of this invention.
 - A composition for use in the treatment of herpes virus infection, comprising a polynucleotide, polypeptide, or antibody of this invention.
 - 20 • A method of determining whether a pharmaceutical candidate is useful for treating gamma herpes infection, comprising the steps of: contacting a peptide of this invention with the pharmaceutical candidate; and determining whether a biochemical function of the polypeptide is altered by the pharmaceutical candidate. The biochemical function of the polypeptide determined may be the binding of the polypeptide to a nucleic acid, or DNA polymerase activity.
 - 25 • A method of determining whether a pharmaceutical candidate is useful for treating gamma herpes infection, comprising the steps of: genetically altering a cell using a polynucleotide of this invention, and determining the effect of the pharmaceutical candidate on the cell in comparison with a cell not genetically altered with the polynucleotide.
 - 30 • A method of obtaining a compound for use in treating an individual infected with herpes virus, comprising the steps of: creating a compound capable of binding a region of the polypeptide of this invention involved in interacting with a nucleic acid; and determining whether the compound interferes with a biochemical function of the polypeptide.

BRIEF DESCRIPTION OF THE DRAWINGS

- 35 Figure 1 is a listing of polynucleotide sequences amplified from a DNA polymerase encoding region of RFHV and KSHV, along with the encoded polypeptides. The 475-base fragment of each polynucleotide between primers DFASA and GDTD1B is underlined. Also shown in lower-case letters are oligonucleotides useful as amplification primers aligned with corresponding regions of the DNA polymerase gene. DFASA, VYGA and GDTD1B are oligonucleotides with consensus and degenerate
- 40 segments that can be used to amplify any herpes virus DNA polymerase gene. LSGGA, CTDPA, PCLNA, KMLEA and GISPA are oligonucleotides specific for the RFHV/KSHV subfamily of herpes viruses.

VASGA, ILPCA, PIEAB and PEARB are RFHV-specific primers. SGILA, CLNIA, IEASB and EARFB are KSHV-specific primers. Oligonucleotides that initiate amplification in the direction of the coding sequence (with designations ending in "A") are listed 5'→3'. Oligonucleotides that initiate amplification in the direction opposite to that of the coding sequence (with designations ending in "B") are listed 3'→5', to show alignment with the corresponding sequences in the RFHV and KSHV polynucleotide.

Figure 2 is a listing of the previously known polypeptide sequences of other herpes virus DNA polymerases, showing regions that are relatively conserved between species.

Figure 3 is a listing of previously known polynucleotide sequences of herpes viruses near conserved REGION 2, showing the alignment of oligonucleotides DFASA and DFQSA with the sequences from which they were designed.

Figure 4 is a listing of previously known polynucleotide sequences of herpes viruses near conserved REGION 3, showing the alignment of oligonucleotides VYGA, VYGCA and VYGSQA with the sequences from which they were designed.

Figure 5 is a listing of previously known polynucleotide sequences of herpes viruses near conserved REGION 1, showing the alignment of oligonucleotides GDTD1B and GDTDSQB with the sequences from which they were designed.

Figure 6 is a listing comparing the polynucleotide sequences of DNA polymerase of the gamma herpes virus subfamily. The fragment shown is the 475 base pairs between the hybridizing site of DFASA and GDTD1B.

Figure 7 is a listing comparing polypeptide sequences of DNA polymerase for the same viruses over the same fragment as Figure 6. This figure also shows examples of possible antibody binding regions, including those which are specific for RFHV, KSHV, or the RFHV/KSHV subfamily.

Figure 8 is a comparison of the polypeptide sequence for the fragment encoded between DFASA and GDTD1B across a broader range of herpes viruses. Sequences are shown for herpes viruses of the alpha, beta, and gamma subfamilies, and for endogenous mammalian DNA polymerase.

Figure 9 is a relationship map of DNA polymerases, based on polypeptide sequences shown in Figure 8.

Figure 10 is a listing of the DNA polymerase genes for members of the gamma herpes virus subfamily over the same region as Figure 6. This Figure shows the alignment of oligonucleotides LSGGA, CTDP A, PCLNA, KMLEA and GISPA aligned with the sequences from which they were designed. These oligonucleotides are specific for DNA polymerase from the RFHV/KSHV virus subfamily.

Figure 11 is a Hopp-Woods antigenicity plot for the polypeptide fragment of RFHV encoded between VYGA and GDTD1B. Indicated below are spans of hydrophobic and antigenic residues in the sequence.

Figure 12 is a Hopp-Woods antigenicity plot for the polypeptide fragment of KSHV encoded between DFASA and GDTD1B. Indicated below are spans of hydrophobic and antigenic residues in the sequence.

Figure 13 is a listing of about 2511 nucleotides of the DNA polymerase encoding sequence of KSHV, estimated to be about 3000 nucleotides long, along with the amino acid translation. Additional sequence data is provided in the 5' and 3' direction from the PCR segment shown in Figure 1.

Figure 14 is a listing comparing a portion of the KSHV DNA polymerase amino acid sequence with that of other herpes viruses. Asterisks (*) and bullets (•) indicate conserved residues or conservative

substitutions. Arrows (↑) indicate residues that are conserved amongst other herpes viruses, but different in the KSHV sequence.

Figure 15 is a listing showing known variants of the KSHV DNA polymerase amino acid sequence.

5 Figure 16 is a listing of polynucleotide sequences amplified from a DNA polymerase encoding region of RFHVMm (designated here as RFMm). RFHVMm is a third member of the RFHV/KSHV herpes virus subfamily identified according to the criteria of this invention. Shown for comparison are DNA polymerase encoding regions of RFHV (designated RFMn) and KSHV.

Figure 17 is a listing comparing amino acid sequences encoded in a DNA polymerase encoding region of RFHVMm with corresponding sequences of RFHVMn, KSHV, and three other herpes viruses.

10 Figure 18 is a statistical phylogeneic analysis of the amino acid alignments in Figure 17. The numbers shown are bootstrap values out of 100 repetitions.

Figure 19 is a map showing approximate hybridization positions of Type 1, Type 2, and Type 3 oligonucleotide probes in the DNA polymerase nucleotide sequences of members of the RFHV/KSHV subfamily.

15 Figure 20 is a representative screen for the prevalence of RFHVMn and RFHVMm herpesvirus sequences in *M. nemestrina* monkeys (lanes A-D, I, and J), and *M. mulatta* monkeys (lanes G and H) in a nested amplification assay using virus-specific oligonucleotide primers.

BEST MODE FOR CARRYING OUT THE INVENTION

20

We have discovered and characterized polynucleotides encoding DNA polymerase from RFHV, RFHV2, and KSHV, which are exemplary members of the RFHV/KSHV subfamily of herpes viruses. The polynucleotides obtained, related polynucleotides, and corresponding polypeptides and antibodies are useful in the diagnosis, clinical monitoring, and treatment of herpes virus infections and related conditions.

25 Sources for the polynucleotides from RFHV and KSHV were affected tissue samples taken from *Macaque nemestrina* monkeys with retroperitoneal fibromatosis ("RF") and from humans with Kaposi's sarcoma ("KS"), respectively. We predicted that these conditions were associated with viruses distinct from those responsible for any contemporaneous immunodeficiency. We did not know in advance that the RF and KS associated viruses would be related.

30 We decided to test the premise that viruses associated with both conditions are members of the herpes virus family. Accordingly, we designed oligonucleotides for use in an amplification reaction to obtain polynucleotides encoding a DNA polymerase from a broad spectrum of herpes viruses. Comparing amino acid sequences of herpes viruses that have been previously described, three conserved regions were identified. The corresponding known polynucleotide sequences were used to construct
35 oligonucleotides comprising a degenerate segment and a consensus segment. These oligonucleotides served as primers in amplification reactions that yielded fragments of the DNA polymerase encoding segment from each of the two tissue sources.

The sequences of the polynucleotide fragments obtained from the final step of the amplification reactions are shown in Figure 1 (SEQ. ID NO:1 and SEQ. ID NO:3, respectively). Both sequences are
40 novel, although they contain regions that are highly homologous to regions of DNA polymerase sequences from other herpes viruses. The virus infecting the *M. nemestrina* monkeys was designated

"Retroperitoneal Fibromatosis Herpes Virus" ("RFHV"). The virus infecting the human patients was designated "Kaposi's Sarcoma Herpes Virus" ("KSHV"). The polynucleotide sequences shown include segments at each end corresponding to the hybridizing regions of the DFASA and GDTD1B primers used in the amplification. The 475 base pair fragment between the primers represents an amplified portion of the DNA polymerase gene for RFHV and KSHV.

Since the primers were designed to amplify a broad spectrum of DNA polymerases, we were surprised to find that these two DNA polymerase sequences are apparently more closely related to each other (71% identity at the nucleotide level) than to any other known herpes virus DNA polymerase. The next most closely related polynucleotide sequences are from equine herpes virus 2 (eHV2), saimiri herpes virus 1 (sHV1), and Epstein Barr virus (EBV). We therefore predict that both RFHV and KSHV are members of the herpes gamma subfamily. RFHV and KSHV share with other gamma herpes an association with abnormal cellular or fibrotic growth, and an association with immune abnormalities, including immunosuppression and B cell dysplasias. However, RFHV and KSHV DNA polymerase sequences differ from sHV1 and EBV in the frequency of CpG dinucleotides. RFHV and KSHV DNA polymerase nucleotide sequences and oligonucleotides based upon them define the RFHV/KSHV subfamily as described below. The DNA polymerase sequence of a third member of the subfamily infecting *M. mulatta* monkeys, RFHV2, is also provided.

The degree of conservation between DNA polymerases means that the polynucleotides and polypeptides embodied in this invention are reliable markers amongst different strains of RFHV and KSHV. Because it is a sequestered antigen, DNA polymerase is not under the same degree of immunological pressure to form escape mutants. Furthermore, the sequences are constrained by the critical role that these regions play in the catalytic activity of the DNA polymerase. Thus, the polynucleotides, polypeptides, and antibodies embodied in this invention are useful in such applications as the detection of viral infection in an individual, due to RFHV, KSHV, or other herpes viruses that are of the same subfamily. Embodiments of the invention are also useful in the characterization of herpes virus DNA polymerase, and the design of pharmaceutical therapies.

Because the DNA polymerase plays a critical role in viral replication, it is an appropriate target for pharmacological intervention. Particularly sensitive regions of the molecule are those involved in substrate recognition, template binding, catalysis, and association with regulatory subunits.

Polynucleotides of the RFHV/KSHV subfamily, related oligonucleotide probes and primers, related polypeptides and antigens, related specific antibodies, the preparation and use of these compounds, and related methods and products are described in further detail in the sections that follow.

Abbreviations

The following abbreviations are used herein to refer to species of herpes viruses, and polynucleotides and genes derived therefrom that encode DNA polymerase:

TABLE 1: Abbreviations for Herpes Virus Strains		
Designation	Virus	Provisional Subfamily Assignment
RFHV	simian Retroperitoneal Fibromatosis-associated HerpesVirus	gamma-HerpesVirus
KSHV	human Kaposi's Sarcoma-associated HerpesVirus	
eHV2	equine HerpesVirus 2	
sHV1	saimiri monkey HerpesVirus 1	
hEBV	human Epstein-Barr Virus	
hCMV	human CytoMegaloVirus	beta-HerpesVirus
mCMV	murine CytoMegaloVirus	
gpCMV	guinea pig CytoMegaloVirus	
hHV6	human HerpesVirus 6	alpha-HerpesVirus
hVZV	human Varicella-Zoster Virus	
hHSV1	human Herpes Simplex Virus 1	
hHSV2	human Herpes Simplex Virus 2	
eHV1	equine HerpesVirus 1	
iHV1	ictalurid catfish HerpesVirus	
hPOLd	human endogenous DNA polymerase	eukaryotic delta DNA polymerase
bPOLd	bovine endogenous DNA polymerase	

Definitions

“RFHV” and “KSHV” are viruses of the herpes family detected in tissue samples of infected macaque nemestrina monkeys and humans, respectively. Cells infected with these viruses contain polynucleotides encoding the respective DNA polymerases as described herein. “RFHV” is synonymous with the terms “RFHV1”, “RFHVMn”, and “RFMn”. A third member of the RFHV/KSHV subfamily is a virus identified in a *M. mulatta* monkey. The virus is referred to herein as “RFHV2”. “RFHV2” is synonymous with the terms “RFHVMm” and “RFMm”.

The “RFHV/KSHV subfamily” is a term used herein to refer to a collection of herpes viruses capable of infecting vertebrate species. The subfamily consists of members that have sequences that are more closely related to the corresponding sequences of RFHV or KSHV than either of these viruses are to any other virus listed in Table 1. The sequence comparison may be made at either the polynucleotide or the polypeptide level, and may be across intact genes or proteins, or across fragments thereof. As used herein, the subfamily refers to herpes viruses that contain a portion of a DNA-polymerase-encoding polynucleotide that is more closely identical to the corresponding region of RFHV or KSHV than either of these viruses are to the viruses in Table 1. Preferably, the polynucleotide encoding the polymerase comprises a segment that is at least 69% identical to that of RFHV (SEQ. ID NO:1) or KSHV (SEQ. ID NO:3) between residues 27 and 501; or at least 80% identical to the oligonucleotide LSGGA; or at least

69% identical to the oligonucleotide CTDPA; or at least 80% identical to the oligonucleotide KMLEA; or at least 69% identical to the oligonucleotide GISPA.

As used herein, a "DNA polymerase" is a protein or a protein analog, that under appropriate conditions is capable of catalyzing the assembly of a DNA polynucleotide with a sequence that is complementary to a polynucleotide used as a template. A DNA polymerase may also have other catalytic activities, such as 3'-5' exonuclease activity; any of the activities may predominate. A DNA polymerase may require association with additional proteins or co-factors in order to exercise its catalytic function. "DNA polymerase activity" refers to the catalytic activity directed at DNA polynucleotide assembly. A "DNA polymerase reaction" is any step in a reaction mechanism on the pathway to polymerization of nucleotides, including association with substrates, cofactors, and regulatory subunits, the formation of intermediates, and the formation of reaction products.

The term "DNA polymerase gene" includes any gene that encodes a polypeptide capable of a DNA polymerase reaction. It also includes any gene that is believed to be derived from an ancestral gene that encoded a DNA polymerase, because of homology with other DNA polymerase genes or its location relative to neighboring genes; such a gene may encode a non-functional DNA polymerase analog, a DNA polymerase fragment or mutant, or it may be untranscribed or untranslated.

A "regulatory subunit" for a first polypeptide that has DNA polymerase activity is a second polypeptide that regulates DNA polymerase activity of the first polypeptide when associated with it. UL42 is an example of a regulatory subunit.

"UL42" or "UL42 subunit" is an accessory protein that is encoded in the genome of some herpes viruses. It is capable of associating with the DNA polymerase of the virus. Under certain conditions, it enhances the DNA polymerase activity of a polypeptide encoded by a DNA polymerase gene, and may be required for the virus to replicate. As used herein, the definition is a functional one, and does not depend on the structure or genomic location of the corresponding gene. Thus, a UL42 subunit of RFHV or KSHV may have a sequence that is not essentially identical to the UL42 subunit of other viruses.

The terms "polynucleotide" and "oligonucleotide" are used interchangeably, and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

The term polynucleotide, as used herein, refers interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form.

In the context of polynucleotides, a "linear sequence" or a "sequence" is an order of nucleotides in a polynucleotide in a 5' to 3' direction in which residues that neighbor each other in the sequence are contiguous in the primary structure of the polynucleotide. A "partial sequence" is a linear sequence of part of a polynucleotide which is known to comprise additional residues in one or both directions.

5 "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson-Crick base pairing, Hoogsteen binding, or in any other sequence-specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization
10 reaction may constitute a step in a more extensive process, such as the initiation of a PCR, or the enzymatic cleavage of a polynucleotide by a ribozyme.

Hybridization reactions can be performed under conditions of different "stringency". Conditions that increase the stringency of a hybridization reaction are widely known and published in the art: see, for example, Sambrook Fritsch & Maniatis. Examples of relevant conditions include (in order of increasing
15 stringency): incubation temperatures of 25°C, 37°C, 50°C, and 68°C; buffer concentrations of 10 x SSC, 6 x SSC, 1 x SSC, 0.1 x SSC (where SSC is 0.15 M NaCl and 15 mM citrate buffer) and their equivalent using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 min to 24 h; and washes of increasing duration, increasing frequency, or decreasing buffer concentrations.

"T_m" is the temperature in degrees Centigrade at which 50% of a polynucleotide duplex made of
20 complementary strands hydrogen bonded in an antiparallel direction by Watson-Crick base pairing dissociates into single strands under the conditions of the experiment. T_m may be predicted according to standard formula; for example:

$$T_m = 81.5 + 16.6 \log [Na^+] + 0.41 (\%G/C) - 0.61 (\%F) - 600/L$$

25 where Na⁺ is the cation concentration (usually sodium ion) in mol/L; (%G/C) is the number of G and C residues as a percentage of total residues in the duplex; (%F) is the percent formamide in solution (wt/vol); and L is the number of nucleotides in each strand of the duplex.

A "stable duplex" of polynucleotides, or a "stable complex" formed between any two or more
30 components in a biochemical reaction, refers to a duplex or complex that is sufficiently long-lasting to persist between the formation of the duplex or complex, and its subsequent detection. The duplex or complex must be able to withstand whatever conditions exist or are introduced between the moment of formation and the moment of detection, these conditions being a function of the assay or reaction which is being performed. Intervening conditions which may optionally be present and which may dislodge a
35 duplex or complex include washing, heating, adding additional solutes or solvents to the reaction mixture (such as denaturants), and competing with additional reacting species. Stable duplexes or complexes may be irreversible or reversible, but must meet the other requirements of this definition. Thus, a transient complex may form in a reaction mixture, but it does not constitute a stable complex if it dissociates spontaneously or as a result of a newly imposed condition or manipulation introduced before detection.

When stable duplexes form in an antiparallel configuration between two single-stranded polynucleotides, particularly under conditions of high stringency, the strands are essentially "complementary". A double-stranded polynucleotide can be "complementary" to another polynucleotide, if a stable duplex can form between one of the strands of the first polynucleotide and the second. A complementary sequence predicted from the sequence of a single stranded polynucleotide is the optimum sequence of standard nucleotides expected to form hydrogen bonding with the single-stranded polynucleotide according to generally accepted base-pairing rules.

A "sense" strand and an "antisense" strand when used in the same context refer to single-stranded polynucleotides which are complementary to each other. They may be opposing strands of a double-stranded polynucleotide, or one strand may be predicted from the other according to generally accepted base-pairing rules. Unless otherwise specified or implied, the assignment of one or the other strand as "sense" or "antisense" is arbitrary.

A linear sequence of nucleotides is "identical" to another linear sequence, if the order of nucleotides in each sequence is the same, and occurs without substitution, deletion, or material substitution. It is understood that purine and pyrimidine nitrogenous bases with similar structures can be functionally equivalent in terms of Watson-Crick base-pairing; and the inter-substitution of like nitrogenous bases, particularly uracil and thymine, or the modification of nitrogenous bases, such as by methylation, does not constitute a material substitution. An RNA and a DNA polynucleotide have identical sequences when the sequence for the RNA reflects the order of nitrogenous bases in the polyribonucleotide, the sequence for the DNA reflects the order of nitrogenous bases in the polydeoxyribonucleotide, and the two sequences satisfy the other requirements of this definition. Where at least one of the sequences is a degenerate oligonucleotide comprising an ambiguous residue, the two sequences are identical if at least one of the alternative forms of the degenerate oligonucleotide is identical to the sequence with which it is being compared. For example, AYAAA is identical to ATAAA, if AYAAA is a mixture of ATAAA and ACAAA.

When comparison is made between polynucleotides, it is implicitly understood that complementary strands are easily generated, and the sense or antisense strand is selected or predicted that maximizes the degree of identity between the polynucleotides being compared. For example, where one or both of the polynucleotides being compared is double-stranded, the sequences are identical if one strand of the first polynucleotide is identical with one strand of the second polynucleotide. Similarly, when a polynucleotide probe is described as identical to its target, it is understood that it is the complementary strand of the target that participates in the hybridization reaction between the probe and the target.

A linear sequence of nucleotides is "essentially identical" to another linear sequence, if both sequences are capable of hybridizing to form duplexes with the same complementary polynucleotide. Sequences that hybridize under conditions of greater stringency are more preferred. It is understood that hybridization reactions can accommodate insertions, deletions, and substitutions in the nucleotide sequence. Thus, linear sequences of nucleotides can be essentially identical even if some of the nucleotide residues do not precisely correspond or align. Sequences that correspond or align more closely to the invention disclosed herein are comparably more preferred. Generally, a polynucleotide region of about 25 residues is essentially identical to another region, if the sequences are at least about 80% identical; more preferably, they are at least about 90% identical; more preferably, they are at least about

95% identical; still more preferably, the sequences are 100% identical. A polynucleotide region of 40 residues or more will be essentially identical to another region, after alignment of homologous portions if the sequences are at least about 75% identical; more preferably, they are at least about 80% identical; more preferably, they are at least about 85% identical; even more preferably, they are at least about 90% identical; still more preferably, the sequences are 100% identical.

In determining whether polynucleotide sequences are essentially identical, a sequence that preserves the functionality of the polynucleotide with which it is being compared is particularly preferred. Functionality can be determined by different parameters. For example, if the polynucleotide is to be used in reactions that involve hybridizing with another polynucleotide, then preferred sequences are those which hybridize to the same target under similar conditions. In general, the T_m of a DNA duplex decreases by about 1°C for every 1% decrease in sequence identity for duplexes of 200 or more residues; or by about 5°C for duplexes of less than 40 residues, depending on the position of the mismatched residues (see, e.g., Meinkoth et al.). Essentially identical sequences of about 100 residues will generally form a stable duplex with each other's respective complementary sequence at about 20°C less than T_m ; preferably, they will form a stable duplex at about 15°C less; more preferably, they will form a stable duplex at about 10°C less; even more preferably, they will form a stable duplex at about 5°C less; still more preferably, they will form a stable duplex at about T_m . In another example, if the polypeptide encoded by the polynucleotide is an important part of its functionality, then preferred sequences are those which encode identical or essentially identical polypeptides. Thus, nucleotide differences which cause a conservative amino acid substitution are preferred over those which cause a non-conservative substitution, nucleotide differences which do not alter the amino acid sequence are more preferred, while identical nucleotides are even more preferred. Insertions or deletions in the polynucleotide that result in insertions or deletions in the polypeptide are preferred over those that result in the down-stream coding region being rendered out of phase; polynucleotide sequences comprising no insertions or deletions are even more preferred. The relative importance of hybridization properties and the encoded polypeptide sequence of a polynucleotide depends on the application of the invention.

A polynucleotide has the same "characteristics" of another polynucleotide if both are capable of forming a stable duplex with a particular third polynucleotide under similar conditions of maximal stringency. Preferably, in addition to similar hybridization properties, the polynucleotides also encode essentially identical polypeptides.

"Conserved" residues of a polynucleotide sequence are those residues which occur unaltered in the same position of two or more related sequences being compared. Residues that are relatively conserved are those that are conserved amongst more related sequences than residues appearing elsewhere in the sequences.

"Related" polynucleotides are polynucleotides that share a significant proportion of identical residues.

As used herein, a "degenerate" oligonucleotide sequence is a designed sequence derived from at least two related originating polynucleotide sequences as follows: the residues that are conserved in the originating sequences are preserved in the degenerate sequence, while residues that are not conserved in the originating sequences may be provided as several alternatives in the degenerate sequence. For example, the degenerate sequence AYASA may be designed from originating sequences ATACA and

ACAGA, where Y is C or T and S is C or G. Y and S are examples of "ambiguous" residues. A degenerate segment is a segment of a polynucleotide containing a degenerate sequence.

It is understood that a synthetic oligonucleotide comprising a degenerate sequence is actually a mixture of closely related oligonucleotides sharing an identical sequence, except at the ambiguous positions. Such an oligonucleotide is usually synthesized as a mixture of all possible combinations of nucleotides at the ambiguous positions. Each of the oligonucleotides in the mixture is referred to as an "alternative form". The number of forms in the mixture is equal to

$$\prod_{i=1}^n k_i$$

where k_i is the number of alternative nucleotides allowed at each position.

As used herein, a "consensus" oligonucleotide sequence is a designed sequence derived from at least two related originating polynucleotide sequences as follows: the residues that are conserved in all originating sequences are preserved in the consensus sequence; while at positions where residues are not conserved, one alternative is chosen from amongst the originating sequences. In general, the nucleotide chosen is the one which occurs in the greatest frequency in the originating sequences. For example, the consensus sequence AAAAAA may be designed from originating sequences CAAAA, AAGAA, and AAAAT. A consensus segment is a segment of a polynucleotide containing a consensus sequence.

A polynucleotide "fragment" or "insert" as used herein generally represents a sub-region of the full-length form, but the entire full-length polynucleotide may also be included.

Different polynucleotides "correspond" to each other if one is ultimately derived from another. For example, messenger RNA corresponds to the gene from which it is transcribed. cDNA corresponds to the RNA from which it has been produced, such as by a reverse transcription reaction, or by chemical synthesis of a DNA based upon knowledge of the RNA sequence. cDNA also corresponds to the gene that encodes the RNA. Polynucleotides also "correspond" to each other if they serve a similar function, such as encoding a related polypeptide, in different species, strains or variants that are being compared.

A "probe" when used in the context of polynucleotide manipulation refers to an oligonucleotide which is provided as a reagent to detect a target potentially present in a sample of interest by hybridizing with the target. Usually, a probe will comprise a label or a means by which a label can be attached, either before or subsequent to the hybridization reaction. Suitable labels include, but are not limited to radioisotopes, fluorochromes, chemiluminescent compounds, dyes, and proteins, including enzymes.

A "primer" is an oligonucleotide, generally with a free 3' -OH group, that binds to a target potentially present in a sample of interest by hybridizing with the target, and thereafter promotes polymerization of a polynucleotide complementary to the target.

Processes of producing replicate copies of the same polynucleotide, such as PCR or gene cloning, are collectively referred to herein as "amplification" or "replication". For example, single or double-

stranded DNA may be replicated to form another DNA with the same sequence. RNA may be replicated, for example, by an RNA-directed RNA polymerase, or by reverse-transcribing the DNA and then performing a PCR. In the latter case, the amplified copy of the RNA is a DNA with the identical sequence.

5 A "polymerase chain reaction" ("PCR") is a reaction in which replicate copies are made of a target polynucleotide using one or more primers, and a catalyst of polymerization, such as a reverse transcriptase or a DNA polymerase, and particularly a thermally stable polymerase enzyme. Generally, a PCR involves reiteratively forming three steps: "annealing", in which the temperature is adjusted such that oligonucleotide primers are permitted to form a duplex with the polynucleotide to be amplified;
10 "elongating", in which the temperature is adjusted such that oligonucleotides that have formed a duplex are elongated with a DNA polymerase, using the polynucleotide to which they've formed the duplex as a template; and "melting", in which the temperature is adjusted such that the polynucleotide and elongated oligonucleotides dissociate. The cycle is then repeated until the desired amount of amplified polynucleotide is obtained. Methods for PCR are taught in U.S. Patent Nos. 4,683,195 (Mullis) and
15 4,683,202 (Mullis et al.).

Elements within a gene include but are not limited to promoter regions, enhancer regions, repressor binding regions, transcription initiation sites, ribosome binding sites, translation initiation sites, protein encoding regions, introns and exons, and termination sites for transcription and translation.

A "control element" or "control sequence" is a nucleotide sequence involved in an interaction of
20 molecules that contributes to the functional regulation of a polynucleotide, including replication, duplication, transcription, splicing, translation, or degradation of the polynucleotide. The regulation may affect the frequency, speed, or specificity of the process, and may be enhancing or inhibitory in nature. Control elements are known in the art. For example, a "promoter" is an example of a control element. A promoter is a DNA region capable under certain conditions of binding RNA polymerase and initiating
25 transcription of a coding region located downstream (in the 3' direction) from the promoter.

"Operatively linked" refers to a juxtaposition of genetic elements, wherein the elements are in a relationship permitting them to operate in the expected manner. For instance, a promoter is operatively linked to a coding region if the promoter helps initiate transcription of the coding sequence. There may be intervening residues between the promoter and coding region so long as this functional relationship
30 is maintained.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation,
35 lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

In the context of polypeptides, a "linear sequence" or a "sequence" is an order of amino acids in a polypeptide in an N-terminal to C-terminal direction in which residues that neighbor each other in the sequence are contiguous in the primary structure of the polypeptide. A "partial sequence" is a linear

sequence of part of a polypeptide which is known to comprise additional residues in one or both directions.

A linear sequence of amino acids is "essentially identical" to another sequence if the two sequences have a substantial degree of sequence identity. It is understood that the folding and the biochemical function of proteins can accommodate insertions, deletions, and substitutions in the amino acid sequence. Thus, linear sequences of amino acids can be essentially identical even if some of the residues do not precisely correspond or align. Sequences that correspond or align more closely to the invention disclosed herein are more preferred. It is also understood that some amino acid substitutions are more easily tolerated. For example, substitution of an amino acid with hydrophobic side chains, aromatic side chains, polar side chains, side chains with a positive or negative charge, or side chains comprising two or fewer carbon atoms, by another amino acid with a side chain of like properties can occur without disturbing the essential identity of the two sequences. Methods for determining homologous regions and scoring the degree of homology are well known in the art; see for example Altschul et al. and Henikoff et al. Well-tolerated sequence differences are referred to as "conservative substitutions". Thus, sequences with conservative substitutions are preferred over those with other substitutions in the same positions; sequences with identical residues at the same positions are still more preferred. Generally, a polypeptide region of about 25 residues is essentially identical to another region if the sequences are at least about 80% identical; more preferably, they are at least about 85% identical; more preferably, they are at least about 90% identical; more preferably, they are at least about 95% identical; still more preferably, the sequences are 100% identical. A polypeptide region of 40 residues or more will be essentially identical to another region, after alignment of homologous portions, if the sequences are at least about 70% identical; more preferably, they are at least about 70% identical, and comprise at least another 10% which are either identical or are conservative substitutions; more preferably, they are at least about 80% identical; more preferably, they are at least about 80% identical, and comprise at least another 10% which are either identical or are conservative substitutions; more preferably, they are at least about 90% identical; still more preferably, the sequences are 100% identical.

In determining whether polypeptide sequences are essentially identical, a sequence that preserves the functionality of the polypeptide with which it is being compared is particularly preferred. Functionality may be established by different parameters, such as enzymatic activity, the binding rate or affinity in a substrate-enzyme or receptor-ligand interaction, the binding affinity with an antibody, and X-ray crystallographic structure.

A polypeptide has the same "characteristics" of another polypeptide if it displays the same biochemical function, such as enzyme activity, ligand binding, or antibody reactivity. Preferred characteristics of a polypeptide related to a DNA polymerase or a DNA polymerase fragment are DNA polymerase activity, DNA template binding, and the binding of deoxyribonucleotide triphosphates. Also preferred is a polypeptide that displays the same biochemical function as the polypeptide with which it is being compared, and in addition, is believed to have a similar three-dimensional conformation, as predicted by computer modeling or determined by such techniques as X-ray crystallography.

The "biochemical function" or "biological activity" of a polypeptide includes any feature of the polypeptide detectable by suitable experimental investigation. "Altered" biochemical function can refer to a change in the primary, secondary, tertiary, or quaternary structure of the polypeptide; detectable, for example, by molecular weight determination, circular dichroism, antibody binding, difference spectroscopy, or nuclear magnetic resonance. It can also refer to a change in reactivity, such as the ability to catalyze a certain reaction, or the ability to bind a cofactor, substrate, inhibitor, drug, hapten, or other polypeptide. A substance may be said to "interfere" with the biochemical function of a polypeptide if it alters the biochemical function of the polypeptide in any of these ways.

A "fusion polypeptide" is a polypeptide comprising regions in a different position in the sequence than occurs in nature. The regions may normally exist in separate proteins and are brought together in the fusion polypeptide; or they may normally exist in the same protein but are placed in a new arrangement in the fusion polypeptide. A fusion polypeptide may be created, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship.

An "antibody" (interchangeably used in plural form) is an immunoglobulin molecule capable of specific binding to a target, such as a polypeptide, through at least one antigen recognition site, located in the variable region of the immunoglobulin molecule. As used herein, the term encompasses not only intact antibodies, but also fragments thereof, mutants thereof, fusion proteins, humanized antibodies, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity.

"Immunological recognition" or "immunological reactivity" refers to the specific binding of a target through at least one antigen recognition site in an immunoglobulin or a related molecule, such as a B cell receptor or a T cell receptor.

The term "antigen" refers to the target molecule that is specifically bound by an antibody through its antigen recognition site. The antigen may, but need not be chemically related to the immunogen that stimulated production of the antibody. The antigen may be polyvalent, or it may be a monovalent hapten. Examples of kinds of antigens that can be recognized by antibodies include polypeptides, polynucleotides, other antibody molecules, oligosaccharides, complex lipids, drugs, and chemicals.

An "immunogen" is an antigen capable of stimulating production of an antibody when injected into a suitable host, usually a mammal. Compounds may be rendered immunogenic by many techniques known in the art, including crosslinking or conjugating with a carrier to increase valency, mixing with a mitogen to increase the immune response, and combining with an adjuvant to enhance presentation.

A "vaccine" is a pharmaceutical preparation for human or animal use, which is administered with the intention of conferring the recipient with a degree of specific immunological reactivity against a particular target, or group of targets. The immunological reactivity may be antibodies or cells (particularly B cells, plasma cells, T helper cells, and cytotoxic T lymphocytes, and their precursors) that are immunologically reactive against the target, or any combination thereof. Possible targets include foreign or pathological compounds, such as an exogenous protein, a pathogenic virus, or an antigen expressed by a cancer cell. The immunological reactivity may be desired for experimental

purposes, for the treatment of a particular condition, for the elimination of a particular substance, or for prophylaxis against a particular condition or substance.

A "passive vaccine" is a vaccine that does not require participation of the recipient's immune response to exert its effect. Usually, it is comprised of antibody molecules reactive against the target.

5 The antibodies may be obtained from a donor subject and sufficiently purified for administration to the recipient, or they may be produced in vitro, for example, from a culture of hybridoma cells, or by genetically engineering a polynucleotide encoding an antibody molecule.

An "active vaccine" is a vaccine administered with the intention of eliciting a specific immune response within the recipient, that in turn has the desired immunological reactivity against the target.

10 An active vaccine comprises a suitable immunogen. The immune response that is desired may be either humoral or cellular, systemic or secretory, or any combination of these.

A "reagent" polynucleotide, polypeptide, or antibody, is a substance provided for a reaction, the substance having some known and desirable parameters for the reaction. A reaction mixture may also contain a "target", such as a polynucleotide, antibody, or polypeptide that the reagent is capable of
15 reacting with. For example, in some types of diagnostic tests, the amount of the target in a sample is determined by adding a reagent, allowing the reagent and target to react, and measuring the amount of reaction product. In the context of clinical management, a "target" may also be a cell, collection of cells, tissue, or organ that is the object of an administered substance, such as a pharmaceutical compound.

An "isolated" polynucleotide, polypeptide, protein, antibody, or other substance refers to a
20 preparation of the substance devoid of at least some of the other components that may also be present where the substance or a similar substance naturally occurs or is initially obtained from. Thus, for example, an isolated substance may be prepared by using a purification technique to enrich it from a source mixture. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured in relation to a second, potentially interfering substance present in the
25 source mixture. Increasing enrichments of the embodiments of this invention are increasingly more preferred. Thus, for example, a 2-fold enrichment is preferred, 10-fold enrichment is more preferred, 100-fold enrichment is more preferred, 1000-fold enrichment is even more preferred. A substance can also be provided in an isolated state by a process of artificial assembly, such as by chemical synthesis or recombinant expression.

30 A polynucleotide used in a reaction, such as a probe used in a hybridization reaction, a primer used in a PCR, or a polynucleotide present in a pharmaceutical preparation, is referred to as "specific" or "selective" if it hybridizes or reacts with the intended target more frequently, more rapidly, or with greater duration than it does with alternative substances. Similarly, a polypeptide is referred to as
35 "specific" or "selective" if it binds an intended target, such as a ligand, hapten, substrate, antibody, or other polypeptide more frequently, more rapidly, or with greater duration than it does to alternative substances. An antibody is referred to as "specific" or "selective" if it binds via at least one antigen recognition site to the intended target more frequently, more rapidly, or with greater duration than it does to alternative substances. A polynucleotide, polypeptide, or antibody is said to "selectively inhibit" or "selectively interfere with" a reaction if it inhibits or interferes with the reaction between particular

substrates to a greater degree or for a greater duration than it does with the reaction between alternative substrates.

A "pharmaceutical candidate" or "drug candidate" is a compound believed to have therapeutic potential, that is to be tested for efficacy. The "screening" of a pharmaceutical candidate refers to
5 conducting an assay that is capable of evaluating the efficacy and/or specificity of the candidate. In this context, "efficacy" refers to the ability of the candidate to affect the cell or organism it is administered to in a beneficial way: for example, the limitation of the pathology due to an invasive virus.

The "effector component" of a pharmaceutical preparation is a component which modifies target cells by altering their function in a desirable way when administered to a subject bearing the cells.
10 Some advanced pharmaceutical preparations also have a "targeting component", such as an antibody, which helps deliver the effector component more efficaciously to the target site. Depending on the desired action, the effector component may have any one of a number of modes of action. For example, it may restore or enhance a normal function of a cell, it may eliminate or suppress an abnormal function of a cell, or it may alter a cell's phenotype. Alternatively, it may kill or render dormant
15 a cell with pathological features, such as a virally infected cell. Examples of effector components are provided in a later section.

A "cell line" or "cell culture" denotes higher eukaryotic cells grown or maintained in vitro. It is understood that the descendants of a cell may not be completely identical (either morphologically, genotypically, or phenotypically) to the parent cell.

20 A "host cell" is a cell which has been transformed, or is capable of being transformed, by administration of an exogenous polynucleotide. A "host cell" includes progeny of the original transformant.

"Genetic alteration" refers to a process wherein a genetic element is introduced into a cell other than by natural cell division. The element may be heterologous to the cell, or it may be an additional copy or
25 improved version of an element already present in the cell. Genetic alteration may be effected, for example, by transfecting a cell with a recombinant plasmid or other polynucleotide through any process known in the art, such as electroporation, calcium phosphate precipitation, contacting with a polynucleotide-liposome complex, or by transduction or infection with a DNA or RNA virus or viral vector. The alteration is preferably but not necessarily inheritable by progeny of the altered cell.

30 An "individual" refers to vertebrates, particularly members of a mammalian species, and includes but is not limited to domestic animals, sports animals, and primates, including humans.

The term "primate" as used herein refers to any member of the highest order of mammalian species. This includes (but is not limited to) prosimians, such as lemurs and lorises; tarsioids, such as tarsiers; new-world monkeys, such as squirrel monkeys (*Saimiri sciureus*) and tamarins; old-world
35 monkeys such as macaques (including *Macaca nemestrina*, *Macaca fascicularis*, and *Macaca fuscata*); hylobatids, such as gibbons and siamangs; pongids, such as orangutans, gorillas, and chimpanzees; and hominids, including humans.

The "pathology" caused by a herpes virus infection is anything that compromises the well-being or normal physiology of the host. This may involve (but is not limited to) destructive invasion of the virus
40 into previously uninfected cells, replication of the virus at the expense of the normal metabolism of the

cell, generation of toxins or other unnatural molecules by the virus, irregular growth of cells or intercellular structures (including fibrosis), irregular or suppressed biological activity of infected cells, malignant transformation, interference with the normal function of neighboring cells, aggravation or suppression of an inflammatory or immunological response, and increased susceptibility to other pathogenic organisms and conditions.

"Treatment" of an individual or a cell is any type of intervention in an attempt to alter the natural course of the individual or cell. For example, treatment of an individual may be undertaken to decrease or limit the pathology caused by a herpes virus infecting the individual. Treatment includes (but is not limited to) administration of a composition, such as a pharmaceutical composition, and may be performed either prophylactically, or therapeutically, subsequent to the initiation of a pathologic event or contact with an etiologic agent.

It is understood that a clinical or biological "sample" encompasses a variety of sample types obtained from a subject and useful in an in vitro procedure, such as a diagnostic test. The definition encompasses solid tissue samples obtained as a surgical removal, a pathology specimen, or a biopsy specimen, tissue cultures or cells derived therefrom and the progeny thereof, and sections or smears prepared from any of these sources. Non-limiting examples are samples obtained from infected sites, fibrotic sites, unaffected sites, and tumors. The definition also encompasses blood, spinal fluid, and other liquid samples of biologic origin, and may refer to either the cells or cell fragments suspended therein, or to the liquid medium and its solutes. The definition also includes samples that have been solubilized or enriched for certain components, such as DNA, RNA, protein, or antibody.

Oligonucleotide primers and probes described herein have been named as follows: The first part of the designation is the single amino acid code for a portion of the conserved region of the DNA polymerase they are based upon, usually 4 residues long. This is followed with the letter A or B, indicating respectively that the oligonucleotide is complementary to the sense or anti-sense strand of the DNA polymerase encoding region. Secondary consensus oligonucleotides used for sequencing have the letters SQ at the end of the designation.

General techniques

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, "Molecular Cloning: A Laboratory Manual", Second Edition (Sambrook, Fritsch & Maniatis, 1989), "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984), "Animal Cell Culture" (R.I. Freshney, ed., 1987); the series "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (D.M. Weir & C.C. Blackwell, eds.), "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987), "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987); and "Current Protocols in Immunology" (J.E. Coligan et al., eds., 1991).

All patents, patent applications, articles and publications mentioned herein, both supra and infra, are hereby incorporated herein by reference.

Polynucleotides encoding DNA polymerase of the herpes virus RFHV/KSHV subfamily

This invention embodies isolated polynucleotide segments derived from DNA polymerase genes present in herpes viruses, preferably that encode a fragment of a polypeptide that is capable of a DNA polymerase reaction. Polynucleotides provided are from the RFHV/KSHV subfamily of herpes viruses. Preferred polynucleotides are those encoding a fragment of a DNA polymerase from either RFHV or KSHV. Preferred fragments are those that have been amplified and isolated from the DNA polymerase gene, as described in the Examples below. Exemplary fragments are shown in Figure 1, and designated SEQ. ID NO:1 and SEQ. ID NO:3, respectively. Especially preferred are polynucleotides comprising the sequence between residues 27 and 501 of the RFHV sequence (SEQ. ID NO:1), and the sequence between residues 27 and 329 of the KSHV sequence (SEQ. ID NO:3).

The polynucleotide segments of RFHV and KSHV between residues 27 and 501 (the 475 base pair fragment underlined in Figure 1) are 71% identical. Shared residues are indicated in Figure 1 by "***". The largest number of consecutive bases shared between RFHV and KSHV within this segment is 17.

The 475 base pair fragments of RFHV and KSHV are more identical to each other than either of them are to the corresponding segment of any of the previously sequenced herpes viruses of Table 1. The next most closely related sequence is the DNA polymerase from the eHV2 virus, which is about 68% identical in this region to either RFHV or KSHV. Contained within this region is a first 20 base pair subfragment (SEQ. ID NO:110) and a second 20 base pair subfragment (SEQ. ID NO:111) which is shared identically between eHV2 and RFHV. The 475 base pair region is less than about 65% identical between either RFHV or KSHV and the other known DNA polymerase sequences from herpes viruses capable of infecting primates, including SHV1 and EBV. The longest subfragment shared identically between RFHV or KSHV, and SHV1, is about 14 bases in length. The longest subfragment shared identically between RFHV or KSHV, and EBV, is about 15 bases in length. It is predicted that polynucleotide sequences are more likely to be conserved between herpes virus DNA polymerase encoding regions than with other polynucleotides.

Therefore, other than the two subfragments shared with eHV2, it is believed that any subfragment of the RFHV or KSHV sequence of 18 base pairs or longer will be unique to the RFHV/KSHV subfamily, or to particular herpes virus species and variants within the subfamily.

This invention embodies subfragments contained in the DNA polymerase gene of the RFHV/KSHV subfamily, preferably contained in the region corresponding to the 475 base pair fragment between residues 27-501, as shown in Figure 1. Preferably, the sub-fragments are at least about 16 residues in length; more preferably they are at least 18 residues in length; more preferably they are at least 20 nucleotides in length; more preferably they are at least about 25 nucleotides in length; more preferably they are at least about 35 nucleotides in length; still more preferably they are at least about 50 nucleotides in length; yet more preferably they are at least about 75 nucleotides in length, and even more preferably they are 100 nucleotides in length or more. Also embodied in this invention are polynucleotides comprising the entire open reading frame of each respective herpes virus DNA polymerase.

To predict the role encoded peptide fragments play in the biological function of the DNA polymerase, comparisons may be made with other DNA polymerases. Conserved regions in the amino acid sequence of DNA polymerase from various herpes viruses are shown in Figure 2. The areas labeled ExoI, ExoII,

and ExoIII have been shown to be important binding sites for metal ligands at the 3'-5' exonuclease active site (Derbyshire et al., Bernard et al. (1989), Simon et al., Soengas et al.). The area designated as REGION 1 has been shown to be important in polymerization activity, and functions both as a drug binding site and polymerization substrate (deoxyribonucleotide triphosphate) binding site (Dorsky et al. (1988, 5 1990), Bernard et al. (1990)). A mutation of the amino acid G to A in this region of herpes simplex (HSV) 1 DNA polymerase inhibits polymerase activity in virus-infected cells. A mutation of F to C, Y or M yield different sensitivities to drugs such as nucleoside and pyrophosphate analogs, and aphidicolin. REGION 2 and REGION 3 of the HSV1 DNA polymerase appear to be involved in drug and substrate recognition (Gibbs et al. (1988a, 1988b), Basco et al. (1993)). REGION 3 is involved in binding to the DNA template 10 (Basco et al. (1992)). REGION 7 may be important in polymerization activity (Basco et al. (1993)). In some herpes viruses such as HSV1, amino acids near the C-terminal are involved in binding to a regulatory subunit known as UL42, encoded elsewhere in the herpes genome, and essential for DNA polymerase activity associated with replication of the virus (Dignard et al., Stow).

The RFHV and KSHV polynucleotides shown in Figure 1 are near regions of the polynucleotide that 15 encode functionally important parts of the DNA polymerase. Specifically, the oligonucleotides DFASA, VYGA, and GDTD1B map respectively to REGION 2, REGION 3, and REGION 1. The fragment between DFASA and GDTD1B obtained for KSHV encompasses the entire REGION 4 and REGION 3 sequences, and overlaps with the REGION 2 and REGION 1 sequences.

The RFHV/KSHV subfamily consists of members that have sequences that are more closely identical 20 to the corresponding sequences of RFHV or KSHV, than RFHV or KSHV are to any other virus listed in Table 1. Preferred members of the family may be identified on the basis of the sequence of the DNA polymerase gene in the region corresponding to that of Figure 1. Table 2 provides the degree of sequence identities in this region:

TABLE 2: Sequence Identities Between DNA Polymerase of Select Herpes Viruses and RFHV and KSHV							
Viral DNA Poly-merase Sequence	SEQ. ID NO:	Identity to RFHV fragment (SEQ. ID NO:1)			Identity to KSHV fragment (SEQ. ID NO:3)		
		Bases 27-501	Bases 27-329	Bases 330-501	Bases 27-501	Bases 29-329	Bases 320-501
RFHV	1	(100%)	(100%)	(100%)	71%	72%	70%
KSHV	3	71%	72%	70%	(100%)	(100%)	(100%)
eHV2	23	68%	68%	67%	68%	71%	63%
sHV1	24	59%	60%	59%	62%	65%	58%
EBV	25	64%	66%	58%	62%	62%	57%
hCMV	26	53%	54%	< 50%	49%	49%	< 50%
hHV6	27	46%	52%	< 50%	48%	50%	< 50%
hVZV	28	45%	46%	< 50%	48%	47%	< 50%
hHSV1	29	53%	58%	< 50%	53%	53%	< 50%

The percentage of sequence identity is calculated by first aligning the encoded amino acid sequence, determining the corresponding alignment of the encoding polynucleotide, and then counting the number of residues shared between the sequences being compared at each aligned position. No penalty is imposed for the presence of insertions or deletions, but insertions or deletions are permitted only where required to accommodate an obviously increased number of amino acid residues in one of the sequences being aligned. Offsetting insertions just to improve sequence alignment are not permitted at either the polypeptide or polynucleotide level. Thus, any insertions in the polynucleotide sequence will have a length which is a multiple of 3. The percentage is given in terms of residues in the test sequence that are identical to residues in the comparison or reference sequence.

The degree of identity between viruses in Table 2 has been calculated for segments of the RFHV and KSHV sequence numbered as shown in Figure 1.

Preferred DNA polymerase-encoding polynucleotide sequences of this invention are those derived from the RFHV/KSHV herpes virus subfamily. They include those sequences that are at least 69% identical with the RFHV or KSHV sequence between bases 27 and 501 as shown in Figure 1; more preferably, the sequences are at least 70% identical; more preferably, the sequences are at least about 72% identical; more preferably, the sequences are at least about 75% identical; more preferably, the sequences are at least about 80% identical; more preferably, the sequences are at least about 85% identical; more preferably, the sequences are at least about 90% identical; even more preferably, the sequences are over 95% identical. Also preferred are sequences that are at least 69% identical to the RFHV sequence between bases 27 and 329; more preferably, they are 70% identical; more preferably, they are at least 72% identical; more preferably, they are at least 75% identical; more preferably, they are at least 80% identical; more preferably, the sequences are at least 90% identical; even more

preferably, the sequences are at least 95% identical. Also preferred are sequences that are at least 72% identical to the KSHV sequence between bases 27 and 329; more preferably, they are at least 75% identical; more preferably, they are at least 80% identical; more preferably, they are at least 90% identical; even more preferably, they are 95% identical or more.

- 5 Other preferred DNA polymerase-encoding polynucleotide sequences may be identified by the percent identity with RFHV/KSHV subfamily-specific oligonucleotides, described in more detail in a further section. The percent identity of RFHV and KSHV DNA polymerase with example oligonucleotides is shown in Table 3:

TABLE 3: Sequence Identities Between DNA Polymerase of Select Herpes Viruses and RFHV/KSHV Subfamily Specific Oligonucleotides						
Viral DNA Poly-merase Sequence	SEQ. ID NO:	Identity to LSGGA (SEQ. ID NO:107)	Identity to CTDPA (SEQ. ID NO:108)	Identity to PCLNA (SEQ. ID NO:21)	Identity to KMLEA (SEQ. ID NO:22)	Identity to GISPA (SEQ. ID NO:109)
RFHV	1	92%	86%	93%	94%	100%
KSHV	3	96%	86%	93%	88%	90%
eHV2	23	77%	55%	93%	72%	66%
sHV1	24	65%	62%	76%	78%	66%
EBV	25	65%	66%	73%	78%	66%
hCMV	26	< 50%	< 50%	54%	53%	48%
hHV6	27	< 50%	< 50%	< 50%	47%	38%
hVZV	28	54%	< 50%	< 50%	< 50%	38%
hHSV1	29	50%	< 50%	50%	58%	52%

10 The percent identity shown in Table 3 was calculated for the corresponding residues of the viral sequences, aligned as shown in Figure 6.

- Preferred DNA polymerase sequences are those which over the corresponding region are at least about 80% identical to LSGGA; more preferably they are at least about 83% identical; more preferably they are at least about 86% identical; more preferably they are at least about 90% identical; even more preferably, they are at least 95% identical. Other preferred DNA polymerase sequences are those which over the corresponding region are at least about 69% identical to CTDPA; more preferably they are at least about 72% identical; more preferably they are at least about 75% identical; more preferably they are at least about 80% identical; more preferably they are at least about 85% identical; even more preferably, they are at least about 95% identical. Other preferred DNA polymerase sequences are those which over the corresponding region are at least about 95% identical to PCLNA. Other preferred DNA polymerase sequences are those which over the corresponding region are at least about 80% identical to KMLEA; more preferably they are at least about 83% identical; more preferably they are at least about 86% identical; more preferably they are at least about 90% identical; even more preferably, they are at least 95% identical or more. Other preferred DNA polymerase sequences are those which

over the corresponding region are at least about 69% identical to GISPA; more preferably they are at least about 72% identical; more preferably they are at least about 75% identical; more preferably they are at least about 80% identical; more preferably they are at least about 85% identical; even more preferably, they are at least about 95% identical.

5 DNA polymerase encoding sequences from members of the RFHV/KSHV subfamily identified by any of the aforementioned sequence comparisons, using either RFHV or KSHV sequences, or the subfamily-specific oligonucleotides, are equally preferred. Especially preferred are DNA polymerase encoding sequences of RFHV and KSHV. Also embodied in this invention are fragments of DNA polymerase encoding sequences of the subfamily, and longer polynucleotides comprising such
10 polynucleotide fragments.

The polynucleotide sequences described in this section provide a basis for obtaining the synthetic oligonucleotides, proteins and antibodies outlined in the sections that follow. These compounds may be prepared by standard techniques known to a practitioner of ordinary skill in the art, and may be used for a number of investigative, diagnostic, and therapeutic purposes, as described below.

15

Preparation of polynucleotides

Polynucleotides and oligonucleotides of this invention may be prepared by any suitable method known in the art. For example, oligonucleotide primers can be used in a PCR amplification of DNA
20 obtained from herpes virus infected tissue, as in Example 3 and Example 5, described below. Alternatively, oligonucleotides can be used to identify suitable bacterial clones of a DNA library, as described below in Example 10.

Polynucleotides may also be prepared directly from the sequence provided herein by chemical synthesis. Several methods of synthesis are known in the art, including the triester method and the
25 phosphite method. In a preferred method, polynucleotides are prepared by solid-phase synthesis using mononucleoside phosphoramidite coupling units. See, for example Horise et al., Beaucage et al., Kumar et al., and U.S. Patent No. 4,415,732.

A typical solid-phase synthesis involves reiterating four steps: deprotection, coupling, capping, and oxidation. This results in the stepwise synthesis of an oligonucleotide in the 3' to 5' direction.

30 In the first step, the growing oligonucleotide, which is attached at the 3'-end via a (-O-) group to a solid support, is deprotected at the 5' end. For example, the 5' end may be protected by a -ODMT group, formed by reacting with 4,4'-dimethoxytrityl chloride (DMT-Cl) in pyridine. This group is stable under basic conditions, but is easily removed under acid conditions, for example, in the presence of dichloroacetic acid (DCA) or trichloroacetic acid (TCA). Deprotection provides a 5' -OH reactive group.

35 In the second step, the oligonucleotide is reacted with the desired nucleotide monomer, which itself has first been converted to a 5'-protected, 3'-phosphoramidite. The 5' -OH of the monomer may be protected, for example, in the form of a -ODMT group, and the 3'-OH group may be converted to a phosphoramidite, such as -OP(OR')NR₂; where R is the isopropyl group -CH(CH₃)₂; and R' is, for example, -H (yielding a phosphoramidite diester), or -CH₃, -CH₂CH₃, or the beta-cyanoethyl group -CH₂CH₂CN
40 (yielding a phosphoramidite triester). The 3'-phosphoramidite group of the monomer reacts with the 5' -OH group of the growing oligonucleotide to yield the phosphite linkage 5'-OP(OR')O-3'.

(yielding a phosphoramidite triester). The 3'-phosphoramidite group of the monomer reacts with the 5' -OH group of the growing oligonucleotide to yield the phosphite linkage 5'-OP(OR')O-3'.

In the third step, oligonucleotides that have not coupled with the monomer are withdrawn from further synthesis to prevent the formation of incomplete polymers. This is achieved by capping the remaining 5' -OH groups, for example, in the form of acetates (-OC(O)CH₃,) by reaction with acetic anhydride (CH₃C(O)-O-C(O)CH₃).

In the fourth step, the newly formed phosphite group (i.e., 5'-OP(OR')O-3') is oxidized to a phosphate group (i.e., 5'-OP(=O)(OR')O-3'); for example, by reaction with aqueous iodine and pyridine.

The four-step process may then be reiterated, since the oligonucleotide obtained at the end of the process is 5'-protected and is ready for use in step one. When the desired full-length oligonucleotide has been obtained, it may be cleaved from the solid support, for example, by treatment with alkali and heat. This step may also serve to convert phosphate triesters (i.e., when R' is not -H) to the phosphate diesters (-OP(=O)₂O-), and to deprotect base-labile protected amino groups of the nucleotide bases.

Polynucleotides prepared by any of these methods can be replicated to provide a larger supply by any standard technique, such as PCR amplification or gene cloning.

Cloning and expression vectors comprising a DNA polymerase encoding polynucleotide

Cloning vectors and expression vectors are provided in this invention that comprise a sequence encoding a herpes virus DNA polymerase or variant or fragment thereof. Suitable cloning vectors may be constructed according to standard techniques, or may be selected from the large number of cloning vectors available in the art. While the cloning vector selected may vary according to the host cell intended to be used, useful cloning vectors will generally have the ability to self-replicate, may possess a single target for a particular restriction endonuclease, and may carry genes for a marker that can be used in selecting transfected clones. Suitable examples include plasmids and bacterial viruses; e.g., pUC18, mp18, mp19, pBR322, pMB9, ColE1, pCR1, RP4, phage DNAs, and shuttle vectors like pSA3 and pAT28.

Expression vectors generally are replicable polynucleotide constructs that encode a polypeptide operatively linked to suitable transcriptional and translational controlling elements. Examples of transcriptional controlling elements are promoters, enhancers, transcription initiation sites, and transcription termination sites. Examples of translational controlling elements are ribosome binding sites, translation initiation sites, and stop codons. Protein processing elements may also be included: for example, regions that encode leader or signal peptides and protease cleavage sites required for translocation of the polypeptide across the membrane or secretion from the cell. The elements employed would be functional in the host cell used for expression. The controlling elements may be derived from the same DNA polymerase gene used in the vector, or they may be heterologous (i.e., derived from other genes and/or other organisms).

Polynucleotides may be inserted into host cells by any means known in the art. Suitable host cells include bacterial cells such as E. coli, mycobacteria, other procaryotic microorganisms and eukaryotic cells (including fungal cells, insect cells, plant cells, and animal cells). The cells are transformed by inserting the exogenous polynucleotide by direct uptake, endocytosis, transfection, f-mating, or electroporation.

Subsequently, the exogenous polynucleotide may be maintained within the cell as a non-integrated vector, such as a plasmid, or may alternatively be integrated into the host cell genome.

Cloning vectors may be used to obtain replicate copies of the polynucleotides they contain, or as a means of storing the polynucleotides in a depository for future recovery. Expression vectors and host cells may be used to obtain polypeptides transcribed by the polynucleotides they contain. They may also be used in assays where it is desirable to have intact cells capable of synthesizing the polypeptide, such as in a drug screening assay.

Synthetic oligonucleotides for herpes virus DNA polymerase useful as hybridization probes and amplification primers

Oligonucleotides designed from sequences of herpes virus DNA polymerase, as embodied in this invention, can be used as probes to identify related sequences, or as primers in an amplification reaction such as a PCR.

Different oligonucleotides with different properties are described in the sections that follow. Oligonucleotides designated as Type 1 are designed to hybridize with polynucleotides encoding any herpes virus DNA polymerase, and may be used to detect previously known species of herpes virus. They may also be used to detect and characterize new species of herpes virus. Oligonucleotides designated as Type 2 are designed to hybridize with DNA polymerase encoding polynucleotides of the RFHV/KSHV subfamily, including members not yet identified, but not with polynucleotides of other herpes viruses. Oligonucleotides designated as Type 3 are designed to hybridize specifically with polynucleotides encoding DNA polymerase only from RFHV, or alternatively from KSHV.

Preferred examples of Type 1 oligonucleotides are listed in Table 4. These oligonucleotides have a specificity for DNA polymerase encoding polynucleotides of a broad range of herpes viruses.

TABLE 4: Type 1 Oligonucleotides used for Detecting, Amplifying, or Characterizing Herpes Virus Polynucleotides encoding DNA Polymerase						
Designation	Sequence (5' to 3')	Length	No. of forms	Target:	Orientation	SEQ ID:
DFASA	GTGTTGCGACTTYGCNAGYYTNT AYCC	26	256	Herpes DNA polymerase	5'→3'	5
DFQSA	GTGTTGCGACTTYCARAGYYTNT AYCC	26	128	Herpes DNA polymerase, especially the beta subfamily	5'→3'	6
VYGA	ACGTGCAACGCGGTGTAYGGN KTNACNGG	29	256	Herpes DNA polymerase	5'→3'	7
VYGCA	ACGTGCAACGCGGTGTACGGS GTSACSGG	29	8	Herpes DNA polymerase (GC-rich)	5'→3'	8
VYGSQA	ACGTGCAACGCGGTGTA	17	1	Herpes DNA polymerase	5'→3'	9
GDTD1B	CGGCATGCGACAAACACGGAG TCNGTRTCNCCRTA	35	64	Herpes DNA polymerase	3'→5'	11
GTDTSQB	CGGCATGCGACAAACACGGA	20	1	Herpes DNA polymerase	3'→5'	12

The orientation indicated is relative to the encoding region of the polynucleotide. Oligomers with a 5'→3' orientation will hybridize to the strand antisense to the coding strand and initiate amplification in the direction of the coding sequence. Oligomers with a 3'→5' orientation will hybridize to the coding strand and initiate amplification in the direction opposite to the coding sequence.

These oligonucleotides have been designed with several properties in mind: 1) sensitivity for target DNA even when present in the source material at very low copy numbers; 2) sufficient specificity to avoid hybridizing with unwanted sequences; for example, endogenous DNA polymerase sequences present in the host; 3) sufficient cross-reactivity so that differences between an unknown target and the sequence used to design it do not prevent the oligonucleotide from forming a stable duplex with the target.

For some applications, a particularly effective design is oligonucleotides that have a degenerate segment at the 3' end, designed from a region of at least 2 known polynucleotides believed to be somewhat conserved with the polynucleotide target. The various permutations of the ambiguous residues help ensure that at least one of the alternative forms of the oligonucleotide will be able to hybridize with the target. Adjacent to the degenerate segment at the 5' end of the oligonucleotide is a consensus segment which strengthens any duplex which may form and permits hybridization or amplification reactions to be done at higher temperatures. The degenerate segment is located at the 3' end of the molecule to increase the likelihood of a close match between the oligonucleotide and the target at the site where elongation begins during a polymerase chain reaction.

The ambiguous residues in the degenerate part of the sequences are indicated according to the following code:

TABLE 5: Single Letter Codes for Ambiguous Positions	
Code	Represents
R	A or G (purine)
Y	C or T (pyrimidine)
W	A or T
S	C or G
M	A or C
K	G or T
B	C or G or T (not A)
D	A or G or T (not C)
H	A or C or T (not G)
V	A or C or G (not T)
N	A or C or G or T

The Type 1 oligonucleotides shown in Table 4 are generally useful for hybridizing with DNA polymerase encoding polynucleotide segments. This may be conducted to detect the presence of the polynucleotide, or to prime an amplification reaction so that the polynucleotide can be characterized further. Suitable targets include polynucleotides encoding a region of a DNA polymerase from a wide spectrum of herpes viruses, including those in the alpha, beta, and gamma herpes viruses, those infecting any vertebrate animal, including humans and non-human primates, whether or not the polymerase or the virus has been previously known or described. Non-limiting examples include polynucleotides encoding DNA polymerase from any of the herpes viruses listed in Table 1. We have used these oligonucleotides to obtain segments of the DNA polymerase from RFHV, KSHV, EBV, HSV1, HHV6 and HHV7 – a group that includes representatives from the alpha, beta, and gamma subfamilies.

The oligonucleotides may be used, inter alia, to prime a reaction to amplify a region of the target polynucleotide in the 3' direction from the site where the oligonucleotide hybridizes. DFASA, DFQSA, VYGA, VYGCA and GDTD1B are oligonucleotides with a consensus segment adjoining a degenerate segment, and are useful for that purpose, and also may be used when the sequence of the target DNA is unknown. Selection between oligonucleotides DFASA and DFQSA depends on the sequence of the target polynucleotide. DFQSA promotes amplification of HHV6-like sequences somewhat better than other sequences; DFASA promotes amplification of both HHV6- and non-HHV6-like sequences. VYGA has a broad cross-reactivity and is especially useful as a primer for a second amplification reaction preformed using polynucleotides first amplified by another primer, such as DFASA. VYGCA is a GC-rich analog of VYGA, producing less complex amplification mixtures and allowing hybridization reactions to occur at higher temperatures. VYGSQA and GDTD5QB are specific non-degenerate oligonucleotides which can be used, inter alia, to sequence amplification products made with VYGA or

GDTD1B, respectively; or for more specific amplification of a target polynucleotide after a preliminary amplification with a degenerate primer.

5 A preferred source of DNA for use as a target for the oligonucleotides of Table 4 is any biological sample (including solid tissue and tissue cultures), particularly of vertebrate animal origin, known or suspected to harbor a herpes virus. DNA is extracted from the source by any method known in the art, including extraction with organic solvents or precipitation at high salt concentration.

10 A preferred method of amplification is a polymerase chain reaction: see generally U.S. Patent No. 4,683,195 (Mullis) and U.S. 4,683,202 (Mullis et al.); see U.S. 5,176,995 (Sninsky et al.) for application to viral polynucleotides. An amplification reaction may be conducted by combining the target polynucleotide to be amplified with short oligonucleotides capable of hybridizing with the target and acting as a primer for the polymerization reaction. Also added are substrate mononucleotides and a heat-stable DNA-dependent DNA polymerase, such as Taq. The conditions used for amplification reactions are generally known in the art, and can be optimized empirically using sources of known viruses, such as RFHV, KSHV, EBV or HSV1. Conditions can be altered, for example, by changing the
15 time and temperature of the amplification cycle, particularly the hybridization phase; changing the molarity of the oligonucleotide primers; changing the buffer concentration; and changing the number of amplification cycles. Fine-tuning the amplification conditions is a routine matter for a practitioner of ordinary skill in the art.

20 In one method, a single primer of this invention is used in the amplification, optionally using a second primer, such as a random primer, to initiate replication downstream from the first primer and in the opposite direction. In a preferred method, at least two of the primers of this invention are used in the same reaction to initiate replication in opposite directions. The use of at least two specific primers enhances the specificity of the amplification reaction, and defines the size of the fragment for comparison between samples. For example, amplification may be performed using primers DFASA and GDTD1B. More preferred is the use of all three primers in a nested fashion to enhance the
25 amplification. Nesting is accomplished by performing a first amplification using primers that encompass an intermediate fragment comprising a binding site for a third primer. This is followed by a second amplification using the third primer, thereby providing a final fragment that is a subfragment of the intermediate fragment. Particularly preferred is a first amplification using primer DFASA and primer GDTD1B, followed by a second amplification using primer VYGA and primer GDTD1B. When
30 performed on a polynucleotide from a DNA polymerase gene of RFHV or KSHV, the size of the fragment is about 236 bases.

35 The amplified polynucleotides can be characterized at any stage during the amplification reaction, for example, by size determination. Preferably, this is performed by running the polynucleotide on a gel of about 1-2% agarose. If present in sufficient quantity, the polynucleotide in the gel can be stained with ethidium bromide and detected under ultraviolet light. Alternatively, the polynucleotide can be labeled with a radioisotope such as ³²P or ³⁵S before loading on a gel of about 6% polyacrylamide, and the gel can subsequently be used to produce an autoradiogram. A preferred method of labeling the amplified polynucleotide is to end-label an oligonucleotide primer such as VYGA or VYGSQA with ³²P

using a polynucleotide kinase and gamma-[³²P]-ATP, and continuing amplification for about 5-15 cycles.

If desired, size separation may also be used as a step in the preparation of the amplified polynucleotide. This is particularly useful when the amplification mixture is found to contain artifact polynucleotides of different size, such as may have arisen through cross-reactivity with undesired targets. A separating gel, such as described in the preceding paragraph, is dried onto a paper backing and used to produce an autoradiogram. Positions of the gel corresponding to the desired bands on the autoradiogram are cut out and extracted by standard techniques. The extracted polynucleotide can then be characterized directly, cloned, or used for a further round of amplification.

Unwanted polynucleotides in the mixture from an amplification reaction can also be proportionally reduced by shifting to more specific oligonucleotide primers. For example, an initial 3-5 cycles of amplification can be conducted using primers VYGA and GDTD1B at 1/5 to 1/25 the normal amount. Then a molar excess (for example, 50 pmol) of GDTDSQB and/or VYGSQA are added, and the amplification is continued for an additional 30-35 cycles. This reduces the complexity of the oligonucleotides present in the amplification mixture, and enables the reaction temperatures to be increased to reduce amplification of unwanted polynucleotides.

Preferred examples of Type 2 oligonucleotides are listed in Table 6:

TABLE 6: Type 2 Oligonucleotides Specific for Polynucleotides Encoding DNA Polymerase from Viruses of the RFHV/KSHV Subfamily						
Designation	Sequence (5' to 3')	Length	No. of forms	Target:	Orientation	SEQ ID
LSGGA	TACGAAACCTTTGACCTNAGY GGNGG	26	32	DNA polymerase of the RFHV/KSHV subfamily	5'→3'	107
CTDPA	CGCAAGAACCTGGCCTCNTG YACNGAYCC	29	64		5'→3'	108
PCLNA	GTCGCCTCTGGCATCCTNCC NTGYCTNAA	29	128		5'→3'	21
KMLEA	CAGGGCCGGAAGATGCTGG ARACRTCNCARGC	32	32		5'→3'	22
GISPA	TCTCAGGCGTTCGTAGARGG NATHTCNCC	29	96		5'→3'	109

LSGGA, CTDPA, PCLNA, KMLEA and GISPA are all oligonucleotides with a consensus segment at the 5' end joined directly to a degenerate segment at the 3' end. They are capable of forming stable duplexes with a polynucleotide encoding DNA polymerase from either RFHV, KSHV, or from other viruses of the RFHV/KSHV subfamily. They can be used for any purpose in which such specificity is desired, such as the detection or amplification of polynucleotides from the RFHV/KSHV subfamily.

In one application, these Type 2 oligonucleotides are used individually or in combination as amplification primers. In one example of this application, the oligonucleotides are used directly on DNA

obtained from a tissue sample to obtain a DNA polymerase segment derived from RFHV, KSHV, or closely related viruses, but not more distantly related viruses such as EBV, CMV or HSV. In another example, the DNA from a tissue sample is first amplified with a less specific set of probes, such as DFASA or VYGA, in combination with GDTD1B. One of the oligonucleotides of Table 6 is then used in a second round of amplification, thereby providing a sensitive nested amplification assay which is specific for RFHV, KSHV, and other members of the RFHV/KSHV subfamily.

In another application, Type 2 oligonucleotides, or oligonucleotides comprising these sequences or fragments thereof, are used as probes in a detection assay. For example, they can be provided with a suitable label such as ^{32}P , and then used in a hybridization assay with a suitable target, such as DNA amplified using DFASA and/or VYGA, along with GDTD1B.

Preferred examples of Type 3 oligonucleotides are shown in Table 7:

TABLE 7: Type 3 Oligonucleotides Specific for Polynucleotides Encoding DNA Polymerase from RFHV or KSHV						
Designation	Sequence (5' to 3')	Length	No. off forms	Target:	Orientation	SEQ ID:
VASGA	CGTCGCTTCCGGCATCCTAC C	21	1	RFHV DNA polymerase	5'→3'	13
ILPCA	GGCATCCTACCGTGCCTGAA C	21	1		5'→3'	14
PIEAB	CCGGAGACGCCTCGATCGGT C	21	1		3'→5'	15
PEARB	AACCTGGCTTCCGGAGACGC C	21	1		3'→5'	16
SGILA	GCGTTGCCTCTGGCATACTG	20	1	KSHV DNA polymerase	5'→3'	17
CLNIA	CTGCCTTGCCTAAACATAGC G	21	1		5'→3'	18
IEASB	GGTGAGACGTCTATTGGCCT	20	1		3'→5'	19
EARFB	AATCGGGCGTCGGGTGAGAC G	21	1		3'→5'	20

These are non-degenerate oligonucleotides designed to be specific for DNA polymerase encoding polynucleotides of particular herpes viruses; namely RFHV or KSHV. The particular sequence chosen is from a segment of the encoding region that is more different from that of the other virus than neighboring segments.

VASGA, ILPCA, PIEAB, and PEARB are specific non-degenerate oligonucleotides for the RFHV DNA polymerase, and can be used in hybridization reactions conducted at high stringency. For example, they can be used alone or in combination as primers for amplifying a target polynucleotide encoding RFHV DNA polymerase. Preferably, the amplification is done using the oligonucleotides in a nested fashion: e.g., a first amplification is conducted using VASGA and PEARB as primers; then a second amplification is conducted using ILPCA and PIEAB as primers.

Similarly, SGILA, CLNIA, IEASB, and EARFB are specific non-degenerate oligonucleotides for the KSHV DNA polymerase, and can be used in a similar fashion, including as primers for an amplification reaction. Preferably, the amplification is done using the oligonucleotides in a nested fashion: e.g., a first amplification is conducted using SGILA and EARFB as primers; then a second amplification is conducted using CLNIA and IEASB as primers. This provides an extremely sensitive amplification assay that is specific for KSHV DNA polymerase.

Practitioners skilled in the art will immediately recognize that oligonucleotides of Types 1, 2, and 3 (in particular, those shown in Tables 4, 6, and 7) can be used in combination with each other in a PCR to amplify different sections of a DNA polymerase encoding polynucleotide. The specificity of the amplification reaction generally is determined by the primer with the least amount of cross reactivity. The size and location of the amplified fragment is determined by the primers used in the final round of amplification. For example, LSSGA used in combination with GDTD1B will amplify about 361 bases of DNA polymerase encoding polynucleotide from a virus of the RFHV/KSHV subfamily. Similarly, VYGA used in combination with PEARB will amplify about 444 bases of DNA polymerase encoding polynucleotide from RFHV. Suitable combinations of oligonucleotides may be used as amplification primers in a nested fashion.

Use of synthetic oligonucleotides to characterize polynucleotide targets

As described in the previous section, the oligonucleotides embodied in this invention, can be used as primers for amplification of polynucleotides encoding a herpes virus DNA polymerase, particularly in a polymerase chain reaction.

The conditions for conducting the PCR depend on the nature of the oligonucleotide being used. In particular, when using oligonucleotides comprising a degenerate segment, or a consensus segment that is only partly identical to the corresponding segment of the target, and when the target polynucleotide comprises an unknown sequence, the selection of conditions may be important to the success of the amplification. Optimizing conditions for a new primer or new polynucleotide target are routine for a practitioner of ordinary skill. What follows is a guide to assist in that objective.

First, the temperature of the annealing step of the PCR is optimized to increase the amount of target polynucleotide being amplified above the amount of unrelated polynucleotide amplified. Ideally, the temperature permits the primers to hybridize with the target sequence but not with other sequences. For primers comprising a consensus segment, the temperature of the annealing step is generally at least about 55°C; preferably it is at least about 60°C. Primers which are virus-specific are more selective, and may be effective over a broader temperature range; between 50°C and 65°C.

Second, the buffer conditions are optimized. We have found that buffers supplied with commercial preparations of Taq polymerase are sometimes difficult to use, in part because of a critical dependence on the concentration of magnesium ion. PCRs performed using the oligonucleotides of this invention generally are more easily performed using a buffer such as that suggested by M. Wigler (Lisitsyn et al.). Preferably, the final PCR reaction mixture contains $(\text{NH}_4)_2\text{SO}_4$ instead of KCl as the principal ion source. Preferably, the concentration of $(\text{NH}_4)_2\text{SO}_4$ in the final reaction mixture is about 5-50 mM, more preferably about 10-30 mM, even more preferably 16 mM. The buffering component is preferably Tris, preferably at a

final concentration of about 67 mM and a pH of about 8.8. Under these conditions, the MgCl_2 concentration is less critical. Preferably the final concentration is about 1-10 mM, more preferably it is about 3-6 mM, optimally it is about 4 mM. The reaction mixture may also contain about 10 mM β -mercaptoethanol and 0.05-1 mg/mL bovine serum albumin. An especially preferred buffer is WB4 buffer
5 (67 mM Tris buffer pH 8.8, 4 mM MgCl_2 , 16 mM $(\text{NH}_4)_2\text{SO}_4$, 10 mM β -mercaptoethanol and 0.1 mg/mL albumin. Preferred conditions for performing the reaction are provided below in Example 3.

Amplification reactions using any the oligonucleotides of this invention as primers yield polynucleotide fragments encoding a portion of a DNA polymerase. These fragments can be characterized by a number of techniques known to a practitioner of ordinary skill in the art. Some non-limiting methods for
10 characterizing a fragment are as follows:

In one method, a fragment may be sequenced according to any method of sequence determination known in the art, including the Maxam & Gilbert method, or the Sanger & Nicholson method. Alternatively, the fragment may be submitted to any of the commercial organizations that provide a polynucleotide sequencing service. The fragment may optionally be cloned and/or amplified before sequencing. The
15 nucleotide sequence can be used to predict the amino acid sequence encoded by the fragment. Sequence data can be used for comparison with other sequenced DNA polymerases, either at the polynucleotide level or the amino acid level, to identify the species of herpes virus present in the original source material. Sequence data can also be used in modeling algorithms to predict antigenic regions or three-dimensional structure.

In a second method of characterizing, the size of the fragment can be determined by any suitable method, such as running on a polyacrylamide or agarose gel, or centrifuging through an appropriate density gradient. For example, for RFHV and KSHV, the fragment between VYGA and GDTD1B is about 172 bases. Hence, the length of the entire amplified fragment including primer binding regions is about 236 bases. The corresponding EBV fragment contains an additional 9 base pairs. The EBV fragment can
25 therefore be distinguished from that of RFHV or KSHV, for example, by running amplified polynucleotide fragments from each in neighboring lanes of a separating gel, or by running the EBV fragment beside suitable molecular weight standards. Polynucleotide fragments identical in size to that of RFHV and KSHV may be derived from a variant strain of one of these viruses, or a closely related species. Fragments substantially different in size are more likely to be derived from a different herpes virus.

In a third method of characterizing, a fragment can be tested by attempting to hybridize it with an oligonucleotide probe. In a preferred example, a fragment is tested for relatedness to the DNA polymerase encoding region of RFHV or KSHV. The test is conducted using a probe comprising a sequence of a DNA polymerase encoding region, or its genetic complement. Suitable probes are polynucleotides comprising
30 sequences from RFHV or KSHV, a mixture of such polynucleotides, or a polynucleotide comprising a degenerate sequence derived from RFHV and KSHV, such as the oligonucleotides listed in Table 6.

The length and nature of the probe and the hybridization conditions are selected depending on the objectives of the test. If the objective is to detect only polynucleotides from RFHV or KSHV, including minor variants, then hybridization is performed under conditions of high stringency. A sequence from the respective RFHV or KSHV DNA polymerase is used. Longer length sequences improve the specificity of
40 the test and can be used under conditions of higher stringency. Preferably, the probe will comprise a DNA

polymerase sequence of at least about 30 nucleotides; more preferably, the sequence will be at least about 50 nucleotides; even more preferably, the sequence will be at least about 75 nucleotides in length.

If the objective is to detect polynucleotides that are related to RFHV or KSHV, such as in a screening test or a test to recruit previously undescribed viruses of the RFHV/KSHV subfamily, then different conditions are chosen. Sequences from RFHV or KSHV may be used, but a mixture of the two or a degenerate probe is generally preferred. The length of the sequence and the conditions of the hybridization reaction are selected to provide sufficient specificity to exclude unwanted sequences, but otherwise provide a maximum degree of cross-reactivity amongst potential targets. Suitable conditions can be predicted using the formulas given earlier, by calculating the T_m and then calculating the corresponding temperature for the maximum degree of mismatch to be tolerated. The suitability of the conditions can be tested empirically by testing the cross-reactivity of the probes with samples containing known target polynucleotides encoding herpes DNA polymerases.

The minimum degree of complementarity required for a stable duplex to form under the conditions of the assay will determine what DNA polymerase sequences will hybridize with the probe. Consider, for example, a target obtained from a human or non-human primate, amplified to produce a fragment corresponding to bases 330-501 of Figure 1, and then probed with the corresponding fragment of the RFHV polynucleotide. According to the data in Table 2, if the hybridization reaction is performed under conditions that require only about 50% identity for a stable duplex to form, the probe may hybridize with targets from any of the sequenced gamma herpes DNA polymerase genes, including EBV and sHV1. If the reaction is performed under conditions that require at least about 62% identity between probe and target, preferably at least about 65% identity, more preferably at least about 68% identity, and even more preferably at least about 70% identity for a stable duplex to form, the assay will detect a target polynucleotide from RFHV, KSHV, or from a related herpes virus DNA polymerase that has not yet been sequenced. Polynucleotides encoding DNA polymerase from EBV or sHV1 are not expected to form a stable duplex under these conditions. A polynucleotide encoding DNA polymerase from eHV2 is not expected to be present in the DNA tested, because eHV2 is not believed to be capable of infecting primates.

It is possible to combine characterization by size and characterization by hybridization. For example, the amplified polynucleotide may be separated on a gel of acrylamide or agarose, blotted to a membrane of suitable material, such as nitrocellulose, and then hybridized with a probe with a suitable label, such as ^{32}P . The presence of the label after washing reflects the presence of hybridizable material in the sample, while the migration distance compared with appropriate molecular weight standards reflects the size of the material. A fragment sequence hybridizing with one of the aforementioned probes under conditions of high stringency but having an unexpected size would indicate a DNA polymerase sequence with a high degree of identity to the probe, but distinct from RFHV or KSHV.

Use of polynucleotides and oligonucleotides to detect herpes virus infection

Polynucleotides encoding herpes virus DNA polymerase, and synthetic oligonucleotides based thereupon, as embodied in this invention, are useful in the diagnosis of clinical conditions associated with herpes virus infection. For example, the presence of detectable herpes DNA polymerase in a clinical

sample may suggest that the respective herpes virus participated as an etiologic agent in the development of the condition. The presence of polymerase in a particular tissue, but not in surrounding tissue, may be useful in the localization of an infected lesion. Differentiating between gamma herpes virus and other herpes viruses in clinical samples, or differentiating between RFHV, KSHV, and EBV, may be useful in predicting the clinical course of an infection or selecting a drug suitable for treatment.

In addition, since DNA polymerase is actively involved in the replication of the herpes virus, it may be preferred over other markers for certain applications. DNA polymerase is not expressed in the latent state of Varicella-Zoster herpes, but is expressed in the replicative state (Meier et al.). Thus, an assay for DNA polymerase may help determine whether an individual infected with gamma herpes is currently in an active phase of the disease. The capacity of a strain of HSV1 to move from the eye to the brain is related to DNA polymerase activity (Yeung et al.). Thus, an assay for DNA polymerase may help predict the aggressiveness or invasiveness of a gamma herpes infection.

The procedures for conducting diagnostic tests are extensively known in the art, and are routine for a practitioner of ordinary skill. Generally, to perform a diagnostic method of this invention, one of the compositions of this invention is provided as a reagent to detect a target in a clinical sample with which it reacts. For example, a polynucleotide of this invention may be used as a reagent to detect a DNA or RNA target, such as might be present in a cell infected with a herpes virus. A polypeptide of this invention may be used as a reagent to detect a target with which it is capable of forming a specific complex, such as an antibody molecule or (if the polypeptide is a receptor) the corresponding ligand. An antibody of this invention may be used as a reagent to detect a target it specifically recognizes, such as a polypeptide expressed by virally infected cells.

The target is supplied by obtaining a suitable tissue sample from an individual for whom the diagnostic parameter is to be measured. Relevant test samples are those obtained from individuals suspected of harboring a herpes virus. Many types of samples are suitable for this purpose, including those that are obtained near the suspected site of infection or pathology by biopsy or surgical dissection, in vitro cultures of cells derived therefrom, solubilized extracts, blood, and blood components. If desired, the target may be partially purified from the sample or amplified before the assay is conducted. The reaction is performed by contacting the reagent with the sample under conditions that will allow a complex to form between the reagent and the target. The reaction may be performed in solution, or on a solid tissue sample, for example, using histology sections. The formation of the complex is detected by a number of techniques known in the art. For example, the reagent may be supplied with a label and unreacted reagent may be removed from the complex; the amount of remaining label thereby indicating the amount of complex formed. Further details and alternatives for complex detection are provided in the descriptions that follow.

To determine whether the amount of complex formed is representative of herpes infected or uninfected cells, the assay result is preferably compared with a similar assay conducted on a control sample. It is generally preferable to use a control sample which is from an uninfected source, and otherwise similar in composition to the clinical sample being tested. However, any control sample may be suitable provided the relative amount of target in the control is known or can be used for comparative purposes. It is often preferable to conduct the assay on the test sample and the control sample

simultaneously. However, if the amount of complex formed is quantifiable and sufficiently consistent, it is acceptable to assay the test sample and control sample on different days or in different laboratories.

Accordingly, polynucleotides encoding DNA polymerase of the RFHV/KSHV subfamily, and the synthetic oligonucleotides embodied in this invention, can be used to detect gamma herpes virus polynucleotide that may be present in a biological sample. General methods for using polynucleotides in specific diagnostic assays are well known in the art: see, e.g., Patent Application JP 5309000 (Iatron).

An assay employing a polynucleotide reagent may be rendered specific, for example: 1) by performing a hybridization reaction with a specific probe; 2) by performing an amplification with a specific primer, or 3) by a combination of the two.

To perform an assay that is specific due to hybridization with a specific probe, a polynucleotide is chosen with the required degree of complementarity for the intended target. Preferred probes include polynucleotides of at least about 16 nucleotides in length encoding a portion of the DNA polymerase of RFHV, KSHV, or a member of the RFHV/KSHV subfamily. Increasingly preferred are probes comprising at least about 18, 20, 25, 30, 50, or 100 nucleotides of the DNA polymerase encoding region. Also preferred are degenerate probes capable of forming stable duplexes with polynucleotides of the RFHV/KSHV subfamily, but not with that of other herpes viruses.

The probe is generally provided with a label. Some of the labels often used in this type of assay include radioisotopes such as ^{32}P and ^{33}P , chemiluminescent or fluorescent reagents such as fluorescein, and enzymes such as alkaline phosphatase that are capable of producing a colored solute or precipitant. The label may be intrinsic to the reagent, it may be attached by direct chemical linkage, or it may be connected through a series of intermediate reactive molecules, such as a biotin-avidin complex, or a series of inter-reactive polynucleotides. The label may be added to the reagent before hybridization with the target polynucleotide, or afterwards. To improve the sensitivity of the assay, it is often desirable to increase the signal ensuing from hybridization. This can be accomplished by using a combination of serially hybridizing polynucleotides or branched polynucleotides in such a way that multiple label components become incorporated into each complex. See U.S. Patent No. 5,124,246 (Urdea et al.).

If desired, the target polynucleotide may be extracted from the sample, and may also be partially purified. To measure viral particles, the preparation is preferably enriched for DNA; to measure active transcription of DNA polymerase, the preparation is preferably enriched for RNA. Generally, it is anticipated that the level of polynucleotide of a herpes virus will be low in clinical samples: there may be just a few copies of DNA encoding the polymerase per cell where the virus is latent, or up to several hundred copies of DNA per cell where the virus is replicating. The level of mRNA will be higher in cells where the polymerase is actively expressed than those where the polymerase gene is inactive. It may therefore be desirable to enhance the level of target in the sample by amplifying the DNA or RNA. A suitable method of amplification is a PCR, which is preferably conducted using one or more of the oligonucleotide primers embodied in this invention. RNA may be amplified by making a cDNA copy using a reverse transcriptase, and then conducting a PCR using the aforementioned primers.

The target polynucleotide can be optionally subjected to any combination of additional treatments, including digestion with restriction endonucleases, size separation, for example by electrophoresis in agarose or polyacrylamide, and affixation to a reaction matrix, such as a blotting material.

Hybridization is allowed to occur by mixing the reagent polynucleotide with a sample suspected of containing a target polynucleotide under appropriate reaction conditions. This may be followed by washing or separation to remove unreacted reagent. Generally, both the target polynucleotide and the reagent must be at least partly equilibrated into the single-stranded form in order for complementary sequences to hybridize efficiently. Thus, it may be useful (particularly in tests for DNA) to prepare the sample by standard denaturation techniques known in the art.

The level of stringency chosen for the hybridization conditions depends on the objective of the test. If it is desired that the test be specific for RFHV or KSHV, then a probe comprising a segment of the respective DNA polymerase is used, and the reaction is conducted under conditions of high stringency. For example, a preferred set of conditions for use with a preferred probe of 50 nucleotides or more is 6 x SSC at 37°C in 50% formamide, followed by a wash at low ionic strength. This will generally require the target to be at least about 90% identical with the polynucleotide probe for a stable duplex to form. The specificity of the reaction for RFHV or KSHV can also be increased by increasing the length of the probe used. Thus, longer probes are particularly preferred for this application of the invention.

Alternatively, if it is desired that the test be able to detect gamma herpes viruses related to RFHV or KSHV, then a lower stringency is used. Suitable probes include fragments from the RFHV or KSHV DNA polymerase, a mixture thereof, or degenerate oligonucleotides such as those listed in Table 6.

Appropriate hybridization conditions are determined to permit hybridization of the probe only to DNA polymerase sequences that have the desired degree of identity with the probe. The stringency required depends on the length of the polynucleotide probe, and the degree of identity between the probe and the desired target sequence. Consider, for example, a probe consisting of the KSHV polynucleotide fragment between the hybridization sites of DFASA and GDTD1B. Conditions requiring a minimum identity of 55% would result in a stable duplex formed with a corresponding polynucleotide of KSHV, RFHV, and EBV; conditions requiring a minimum identity of 68% would result in a stable duplex forming with a polynucleotide from KSHV, RFHV, or a related polynucleotide, but not EBV; conditions requiring a minimum identity of 80% would result in a stable duplex forming with a polynucleotide from KSHV, but not RFHV or EBV (see Table 2).

Conditions can be estimated beforehand using the formula given earlier. Preferably, the exact conditions are confirmed by testing the probe with separate samples known to contain polynucleotides, both those desired to be detected and those desired to go undetected in the assay. Such samples may be provided either by synthesizing the polynucleotides from published sequences, or by extracting and amplifying DNA from tissues believed to be infected with the respective herpes virus. Determining hybridization conditions is a matter of routine adjustment for a practitioner of ordinary skill, and does not require undue experimentation. Since eHV2, sHV1 and EBV are more closely identical to RFHV or KSHV than members of the alpha and beta subfamilies, conditions that exclude polynucleotides of those viruses will generally also exclude the other herpes viruses listed in Table 1. In addition, if it is believed that certain viruses will not be present in the sample to be tested in the ultimate determination (such as eHV2 in a human tissue sample), then the corresponding target sequences may optionally be omitted when working out the conditions of the assay. Thus, conditions can be determined that would permit an oligonucleotide probe such as LSGGA, CTDPA, KMLEA or GISPA to form a stable duplex both with

polypeptides comprising SEQ. ID NO:1 and SEQ. ID NO:3, but not a sequence selected from the group consisting of SEQ. ID NO:23 to SEQ. ID NO:29. Conditions can also be determined that would permit an oligonucleotide probe such as PCLNA (SEQ. ID NO:21) or any suitable fragment comprising at least 18 or more consecutive bases of SEQ. ID NO:1 or SEQ. ID NO:3 to form a stable duplex both with a polynucleotide comprising SEQ. ID NO:1 and with a polynucleotide comprising SEQ. ID NO:3, but not a polynucleotide comprising one of SEQ. ID NO:23 to SEQ. ID NO:29.

Alternatively, to conduct an assay that is specific due to amplification with a specific primer. DNA or RNA is prepared from the biological sample as before. Optionally, the target polynucleotide is pre-amplified in a PCR using primers which are not species specific, such as those listed in Table 4. The target is then amplified using specific primers, such as those listed in Table 6 or Table 7. For example, if it is desired that the test be specific for RFHV, then VASGA, ILPCA, PIEAB, PEARB, or a combination thereof may be used. If it is desired that the test be specific for KSHV, then SGILA, CLNIA, IEASB, EARFB, or a combination thereof may be used. If it is desired that the test be able to detect gamma herpes viruses related to RFHV or KSHV, then degenerate or cross-reactive probes, such as those listed in Table 6, or a combination thereof may be used. In a preferred embodiment, two rounds of amplification are performed, using oligonucleotide primers in a nested fashion: virus-specific or non-specific in the first round; virus-specific in the second round. This provides an assay which is both sensitive and specific.

Use of a specific primer during amplification is sufficient to provide the required specificity. A positive test may be indicated by the presence of sufficient reaction product at the end of the amplification series. Amplified polynucleotide can be detected, for example, by blotting the reaction mixture onto a medium such as nitrocellulose and staining with ethidium bromide. Alternatively, a radiolabeled substrate may be added to the mixture during a final amplification cycle; the incorporated label may be separated from unincorporated label (e.g., by blotting or by size separation), and the label may be detected (e.g. by counting or by autoradiography). If run on a gel of agarose or polyacrylamide, the size of the product may help confirm the identity of the amplified fragment. Specific amplification can also be followed by specific hybridization, by using the amplification mixture obtained from the foregoing procedure as a target source for the hybridization reaction outlined earlier.

Use of polynucleotides for gene therapy

Embodied in this invention are pharmaceuticals comprising virus-specific polynucleotides, polypeptides, or antibodies as an active ingredient. Such compositions may decrease the pathology of the virus or infected cells on their own, or render the virus or infected cells more susceptible to treatment by non-specific pharmaceutical compounds.

Polynucleotides of this invention encoding part of a herpes virus DNA polymerase may be used, for example, for administration to an infected individual for purposes of gene therapy (see generally U.S. Patent No. 5,399,346: Anderson et al.). The general principle is to administer the polynucleotide in such a way that it interferes with the expression of the corresponding gene, such as by complexing with the gene itself or with the RNA transcribed from the gene. Entry of the polynucleotide into the cell is facilitated by suitable techniques known in the art, such as providing the polynucleotide in the form of a suitable vector,

or encapsulation of the polynucleotide in a liposome. The polynucleotide may be injected systemically, or provided to the site of infection by an antigen-specific homing mechanism, or by direct injection.

A preferred mode of gene therapy is to provide the polynucleotide in such a way that it will replicate inside the cell, enhancing and prolonging the interference effect. Thus, the polynucleotide is operatively
 5 linked to a suitable promoter, such as the natural promoter of the corresponding gene, a heterologous promoter that is intrinsically active in infected cells, or a heterologous promoter that can be induced by a suitable agent. Preferably, the construct is designed so that the polynucleotide sequence operatively linked to the promoter is complementary to the sequence of the corresponding gene. Thus, once
 10 integrated into the cellular genome, the transcript of the administered polynucleotide will be complementary to the transcript of the gene, and capable of hybridizing with it. This approach is known as anti-sense therapy.

RFHV/KSHV subfamily polypeptides with DNA polymerase activity and fragments thereof

15 The RFHV and KSHV polynucleotides shown in Figure 1 each have an open reading frame. The polypeptides encoded are respectively designated SEQ. ID NO:2 and SEQ. ID NO:4. The polypeptides have a significant number of homologous residues to DNA polymerases of other sequenced herpes viruses. They are more closely identical to each other within this fragment than to the corresponding
 20 fragment of the other sequenced viruses. The fragment is believed to encompass residues that are near the nucleotide substrate binding site of the intact protein. This region may play a role in the catalytic activity of the polymerase. Polypeptides with DNA polymerase activity from other members of the RFHV/KSHV subfamily are expected to share a large proportion of identical residues over this region. In general, residues conserved between RFHV and KSHV are expected to be relatively conserved within the subfamily.

25 Beginning at about amino acid 89 of SEQ. ID NO:2, there is a linear sequence of about 46 residues that is shared identically between the DNA polymerase of RFHV and KSHV. Beginning at about amino acid 88 of SEQ. ID NO:2, there is a linear sequence of about 31 residues shared between the DNA polymerase of RFHV and eHV2. The sequence shared with eHV2 is listed separately in SEQ. ID NO:112. Also contained in SEQ. ID NO:112 is a sequence of about 26 amino acids shared between RFHV and
 30 sHV1, and two sequences of 12 amino acids shared between RFHV and EBV. Beginning at about amino acid 10 of SEQ. ID NO:4, there is a linear sequence of about 15 residues shared between KSHV and various other gamma herpes viruses. This shared sequence is listed separately in SEQ. ID NO:113. The longest sequence contained in SEQ. ID NOS:2 or 4 but not in SEQ. ID NOS:112 or 113 that is shared with other known herpes virus DNA polymerases is 10 amino acids in length. Hence, any fragment of the
 35 RFHV or KSHV DNA polymerase protein sequence that is 11 amino acids or longer, and not in SEQ. ID NOS:112 or 113, is believed to be specific for the RFHV/KSHV subfamily, or species and variants therein.

This invention embodies both intact DNA polymerase from herpes viruses of the RFHV/KSHV subfamily, and any fragment thereof that is specific for the subfamily. Preferred DNA polymerase fragments of this invention are at least 11 amino acids in length; more preferably they are about 12 amino
 40 acids in length, more preferably they are at least about 15 amino acids in length; even more preferably

they are at least about 20 amino acids in length, still more preferably they are at least about 30 amino acids in length.

The amino acid sequence of the RFHV and KSHV DNA polymerase fragments can be used to identify virus-specific and cross-reactive antigenic regions.

5 In principle, a specific antibody could recognize any amino acid difference between sequences that is not also shared by the species from which the antibody is derived. Antibody binding sites are generally big enough to encompass 5-9 amino acid residues of an antigen, and are quite capable of recognizing a single amino acid difference. Specific antibodies may be part of a polyclonal response arising spontaneously in animals infected with a virus expressing the DNA polymerase. Specific antibodies may also be induced by
10 injecting an experimental animal with either the intact polymerase or a polymerase fragment.

Thus, any peptide of 5 amino acids or more that is unique to RFHV or KSHV is a potential virus-specific antigen, and could be recognized by a RFHV- or KSHV-specific antibody. Peptides of at least 5 amino acids shared between RFHV and KSHV, but not EBV, eHV2 and sHV1 are potential RFHV/KSHV subfamily specific antigens.

15 Some examples of preferred peptides are shown in Table 8. Practitioners in the art will immediately recognize that other peptides with similar specificities may be designed by minor alterations to the length of the peptides listed and/or moving the frame of the peptide a few residues in either direction.

The Class I peptides shown in Table 8 are conserved between all known DNA polymerase polypeptide sequences of the gamma herpes virus subfamily. An antibody directed against one such DNA
20 polymerase in this region is expected to cross-react with the others. Class II peptides are conserved between RFHV and KSHV, but not with sHV1 and EBV. An antibody directed against this region is expected to cross-react between RFHV, KSHV, and other viruses of the RFHV/KSHV subfamily. Class III peptides are different between RFHV and KSHV. An antibody binding to this region, particularly to non-identical residues, is expected to distinguish the RFHV DNA polymerase from the KSHV DNA
25 polymerase.

TABLE 8: Antigen Peptides		
Specificity	Sequence	SEQ. ID NO:
Class I: Shared amongst some members of the RFHV/KSHV subfamily and other gamma herpes viruses	Peptides contained within RTILDKQQLAIKVTCNAVYGFTGVASGILPCL (SEQ. ID NO:112)	
	Peptides contained within SIIQAHNLCYSTLIP (SEQ. ID NO:113)	
	IAETVTL	73
Class II: Shared amongst members of the RFHV/KSHV subfamily ¹	PDDYETF	90
	KRKEIRK	91
	LAKRKEI	92
	LASCTDP	93
	VASGILP ²	74
	GILPCLN	75
	CLNIAET	76
	QGRKMLE	77
	SQAFVE	78
	ARFKVI	73
Class III: RFHV or KSHV specific ³	TGSALHG (RFHV)	94
	PGDSLHL (KSHV)	95
	SALHGHP (RFHV)	96
	DSLHLHP (KSHV)	97
	GHPELTP (RFHV)	98
	LHPHLGP (KSHV)	99
	HLSGGTV (RFHV)	100
	VLSGGLV (KSHV)	101
	TDPTMRT (RFHV)	102
	TDPALKT (KSHV)	103
	LETSQAF (RFHV)	80
	LERSQAF (KSHV)	81
	EGISPTA (RFHV)	82
	EAISPER (KSHV)	83
	ADLLQRP (RFHV)	84
	AGLLRRP (KSHV)	85

TABLE 8: Antigen Peptides		
Specificity	Sequence	
	SEQ. ID NO:	
	QRPIEAS	(RFHV)
	RRPIDVS	(KSHV)
	IEASPEA	(RFHV)
	IDVSPDA	(KSHV)
¹ - Not shared with eHV2, sHV1 or EBV, except where indicated ² - Also shared with eHV2 but not with sHV1 or EBV ³ - Not shared with any other sequenced herpes virus; may be present in some unsequenced RFHV/KSHV subfamily viruses		

Particularly preferred peptides from Classes II and III are QGRKMLE, ARFKVI, RRPIDVS, QRPIEAS, IEASPEA, and IDVSPDA. Given the complete sequence of a DNA polymerase from RFHV and/or KSHV, virus- or subfamily-specific peptides can be predicted for other regions of the molecule by a similar analysis.

Preparation of polypeptides

Polypeptides of this invention, including intact protein, protein fragments, and antigenic regions, can be prepared by several different methods, all of which will be known to a practitioner of ordinary skill. For example, the appropriate strand of the full-length cDNA can be operatively linked to a suitable promoter, and transfected into a suitable host cell. The host cell is then cultured under conditions that allow transcription and translation to occur, and the polypeptide is subsequently recovered. For a description of the expression and recovery of a herpes virus DNA polymerase by transfecting *S. cerevisiae*, see Haffey et al. and Patent Application EP 0337441. For a description of the expression of another herpes virus protein in mammalian cells, see U.S. Patent No. 5,244,792 (Burke et al.).

Polypeptides may also be prepared directly from sequence data by chemical synthesis. Several methods of synthesis are known in the art. A preferred method is the solid-phase Merrifield technique. Alternatively, a polynucleotide encoding the desired polypeptide may be prepared by any of the methods described earlier, and translated using an in vitro translation system, such as the rabbit reticulocyte system. See, e.g., Dorsky et al.

Use of polypeptides to assess herpes virus infection

The polypeptides embodied in this invention may be used to detect or assess the status of a herpes virus infection in an individual in several different applications.

In one application, a polypeptide encoding a portion of a herpes virus DNA polymerase is supplied as a reagent for an assay to detect the presence of antibodies that can specifically recognize it. Such antibodies may be present, for example, in the circulation of an individual with current or past herpes virus infection.

The presence of antibodies to DNA polymerase in the circulation may provide an early indication of a pathological condition. The antibody to hepatitis B virus DNA polymerase is an early indication of acute hepatitis B virus infection (WO 8904964: Fietelson et al.). Antibodies to DNA polymerase are useful in diagnosis of nasopharyngeal carcinoma (Lin et al., Liu et al.). Similarly, it may be useful to monitor for the presence of antibodies to DNA polymerase of KSHV in HIV-infected humans before Kaposi's sarcoma lesions are clinically apparent.

Suitable clinical samples in which to measure antibody levels include serum or plasma from an individual suspected of having a gamma herpes virus infection. The presence of the antibody is determined, for example, by an immunoassay.

A number of immunoassay methods are established in the art for performing the quantitation of antibody using viral peptides (see, e.g., U.S. Patent No. 5,350,671: Houghton et al.). For example, the test sample potentially containing the specific antibody may be mixed with a pre-determined non-limiting amount of the reagent polypeptide. The reagent may contain a directly attached label, such as an enzyme or a radioisotope. For a liquid-phase assay, unreacted reagents are removed by a separation technique, such as filtration or chromatography. Alternatively, the antibody in the sample may be first captured by a reagent on a solid phase. This may be, for example, the specific polypeptide, an anti-immunoglobulin, or protein A. The captured antibody is then detected with a second reagent, such as the specific polypeptide, anti-immunoglobulin, or protein A with an attached label. At least one of the capture reagent or the detecting reagent must be the specific polypeptide. In a third variation, cells or tissue sections containing the polypeptide may be overlaid first with the test sample containing the antibody, and then with a detecting reagent such as labeled anti-immunoglobulin. In all these examples, the amount of label captured in the complex is positively related to the amount of specific antibody present in the test sample. Similar assays can be designed in which antibody in the test sample competes with labeled antibody for binding to a limiting amount of the specific peptide. The amount of label in the complex is then negatively correlated with the amount of specific antibody in the test sample. Results obtained using any of these assays are compared between test samples, and control samples from an uninfected source.

By selecting the reagent polypeptide appropriately, antibodies of a desired specificity may be detected. For example, if the intact DNA polymerase is used, or a fragment comprising regions that are conserved between herpes virus, then antibodies detected in the test samples may be virus specific, cross-reactive, or both. A reagent of this nature is preferred for a general screening assay for herpes virus infection. To render the assay specific for antibodies directed either against RFHV or against KSHV, antigen peptides comprising non-conserved regions of the appropriate viral DNA polymerase are selected, such as those listed in Class III of Table 8. Preferably, a mixture of such peptides is used. To simultaneously detect antibodies against RFHV, KSHV, and closely related viruses of the gamma herpes family, but not SHV1 and EBV, antigen peptides are selected with the properties of those listed in Class II of Table 8. Preferably, a mixture of such peptides is used.

Antibodies stimulated during a herpes virus infection may subside once the infection resolves, or they may persist as part of the immunological memory of the host. In the latter instance, antibodies due to current infection may be distinguished from antibodies due to immunological memory by determining the class of the antibody. For example, an assay may be conducted in which antibody in the test sample is

captured with the specific polypeptide, and then developed with labeled anti-IgM or anti-IgG. The presence of specific antibody in the test sample of the IgM class indicates ongoing infection, while the presence of IgG antibodies alone indicates that the activity is due to immunological memory of a previous infection or vaccination.

5 In another application of the invention, herpes virus encoded DNA polymerase is isolated from a sample, and the amount present is determined by an enzymatic assay. Assays for DNA polymerase activity in a biological sample can be conducted, for example, by extracting the polymerase and performing a suitable polymerization assay. The polymerase may be solubilized by standard techniques from a solid tissue sample or tissue homogenate, for example, by using non-ionic detergents such as TRITON™ X-100
10 or deoxycholate. Alternatively, if the polymerase is secreted by infected cells, it may be possible to perform the assay on a liquid sample, such as plasma or lymph.

Methods for conducting DNA polymerase assays are known in the art. For example, a polymerization mixture is prepared that contains the putative DNA polymerase, a mixture of nucleotides containing at least one labeled nucleotide, a DNA template such as M13 phage DNA, and, if necessary, a
15 regulatory subunit. The mixture is incubated at 37°C for a time sufficient to allow polymerization to occur. Polymerase activity, or lack thereof, is determined by measuring the amount of incorporation of label into the polynucleotide. Optimal conditions for conducting a DNA polymerase assay are readily ascertained without undue experimentation by a practitioner of ordinary skill in the art. For example, conditions for the DNA polymerase of HSV have been published by O'Donnell et al. Optimal conditions for DNA polymerase
20 from RFHV and KSHV are expected to be analogous.

Use of polypeptides as components in active vaccines

An example of how polypeptides embodied in this invention can be effectively used in treatment is
25 through vaccination.

In one embodiment of this application, the polypeptide is administered as part of an active vaccine in order to stimulate antibodies that will react against the pathogenic organism; in this case, a herpesvirus of the RFHV/KSHV subfamily. The development of active vaccines from isolated herpes virus components is known in the art: see, e.g., U.S. Patent Nos. 5,171,568 (Berke et al.). This type of vaccine is especially
30 useful in prophylaxis, since the antibodies it stimulates may be able to neutralize subsequently encountered organisms before they have a chance to invade the host's cells and begin a replicative cycle.

Methods for preparing and administering polypeptide vaccines are known in the art. Peptides may be capable of eliciting an immune response on their own, or they may be rendered more immunogenic by chemical manipulation, such as cross-linking or attaching to a protein carrier like KLH. Preferably, the
35 vaccine also comprises an adjuvant, such as alum, muramyl dipeptides, liposomes, or DETOX™. The vaccine may optionally comprise auxiliary substances such as wetting agents, emulsifying agents, and organic or inorganic salts or acids. It also comprises a pharmaceutically acceptable excipient which is compatible with the active ingredient and appropriate for the route of administration. The desired dose for peptide vaccines is generally from 10 µg to 1 mg, with a broad effective latitude. The vaccine is preferably
40 administered first as a priming dose, and then again as a boosting dose, usually at least four weeks later.

Further boosting doses may be given to enhance the effect. The dose and its timing are usually determined by the person responsible for the treatment.

In another embodiment of this application, the polypeptide is an active ingredient of a vaccine designed to stimulate specific cytotoxic T lymphocytes. This type of vaccine may be especially useful in the treatment of a herpes virus infection already present in a subject. The DNA polymerase of a herpes virus is a suitable target for a cytotoxic T cell vaccine; not only because of its relatively conserved structure, but also because it is an important internal component of the virus. External virus components are expressed by circulating intact virus and defective viral particles, and have the potential of diverting the immune system away from infected cells. However, internal viral components are expressed extracellularly only by virally infected cells, which display them in the context of histocompatibility class I molecules. Such cells are ideal targets for specific cytotoxic T cells, as they represent the site of viral replication and are therefore the virus's most vulnerable location within the host.

Cytotoxic T cell vaccines may comprise different antigenic regions than those required to stimulate antibodies. T cell epitopes are different from antibody epitopes; they generally depend less on conformational context, and/or develop from regions of the peptide capable of folding into an amphipathic alpha-helix. Cytotoxic T cell vaccines may also comprise additional active ingredients or cytokines which may enhance the presentation of the peptide to the T cell population and/or assist in the recruitment of cells of the cytotoxic T cell lineage.

In a variation of either of the preceding embodiments, the immunizing peptide is provided not as an isolated protein or protein fragment, but in the form of an expression vector. A polynucleotide encoding the peptide is operatively linked to suitable controlling elements of transcription and translation, and then transfected into a suitable vector. Suitable vectors include a vaccinia virus, or an attenuated form of a herpes virus.

Use of polypeptides to design or screen anti-viral drugs

Interfering with the DNA polymerase gene or gene product would modify the infection process, or the progress of this disease. It is an objective of this invention to provide a method by which useful pharmaceutical compositions and methods of employing such compounds in the treatment of gamma herpes virus infection can be developed and tested. Particularly preferred are pharmaceutical compounds useful in treating infections by RFHV and KSHV. Suitable drugs are those that interfere with transcription or translation of the DNA polymerase gene, and those that interfere with the catalytic function of the polypeptide encoded by the gene. It is not necessary that the mechanism of interference be known; only that the interference be preferential for reactions associated with the infectious process.

Preferred drugs include those that competitively interfere with the binding of the DNA polymerase to the substrate nucleotide triphosphate, the DNA template. Also preferred are nucleotide analogs that can be incorporated into the polymerizing strand synthesized by the enzyme, but form a dead-end complex that prevents further polymerization (Reardon et al.) Some non-limiting examples of preferred drugs which may be tested by the procedures described herein are aphidicolin, acyclovir, gancyclovir, foscarnet, oosporein, BHCG, PMEA, other nucleotide analogs, isotrenes of these compounds, and other compounds that are structurally or functionally related to those listed.

Also preferred are drugs that interfere with the association of DNA polymerase with regulatory subunits that are necessary for catalytic activity. As described earlier, the UL42 subunit is essential for the DNA polymerase activity of HSV during the replicative process. Small peptides designed from the UL42 sequence inhibit binding between UL42 and the DNA polymerase, and are effective inhibitors of polymerase activity (U.S. Patent No. 5,223,391: Coen et al.). The C-terminal region of the HSV DNA polymerase is responsible for binding the UL42 subunit. It is therefore expected that under certain conditions (such as those required for viral replication), the RFHV and KSHV DNA polymerase will require a regulatory subunit which may or may not be an analog of UL42, in order to express full polymerase activity. Thus, peptides functionally equivalent to those described in U.S. 5,223,391, adapted appropriately for gamma herpes viruses, are expected to have inhibitory activity and be therapeutically useful.

This invention provides methods for screening pharmaceutical candidates to determine which are suitable for clinical use. The methods may be brought to bear on antiviral compounds that are currently known, and those which may be designed in the future.

The method involves combining an active DNA polymerase with the pharmaceutical candidate, and determining whether the biochemical function is altered by the pharmaceutical candidate. The DNA polymerase may be any fragment encoded by the DNA polymerase gene of RFHV or KSHV that has DNA polymerase activity. Suitable fragments may be obtained by expressing a genetically engineered polypeptide encoding the active sites of the molecule, or by cleaving the DNA polymerase with proteases and purifying the active fragments. In a preferred embodiment, the entire DNA polymerase is provided. The reaction mixture will also comprise a suitable DNA template, substrate deoxyribonucleotide triphosphates, and whatever regulatory subunits are necessary for the reaction to proceed. One embodiment of the screening method is to perform a DNA polymerase assay in vitro. The DNA polymerase is provided in isolated form, and mixed with the other reacting compounds in a suitable buffer. A DNA polymerase assay is conducted and monitored as outlined in an earlier section. The amount of polymerase activity per mole or per gram of enzyme in the reaction mixture is measured, for example, by the rate of incorporation of radiolabeled nucleotide into the synthesized strand. The effect of the candidate drug may be determined by running two reactions in parallel, both with the same mixture of reacting substances except that one contains the candidate. Alternatively, the effect of the candidate drug may be determined by adding it to a polymerase reaction in progress, and determining whether the reaction rate is altered. A desirable effect is one that eliminates or decreases the rate of synthesis of the labeled DNA.

Another embodiment of the screening method is to express a polynucleotide encoding an active region of the DNA polymerase in a host cell. Transfection with the polynucleotide may enhance the rate of replication of the host cell, in which case the activity of the polymerase can be monitored by measuring the rate of replication of the cells. Alternatively, activity of the polymerase may be measured as the rate of production of a product, such as a labeled polynucleotide, inside the cell. The effect of the drug can therefore be determined by following its effect on DNA polymerase activity. Suitable control experiments include measuring DNA polymerase activity in the absence of the drug, and measuring the effect of the drug on untransformed host cells.

A further embodiment of the screening method is to measure binding of the pharmaceutical candidate to the isolated DNA polymerase, or a fragment thereof. Compounds that bind to the catalytic site or the

binding site of a regulatory subunit are expected to interfere with DNA polymerase activity. Thus, the entire DNA polymerase, or a fragment comprising the catalytic site or the binding site of a regulatory subunit, is mixed with the pharmaceutical candidate. Binding of the candidate can be measured directly, for example, by providing the candidate in a radiolabeled or stable-isotope labeled form. The presence of label bound to the polymerase can be determined, for example, by precipitating the polymerase with a suitable antibody, or by providing the polymerase attached to a solid phase, and washing the solid phase after the reaction. Binding of the candidate to the polymerase may also be observed as a conformational change in the polymerase, detected for example by difference spectroscopy, nuclear magnetic resonance, or circular dichroism. Alternatively, binding may be determined in a competitive assay: for example, DNA polymerase is mixed with the candidate, and then labeled nucleotide or a fragment of a regulatory subunit is added later. Binding of the candidate to the biochemically relevant site should inhibit subsequent binding of the labeled compound.

This invention also provides for the development of pharmaceuticals for the treatment of herpes infection by rational drug design. See, generally, Hodgson, and Erickson et al. In this embodiment, the three-dimensional structure of the DNA polymerase is determined, either by predictive modeling based on the amino acid sequence, or preferably, by experimental determination. Experimental methods include antibody mapping, mutational analysis, and the formation of anti-idiotypes. Especially preferred is X-ray crystallography. Knowing the three-dimensional structure of the protease, especially the orientation of important amino acid groups near the nucleotide and regulatory subunit binding sites, a compound is designed de novo, or an existing compound is suitably modified. The designed compound will have an appropriate charge balance, hydrophobicity, and/or shape to enable it to attach near an active site of the polymerase, and sterically interfere with the normal biochemical function of that site. Preferably, compounds designed by this method are subsequently tested in a drug screening assay, such as those outlined above.

Antibodies against DNA polymerase and their preparation

The amino acid sequence of the herpes virus DNA polymerases embodied herein are foreign to the hosts they infect. The polymerases are large, and potentially comprise a large number of antigenic regions. They are sequestered within the capsid of the respective virus, and are unlikely to be mimicking host antigens. It is therefore expected that these polymerases will be substantially immunogenic. Antibodies may be generated against them spontaneously by a vertebrate host during the course of an infection with an intact herpes virus. It is also expected that antibodies can be raised in experimental animals by injection of isolated DNA polymerase and suitably prepared fragments. These expectations are supported by the observations described in Example 5 and Example 10.

Antibodies against a polypeptide are generally prepared by any method known in the art. To stimulate antibody production in an animal experimentally, it is often preferable to enhance the immunogenicity of a polypeptide by such techniques as polymerization with glutaraldehyde, or combining with an adjuvant, such as Freund's adjuvant. The immunogen is injected into a suitable experimental animal: preferably a rodent for the preparation of monoclonal antibodies; preferably a larger animal such

as a rabbit or sheep for preparation of polyclonal antibodies. It is preferable to provide a second or booster injection after about 4 weeks, and begin harvesting the antibody source no less than about 1 week later.

Sera harvested from the immunized animals provide a source of polyclonal antibodies. Detailed procedures for purifying specific antibody activity from a source material are known within the art. If
5 desired, the specific antibody activity can be further purified by such techniques as protein A chromatography, ammonium sulfate precipitation, ion exchange chromatography, high-performance liquid chromatography and immunoaffinity chromatography on a column of the immunizing polypeptide coupled to a solid support.

10 Polyclonal antibodies raised by immunizing with an intact DNA polymerase or a fragment comprising conserved sequences may be cross-reactive between herpes viruses. Antibodies that are virus or subfamily specific may be raised by immunizing with a suitably specific antigen, such as those listed above in Table 8. Alternatively, polyclonal antibodies raised against a larger fragment may be rendered specific by removing unwanted activity against other virus DNA polymerases, for example, by passing the antibodies over an adsorbant made from those polymerases and collecting the unbound fraction.

15 Alternatively, immune cells such as splenocytes can be recovered from the immunized animals and used to prepare a monoclonal antibody-producing cell line. See, for example, Harrow & Lane (1988), U.S. Patent Nos. 4,472,500 (Milstein et al.), and U.S. 4,444,887 (Hoffman et al.)

Briefly, an antibody-producing line can be produced inter alia by cell fusion, or by transforming antibody-producing cells with Epstein Barr Virus, or transforming with oncogenic DNA. The treated cells
20 are cloned and cultured, and clones are selected that produce antibody of the desired specificity. Specificity testing can be performed on culture supernatants by a number of techniques, such as using the immunizing polypeptide as the detecting reagent in a standard immunoassay, or using cells expressing the polypeptide in immunohistochemistry. A supply of monoclonal antibody from the selected clones can be purified from a large volume of tissue culture supernatant, or from the ascites fluid of suitably prepared
25 host animals injected with the clone.

Effective variations of this method include those in which the immunization with the polypeptide is performed on isolated cells. Antibody fragments and other derivatives can be prepared by methods of standard protein chemistry, such as subjecting the antibody to cleavage with a proteolytic enzyme. Genetically engineered variants of the antibody can be produced by obtaining a polynucleotide encoding
30 the antibody, and applying the general methods of molecular biology to introduce mutations and translate the variant.

Monoclonal antibodies raised by injecting an intact DNA polymerase or a fragment comprising conserved sequences may be cross-reactive between herpes viruses. Antibodies that are virus or subfamily specific may be raised by immunizing with a suitably specific antigen, as may be selected from
35 Table 8. Alternatively, virus-specific clones may be selected from the cloned hybridomas by using a suitable antigen, such as one selected from Table 8, in the screening process.

Use of antibodies for detecting DNA polymerase in biological samples

40 Antibodies can be used to detect DNA polymerase polypeptides and fragments of viral origin that may be present, for example, in solid tissue samples and cultured cells. Immunohistological techniques to

carry out such determinations will be obvious to a practitioner of ordinary skill. Generally, the tissue is preserved by a combination of techniques which may include freezing, exchanging into different solvents, fixing with agents such as paraformaldehyde, drying with agents such as alcohol, or embedding in a commercially available medium such as paraffin or OCT. A section of the sample is suitably prepared and overlaid with a primary antibody specific for the protein.

The primary antibody may be provided directly with a suitable label. More frequently, the primary antibody is detected using one of a number of developing reagents which are easily produced or available commercially. Typically, these developing reagents are anti-immunoglobulin or protein A, and they typically bear labels which include, but are not limited to: fluorescent markers such as fluorescein, enzymes such as peroxidase that are capable of precipitating a suitable chemical compound, electron dense markers such as colloidal gold, or radioisotopes such as ^{125}I . The section is then visualized using an appropriate microscopic technique, and the level of labeling is compared between the suspected virally infected and a control cell, such as cells surrounding the area of infection or taken from a remote site.

Proteins encoded by a DNA polymerase gene can also be detected in a standard quantitative immunoassay. If the protein is secreted or shed from infected cell in any appreciable amount, it may be detectable in plasma or serum samples. Alternatively, the target protein may be solubilized or extracted from a solid tissue sample. Before quantitating, the protein may optionally be affixed to a solid phase, such as by a blot technique or using a capture antibody.

A number of immunoassay methods are established in the art for performing the quantitation. For example, the protein may be mixed with a pre-determined non-limiting amount of the reagent antibody specific for the protein. The reagent antibody may contain a directly attached label, such as an enzyme or a radioisotope, or a second labeled reagent may be added, such as anti-immunoglobulin or protein A. For a solid-phase assay, unreacted reagents are removed by washing. For a liquid-phase assay, unreacted reagents are removed by some other separation technique, such as filtration or chromatography. The amount of label captured in the complex is positively related to the amount of target protein present in the test sample. A variation of this technique is a competitive assay, in which the target protein competes with a labeled analog for binding sites on the specific antibody. In this case, the amount of label captured is negatively related to the amount of target protein present in a test sample. Results obtained using any such assay are compared between test samples, and control samples from an uninfected source.

Specific antibodies against herpes virus DNA polymerase have a number of uses in developmental, diagnostic and therapeutic work. For example, antibodies can be used in drug screening (see U.S. Patent No. 5,120,639), or to prepare a passive vaccine. They may also be used for detecting herpes virus in a biological sample and for drug targeting, as described in the following sections.

Use of antibodies for drug targeting

An example of how antibodies can be used in therapy of herpes virus infection is in the specific targeting of effector components. Virally infected cells generally display peptides of the virus (including internal viral components) on their cell surface in the context of histocompatibility class I antigens. The peptide therefore provides a marker for infected cells that a specific antibody can bind to. An effector component attached to the antibody therefore becomes concentrated near the infected cells, improving the

effect on those cells and decreasing the effect on uninfected cells. Furthermore, if the antibody is able to induce endocytosis, this will enhance entry of the effector into the cell interior.

For the purpose of targeting, an antibody specific for the viral polypeptide (in this case, a region of a DNA polymerase) is conjugated with a suitable effector component, preferably by a covalent or high-affinity
5 bond. Suitable effector components in such compositions include radionuclides such as ¹³¹I, toxic chemicals, and toxic peptides such as diphtheria toxin. Another suitable effector component is an antisense polynucleotide, optionally encapsulated in a liposome.

In most applications of antibody molecules in human therapy, it is preferable to use human monoclonals, or antibodies that have been humanized by techniques known in the art. This helps prevent
10 the antibody molecules themselves from becoming a target of the host's immune system.

Diagnostic kits

Diagnostic procedures using the polynucleotides, oligonucleotides, peptides, or antibodies of this
15 invention may be performed by diagnostic laboratories, experimental laboratories, practitioners, or private individuals. This invention provides diagnostic kits which can be used in these settings. The presence of a herpes virus in the individual may be manifest in a clinical sample obtained from that individual as an alteration in the DNA, RNA, protein, or antibodies contained in the sample. An alteration in one of these components resulting from the presence of a herpes virus may take the form of an increase or decrease of
20 the level of the component, or an alteration in the form of the component, compared with that in a sample from a healthy individual. The clinical sample is optionally pre-treated for enrichment of the target being tested for. The user then applies a reagent contained in the kit in order to detect the changed level or alteration in the diagnostic component.

Each kit necessarily comprises the reagent which renders the procedure specific: a reagent
25 polynucleotide, used for detecting target DNA or RNA; a reagent antibody, used for detecting target protein; or a reagent polypeptide, used for detecting target antibody that may be present in a sample to be analyzed. The reagent is supplied in a solid form or liquid buffer that is suitable for inventory storage, and later for exchange or addition into the reaction medium when the test is performed. Suitable packaging is provided. The kit may optionally provide additional components that are useful in the procedure. These
30 optional components include buffers, capture reagents, developing reagents, labels, reacting surfaces, means for detection, control samples, instructions, and interpretive information.

Other members of the RFHV/KSHV subfamily

RFHV and KSHV are exemplary members of the RFHV/KSHV subfamily. This invention embodies
35 polynucleotide sequences encoding DNA polymerase of other members of the subfamily, as defined herein. We anticipate that other members of the subfamily will be identified and characterized, including some that are capable of infecting primates, including humans. One such member is another virus infecting monkeys, designated RFHV2. A segment of the DNA polymerase encoding sequence for this
40 virus was cloned from RF tissue obtained from a *Macaca mulatta* monkey, as described in Example 11.

In order to identify and characterize other members of the family, reagents and methods of this invention are applied to DNA extracted from tissue samples suspected of being infected with such a virus. Suitable sources include biological samples obtained from a wide range of conditions occurring in humans and other vertebrates. Preferred are conditions in which the agent is suspected of being lymphotropic, similar to other members of the gamma herpes virus subfamily; for example, infectious mononucleosis of non-EBV origin. More preferred are conditions which resemble in at least one of their clinical or histological features the conditions with which RFHV or KSHV are associated. These include: a) conditions in which fibroproliferation is part of the pathology of the disease, especially in association with collagen deposition, and especially where the fibrous tissue is disorganized; b) conditions involving vascular dysplasia; c) conditions involving malignant transformation, especially but not limited to cells of lymphocyte lineage; d) conditions for which an underlying immunodeficiency contributes to the frequency or severity of the disease; e) conditions which arise idiopathically at multiple sites in an organ or in the body as a whole; f) conditions which epidemiological data suggests are associated with an infectious or environmental agent. Conditions which fulfill more than one of these criteria are comparably more preferred. Some examples of especially preferred conditions include retroperitoneal fibrosis, nodular fibromatosis, pseudosarcomatous fibromatosis, fibrosarcomas, sclerosing mesenteritis, acute respiratory disease syndrome, idiopathic pulmonary fibrosis, diffuse proliferative glomerulonephritis of various types, gliomas, glioblastomas, gliosis, and all types of leukemias and lymphomas.

The process of identification of members of the RFHV/KSHV subfamily preferably involves the use of the methods and reagents provided in this invention, either singularly or in combination.

One method involves amplifying and/or characterizing a polynucleotide encoding a DNA polymerase in the sample. This can be performed, for example, by amplifying the polynucleotide in a reaction such as a PCR, using an RFHV/KSHV subfamily specific oligonucleotide, such as those listed in Table 6, as a primer in the reaction. The presence of amplified reaction product suggests polynucleotide in the sample derived from a member of the RFHV/KSHV subfamily.

Members of the subfamily can also be identified by performing a hybridization assay on the polynucleotide of the sample, using a suitable probe. The polynucleotide to be tested may optionally be amplified before conducting the hybridization assay, such as by using an oligonucleotide listed in Table 4 or Table 6 in a PCR. Preferred probes for the hybridization assay include the oligonucleotides of Table 6.

Other preferred probes are fragments of 16 nucleotides or more of the polynucleotide encoding DNA polymerase from either RFHV or KSHV, preferably contained in SEQ. ID NO:1 or SEQ. ID NO:3. The hybridization reaction is performed under the least stringent conditions wherein the probe will not form a stable duplex with a polynucleotide comprising any of SEQ. ID NOS:23 to 29, but will form a stable duplex with a polynucleotide comprising SEQ. ID NO:1 or a polynucleotide comprising SEQ. ID NO:3, and preferably either one. Formation of a stable duplex with the test polynucleotide under these conditions suggests the presence of a polynucleotide in the sample derived from a member of the RFHV/KSHV subfamily.

Members of the subfamily can also be identified by using a reagent antibody of a specificity that cross-reacts between antigens produced by members of the subfamily, but not with other antigens, including those produced by herpes viruses not members of the subfamily. Methods for producing such

antibodies were outlined in an earlier section. The test is performed, for example, by using the antibodies in an immunohistochemistry study of tissue sections prepared from individuals with the conditions listed above. Positive staining of a tissue section with the antibody suggests the presence of DNA polymerase in the sample from a member of the RFHV/KSHV subfamily, probably because the tissue is infected with the virus. Similarly, if antibodies cross-reactive with RFHV or KSHV antigens but not with other herpes virus antigens are found in the circulation of an individual, this suggests that the individual has been subject to a present or past infection with a member of the RFHV/KSHV subfamily.

Once a member of the RFHV/KSHV subfamily is suspected in a biological sample, it is desirable to obtain a fragment of the DNA polymerase gene corresponding to nucleotides 330-501 of Figure 1. The fragment is sequenced according to standard techniques to determine whether the virus is a bone fide member of the RFHV/KSHV subfamily, as defined herein. A preferred method of identifying members of the RFHV/KSHV subfamily is provided below in Examples 11 and 12.

Once a new member of the RFHV/KSHV subfamily has been identified, other embodiments of this invention may be brought into play for purposes of detection, diagnosis, and pharmaceutical development. Changes to render them suitable for the new subfamily member, if required, are expected to be minor and will be obvious based on the new sequence data, or will be a matter of routine adjustment.

Altered forms of DNA polymerase from the RFHV/KSHV subfamily

This invention also embodies altered forms of DNA polymerase of the RFHV/KSHV subfamily. As described earlier, work with DNA polymerase from other herpes viruses has helped pinpoint active regions and residues of the molecule involved in substrate binding, polymerase activity, or drug resistance. Some of the residues described appear in conserved regions of the polymerase molecule, and are identical between RFHV, KSHV, and the virus in which they were originally described. By analogy, mutation of the same residue in the DNA polymerase of the RFHV/KSHV subfamily is expected to have a similar effect:

TABLE 9: Possible Effect of Amino Acid Substitutions in DNA Polymerase of the RFHV/KSHV Subfamily		
Change	Position	Effect
Y → F	8	Reduction of DNA polymerase activity
N → Y	103	
Y → F or S	168	
G → D	107	
Y → F	168	
G → R	168	
D → G or N	170	
T → K or P	171	
D → A or G	172	
A → V	5	Increased resistance to antiviral compounds
S → N	10	
P → T	85	
T → M	101	
R → S	130	

The numbering of the residues in Table 9 begins with the first amino acid encoded by the entire DNA polymerase polynucleotide fragment of KSHV shown in Figure 1 (i.e., the first amino acid of SEQ. ID NO:4).

5 DNA polymerase activity is believed to be essential for replication of a herpes virus. Mutations shown in Table 9 that are expected to impair DNA polymerase activity may therefore be useful in creating attenuated forms of the respective virus. Other mutations may increase or decrease the resistance of the RFHV or KSHV polymerase to antiviral drugs.

10 Herpes viruses, particularly attenuated forms, are useful in developing viral vectors for therapeutic purposes (Johnson et al., Ward et al.). One such use is in the development of polyvalent vaccines. It is desirable, especially in developing countries, to provide prophylactic vaccines capable of stimulating the immune system against several potential pathogens simultaneously. Viruses that are engineered to express immunogenic peptides of several different pathogens may accomplish this purpose. Herpes viruses may be especially suitable vectors, because the large genome may easily accommodate several

15 kilobases of extra DNA encoding the peptides. Ideally, the viral vector is sufficiently intact to exhibit some biological activity and attract the attention of the host's immune system, while at the same time being sufficiently attenuated not to cause significant pathology. Thus, an attenuated virus of the RFHV/KSHV subfamily may be useful as a vaccine against like virulent forms, and may be modified to express additional peptides and extend the range of immune protection.

20 Another use for attenuated forms of herpes viruses is as delivery vehicles for gene therapy (Latchman et al., Glorioso et al.). In order to be effective, polynucleotides in gene therapy must be

delivered to the target tissue site. In the treatment of fibrotic diseases, malignancies and related conditions, attenuated viral vectors of the RFHV/KSHV subfamily may be preferable over other targeting mechanisms, including other herpes viruses, since they have the means by which to target towards the affected tissues. In this embodiment, the virus is first attenuated, and then modified to contain the polynucleotide that is desired for gene therapy, such as those that are outlined in a previous section.

The foregoing description provides, inter alia, a detailed explanation of how DNA polymerase encoding regions of herpes viruses can be identified and their sequences obtained. Polynucleotide sequences for regions of the DNA polymerase gene of RFHV and KSHV are provided.

The polynucleotide sequences provided are believed to be an accurate rendition of the sequences contained in the polynucleotides from the herpes viruses in the tissue samples used for this study. However, it is recognized that sequences obtained by amplification methods such as PCR may comprise occasional errors in the sequence as a result of amplification. The error rate is estimated to be between about 0.44% and 0.75% for single determinations; about the same rate divided by $\sqrt{(n-1)}$ for the consensus of n different determinations. Nevertheless, the error rate may be as high as 2% or more. Sequences free of amplification errors can be obtained by creating a library of herpes virus polynucleotide sequences, using oligonucleotides such as those provided in Table 7 to select relevant clones, and sequencing the DNA in the selected clones. The relevant methodology is well known to a practitioner of ordinary skill in the art: see, e.g., Example 9.

It is recognized that allelic variants and escape mutants of herpes viruses occur. Polynucleotides and polypeptides may be isolated or derived that incorporate mutations, either naturally occurring, or accidentally or deliberately induced, without departing from the spirit of this invention.

The examples presented below are provided as a further guide to a practitioner of ordinary skill in the art, and are not meant to be limiting in any way.

EXAMPLES

Example 1: Oligonucleotide primers for Herpes Virus DNA polymerase

Amino acid sequences of known herpes virus DNA polymerases were obtained from the PIR protein database, or derived from DNA sequences obtained from the GenBank database. The sequences were aligned by computer-aided alignment programs and by hand. Several conserved regions were apparent. Three of the most highly conserved regions were chosen for design of amplification primers. The regions selected are indicated in Figure 2 as REGION 1, REGION 2, and REGION 3.

Having identified suitable conserved regions from the amino acid sequences, the DNA sequences for these regions were used to design the oligonucleotide primers. The primers were designed to have a degenerate segment of 12-14 base pairs at the 3' end, and a consensus segment of 18-30 bases at the 5' end. This provides primers with optimal sensitivity and specificity.

The degenerate segment extended across the most highly conserved region of herpes virus DNA polymerase sequences, encompassing the least number of alternative codons. The primers could therefore be synthesized with alternative nucleotide residues at the degenerate positions and yield a

minimum number of combinations. There were no more than 256 alternative forms for each of the primers derived.

The consensus segment was derived from the corresponding flanking region of the DNA polymerase sequences. Generally, the consensus segment was derived by choosing the most frequently occurring nucleotide at each position of all the DNA polymerase sequences analyzed. However, selection was biased in favor of C or G nucleotides, to maximize the ability of the primers to form stable duplexes.

Results are shown in Figures 3-5, and summarized in Table 4. Figure 3 shows DNA sequences of known herpes virus DNA polymerase genes near REGION 2. These sequences were used to design the oligonucleotides DFASA and DFQSA, as shown. In a PCR, these oligonucleotides would act as primers by hybridizing with the strand antisense to the coding strand, and initiating polymerization in the same direction as the DNA polymerase encoding sequence. Figure 4 shows DNA sequences near REGION 3, from which the oligonucleotides VYGA, VYGCA and VYGSQA were designed for initiating polymerization in the 5' direction. Figure 5 shows DNA sequences near REGION 3, from which the oligonucleotides GDTD1B and GDTDSQB were designed. These oligonucleotides would hybridize with the coding strand and initiate polymerization in the direction opposite to that of the DNA polymerase encoding sequence.

Synthetic oligonucleotides according to the designed sequences were ordered and obtained from Oligos Etc, Inc.

Example 2: DNA extraction

Biopsy specimens were obtained from Kaposi's sarcoma lesions from human subjects diagnosed with AIDS. Specimens were also obtained from retroperitoneal fibromatosis lesions in a colony of *Macaca nemestrina*, *Macaca fascicularis*, and *Macaca fuscata* at the University of Washington Regional Primate Research Center.

The specimens were fixed in paraformaldehyde and embedded in paraffin, which were processed for normal histological examination.

Fragments of the paraffin samples were extracted with 500 μ L of xylene in a 1.5 mL EPPENDORF™ conical centrifuge tube. The samples were rocked gently for 5 min at room temperature, and the tubes were centrifuged in an EPPENDORF™ bench-top centrifuge at 14,000 rpm for 5 min. After removing the xylene with a Pasteur pipette, 500 μ L of 95% ethanol was added, the sample was resuspended, and then re-centrifuged. The ethanol was removed, and the wash step was repeated. Samples were then air-dried for about 1 hour. 500 μ L of proteinase-K buffer (0.5% TWEEN™ 20, a detergent; 50 mM Tris buffer pH 7.5, 50 mM NaCl) and 5 μ L of proteinase K (20 mg/mL) were added, and the sample was incubated for 3 h at 55°C. The proteinase K was inactivated by incubating at 95°C for 10 min.

Example 3: Obtaining amplified segments of RFHV and KSHV DNA polymerase

The oligonucleotides obtained in Example 1 were used to amplify DNA extracted in Example 2, according to the following protocol.

A first PCR reaction was conducted using 1 μ L of DNA template, 1 μ L of oligonucleotide DFASA (50 pmol/ μ L), 1 μ L of oligonucleotide GDTD1B (50 pmol/ μ L), 10 μ L of 10 x WB4 buffer (0.67 M Tris buffer pH

8.8, 40 mM MgCl₂, 0.16 M (NH₄)₂SO₄, 0.1 M β-mercaptoethanol, 1 mg/mL bovine serum albumin), 1 μL containing 2.5 mM of each of the deoxyribonucleotide triphosphates (dNTPs), 66 μL distilled water, and 50 μL mineral oil. The mixture was heated to 75°C in a Perkin-Elmer (model 480) PCR machine. 0.5 μL Taq polymerase (BRL, 5 U/μL) and 19.5 μL water was then added. 35 cycles of amplification were conducted in the following sequence: 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C.

A second PCR reaction was conducted as follows: to 1 μL of the reaction mixture from the previous step was added 10 μL 9-10 x WB4 buffer, 1 μL dNTPs, 0.5 μL Taq polymerase, 86.5 μL water, and 50 μL mineral oil. The mixture was heated to 75°C, and 1 μL each of oligonucleotide VYGA (50 pmol/μL) and oligonucleotide GDTD1B (50 pmol/μL) was added. 35 cycles of amplification were conducted as before.

Example 4: Sequence of the 236 base fragment

An aliquot of the final amplification mixture of each of the samples was purified by electrophoresis on a 2% agarose gel. Of 9 *M. nemestrina* and 1 *M. fascicularis* samples used, 4 *M. nemestrina* samples yielded amplification product. Amplification product was also obtained from human samples. The agarose gel was stained with ethidium bromide and the DNA was visualized using U.V. light. Bands of the correct size were eluted onto DEAE paper. Each extracted polynucleotide was ligated to a PGEM-T™ vector and transformed into competent bacteria (*E. coli* JM-109). Bacterial clones containing the amplified DNA were picked and cultured. The bacteria were lysed and the DNA was extracted using phenol-chloroform followed by precipitation with ethanol. Sequencing was performed by the Sanger & Nicholson dideoxynucleotide method, using M13 forward and reverse primers.

The length of the fragment in between the primer hybridizing regions was 172 base pairs in length. For the four *M. nemestrina* samples used, all yielded identical sequence data. About 70% of the residues are identical in the fragment between RFHV and KSHV. Compared with the most closely related known sequences of the herpes virus family, differences in between sequences are distributed along the entire length of this fragment. The longest stretch of consecutive nucleotides that is identical between any two sequences in this fragment is 11.

The polypeptide encoded in this fragment is 81% identical between RFHV and KSHV, of which the first 24 residues are 100% identical, and the first 31 are 97% identical. The longest stretch of consecutive amino acids that is identical between RFHV or KSHV and any of the other known herpes virus DNA polymerases in this fragment is 10.

Example 5: RFHV and KSHV specific amplification assays

Four oligonucleotides were prepared based on the sequence of the polynucleotide fragment of the RFHV and KSHV DNA polymerase for use in nested virus-specific amplification reactions. Primers VASGA, ILPCA, PIEAB and PEARB were based on the RFHV sequence; primers SGILA, CLNIA, IEASB, and EARFB were based on the KSHV sequence (Table 7). The RFHV primers were used to amplify DNA samples obtained from the PBL of macaque monkeys as follows:

Uncoagulated whole blood samples were collected from 20 *M. nemestrina* born in the colony at the University of Washington. 30 blood samples were obtained from wild-caught *M. nemestrina*. None of the

animals had overt symptoms of fibromatosis. Plasma and blood cells were separated by centrifugation. Peripheral blood mononuclear cells (PBMC) were prepared by centrifuging the cells through a density gradient, according to standard blood separation techniques. DNA was extracted from the cells according to the method of Example 2. The DNA was then amplified, first using primers VASGA and PEARB, then
5 using primers ILPCA and PIEAB. The conditions of the amplification were similar to that of Example 3. The reaction product was run on an agarose gel, stained with ethidium bromide, and examined under U.V. light.

When the assay was performed in duplicate and under conditions to avoid cross-contamination of PCR reaction products, none of the RF symptom-free monkeys were found to have detectable levels of
10 RFHV polynucleotide encoding DNA polymerase in their peripheral blood by this assay.

PBMC may also be examined by immunohistology techniques to confirm correlation between positive PCR products and RFHV antigenemia. PBMC are coated onto microscope slides, and fixed with a mixture of 50% methanol, 20% acetone and 30% water. They are overlaid with a primary serum, washed, overlaid with FITC-(rabbit anti-monkey IgG) (Nordic Labs), washed again, and then examined by fluorescence
15 microscopy.

Antibody-containing serum may be obtained from a monkey giving a positive RFHV amplification assay result, or an animal immunized with RFHV, or an RFHV extract. Serum from a monkey with a negative result may be used as control. PBMC from animals giving a positive result in the amplification test will also give a positive immunohistology result due to antigenemia of an RFHV antigen component.

To conduct an amplification assay for KSHV, DNA is extracted from tissue suspected of harboring the virus; particularly biopsy samples from human subjects with Kaposi's Sarcoma lesions and body cavity B-cell lymphoma. The DNA is amplified in two stages, using primers SGILA and EARFB in the first stage, and CLNIA and IEASB in the second stage. As before, a positive result is indicated by the presence of abundant polynucleotide in the reaction product, as detected by ethidium bromide staining.
20

25

Example 6: Upstream sequence of the RFHV and KSHV DNA polymerase

DNA from Kaposi's Sarcoma tissue similar to that used in Example 3 was used in additional amplification reactions to obtain a longer fragment of the gene encoding KSHV DNA polymerase. The oligonucleotides DFASA and GDTD1B were used to prime a first-stage amplification reaction, as in
30 Example 3, and the reaction product was separated on an agarose gel. The size of the fragment from DFASA to GDTD1B (now known to be 536 bases long) was estimated from the known sHV1 and EBV sequences, and a corresponding band was recovered from the gel. The extracted polynucleotide was subjected to a second round of amplification using the same primers. The product was cloned into E. coli as in Example 4.
35

Clones containing suitable inserts were identified from three different amplifications of the DNA extracted from the tissue. The clone inserts were sequenced from both ends using vector-specific oligonucleotides (M13 forward and reverse primers). About 160 nucleotides from the 5' end (including the DFASA hybridizing region) and about 233 nucleotides from the 3' end (including the GDTD1B hybridizing
40 region) were sequenced for all three amplifications. The centermost portion of the fragment was sequenced in one of the three amplifications.

A consensus sequence for the fragment was obtained by combining results of the three determinations with the results of Example 4, as appropriate. The data are shown in Figure 1, in comparison with the sequence determined for the RFHV DNA polymerase fragment in Example 4. Numbering of both sequences begins at the first position of primer DFASA.

5 Regions of each sequence corresponding to hybridization sites for DFASA and GDTD1B may not be accurate reflections of the target sequence. The fragment between the primers is believed to represent the DNA from which the polynucleotide used for sequencing was amplified. However, occasional errors may have been introduced during the amplification. Assuming the consensus sequence of KSHV to be an accurate reflection of the sequence of the DNA extracted from the tissue, there was about a 0.75% error rate in the sequence of each amplified product in the nucleotides towards the 5' end, and about a 0.44% error rate in the sequence towards the 3' end, not including the region hybridizing with the primers.

To obtain the corresponding RFHV polynucleotide sequence, DNA from frozen RF tissue of a macaque monkey was first amplified using the broad specificity DNA polymerase primer DFASA in conjunction with the RFHV specific primer PEARB, and then by DFASA in conjunction with the RFHV specific primer PIEAB.

The procedure was as follows: 5 μ L of DNA template was mixed with 1 μ L of each of the primers (50 pmol/ μ L), 10 μ L of 10 x WB4 buffer, 1 μ L 2.5 mM dNTP, 59-65 μ L water, and 60 μ L mineral oil. The temperature was raised to 60°C, and Taq polymerase (0.5 μ L diluted to 20 μ L in water) was added. The DNA was amplified for 35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. 2 μ L of the amplified product was added to 10 μ L 10 x WB4 buffer, 1 μ L 2.5 mM dNTP, 66.5 μ L water, 0.5 μ L Taq polymerase, and 60 μ L mineral oil. The temperature was raised to 60°C, and then a mixture of 1 μ L PIEAB (50 pmol/ μ L), 2 μ L DFASA (50 pmol/ μ L), and 18 μ L of water was added. Amplification cycles were conducted as before. Finally, a third round of amplification was performed to introduce a radiolabel. Oligonucleotide PIEAB was end-labeled with gamma 32 P-ATP, and 1 μ L was added to 20 μ L of the reaction mixture from the previous amplification step, along with 1 μ L 2.5 mM dNTP and 1 μ L Taq polymerase. Amplification was conducted through five cycles of 94°C, 55°C and 72°C, as before.

An aliquot of the radiolabeled reaction product was electrophoresed on a 6% polyacrylamide sequencing gel. A band of the correct size (predicted by analogy with the KSHV sequence) was identified by autoradiography, and cut out of the dried gel. DNA was eluted by incubation in 50 μ L water. A further amplification reaction was performed using 2 μ L of eluted DNA, 10 μ L 10 x WB4 butter, 1 μ L 2.5 mM dNTP, 1 μ L PIEAB (50 pmol/ μ L), 1 μ L DFASA (50 pmol/ μ L), 0.5 μ L Taq polymerase, and 84.5 μ L water. Amplification was conducted through 35 cycles of 95°C for 30 sec, 60°C for 30 sec, and 72°C for 65 sec. The amplified product was isolated using a QUIAEX™ gel extraction kit, and the DNA was cloned into pGEM™-t vector. JM-109 cells were transformed with the DNA, and colonies containing inserts were isolated. Colonies containing inserts of the correct size were used to obtain DNA for sequencing.

Data from these experiments were combined with that from Example 4 to provide the sequence of 536 base pairs corresponding to the RFHV and KSHV DNA polymerase gene. Omitting the outermost primer-hybridizing regions, 475 base pairs of each sequence have been determined for both RFHV and KSHV. These sequences are listed in Figure 6, in comparison with the corresponding region of the DNA polymerase gene from other sequenced gamma herpes viruses. The longest region that is identical

between the RFHV sequence and any of the other viruses is a first 20 base pair subfragment (SEQ. ID NO:110) and a second 20 base pair fragment (SEQ. ID NO:111) shared with eHV2.

Figure 7 shows the corresponding encoded polypeptide sequences. There is a linear sequence of about 31 residues near the middle of SEQ. ID NO:2 shared between the DNA polymerase of RFHV and eHV2. This shared sequence is listed separately in SEQ. ID NO:112. A sequence of 26 amino acids is shared in the same area between RFHV and sHV1, and two sequences of 12 amino acids shared between RFHV and EBV. These areas of homology map near conserved REGION 3 of the other herpes virus DNA polymerase sequences (Figure 2). A second shared sequence occurs near the beginning of SEQ. ID NO:4 between KSHV and other gamma herpes viruses. This sequence maps near conserved REGION 2 of other herpes virus DNA polymerase sequences. This sequence fragment shared between KSHV and other gamma herpes viruses is listed separately in SEQ. ID NO:113.

Figure 8 provides a comparison of the protein sequence across the spectrum of different herpes viruses corresponding to the sequence encoded by the 475 base pair sequence obtained herein for RFHV and KSHV.

The degree of identity between sequences can be used to construct a relationship map between DNA polymerases, as shown in Figure 9. The relationship between the species may reflect the relative ancestral relationship between the polypeptides, and between the organisms that encode them. Based on this analysis, RFHV and KSHV are provisionally assigned to the gamma subfamily of herpes viruses, which also includes eHV2, sHV1 and EBV. Other viruses of the RFHV/KSHV subfamily would be assignable to the herpes virus gamma subfamily on this basis.

Example 7: Oligonucleotide primers and probes for the RFHV/KSHV subfamily

Based on the sequence of the 475 base pair polynucleotide fragment obtained for RFHV and KSHV, five oligonucleotides were designed that could be used either as PCR primers or as hybridization probes with members of the RFHV/KSHV subfamily. These oligonucleotides were designated LSGGA, CTDPA, PCLNA, KMLEA, and GISPA.

These oligonucleotides are shown in Figure 10, alongside the sequences they were derived from. Like the oligonucleotides of Example 1, they have a consensus segment towards the 5' end, and a degenerate segment towards the 3' end. However, these oligonucleotides are based only on the RFHV and KSHV sequences, and will therefore preferentially form stable duplexes with DNA polymerase of the RFHV/KSHV subfamily. Under hybridization conditions that permit them to form stable duplexes with the RFHV or KSHV encoding polynucleotide fragment, they are expected to form stable duplexes with more members of the RFHV/KSHV subfamily than would equal-length polynucleotides of the RFHV or KSHV sequence, either alone or in combination.

Both oligonucleotides are oriented in the same direction. In a PCR amplification reaction, one or the other of these oligonucleotides may be used as primers in combination with a primer with the opposite orientation, such as GDTD1B.

Example 8: Antigenic and immunogenic regions of RFHV and KSHV DNA polymerase

Based on the 475 base pair polynucleotide sequence of the RFHV and KSHV DNA polymerase encoding region, it is possible to predict what sites on the protein unique for each virus, and therefore constitute potential sites for the binding of virus-specific antibodies.

Figure 7 shows example peptides of 6 or 7 amino acids in length. Some of the peptides comprise one or more residues that are distinct either for RFHV or KSHV (Class III), or for the RFHV/KSHV subfamily (Class II) compared with the corresponding gamma herpes virus peptides. These peptides were listed earlier in Table 8. The numbering of the amino acid residues in both Figure 7 and Table 8 begins with the first amino acid coded after the hybridization site of the VYGA primer (nucleotide position 331 of Figure 1).

To confirm that regions contained within this 57-amino acid region of the DNA polymerase may be recognized by antibody, computer analysis was performed to generate Hopp and Woods antigenicity plots.

The Hopp and Woods determination is based in part on the relative hydrophilicity and hydrophobicity of consecutive amino acid residues (Hopp et al).

Results are shown in Figure 11 and Figure 12. The numbering of RFHV begins with the first amino acid coded after the VYGA primer (as in Figure 7). The numbering of the KSHV polypeptide residues in Figure 12 begins with the first amino acid coded after the hybridization site of the DFASA primer (nucleotide position 28 of Figure 1).

Both RFHV and KSHV contain several regions predicted to be likely antibody target sites. For example, the RFHV shows several hydrophobic and antigenic patches along the amino acid sequence. KSHV shows hydrophobic patches beginning at residues 26, 44, 52, 121 and 151; and antigenic patches beginning at residues 8, 37, 45, and 94. The peptides of Figure 7 that correspond to some of these regions may be especially antigenic.

Example 9: Sequencing the complete RFHV and KSHV DNA polymerase coding region

Additional sequence data for the KSHV DNA polymerase encoding region has been obtained to the 5' and 3' direction of the segment described in Example 6.

Two Kaposi's sarcoma samples, designated K-12 and K-15, were used to prepare DNA according to the method of Example 2.

Additional Type 1 oligonucleotide primers were designed to hybridize with herpes virus DNA polymerase nucleic acid sequences flanking the KSHV sequence already obtained. Examples are shown in Table 10:

TABLE 10: Additional Type 1 Oligonucleotides used for Detecting, Amplifying, or Characterizing Herpes Virus Polynucleotides encoding DNA Polymerase						
Designation	Sequence (5' to 3')	Length	No. of forms	Target:	Orientation	SEQ ID:
QAHNA	CCAAGTATCATHCARGCNCAYA A	23	48	Herpes DNA polymerase	5'→3'	105
QAHNB	GGAGTAGCACAARTTTRTGNGC YTG	24	32	Herpes DNA polymerase	3'→5'	106
YGDT1B	AACACAGAGTCNGTRTCNCCR TA	29	64	Herpes DNA polymerase	3'→5'	124
HNLCA	AGCATCATCATGGCCCAYAAAYC TNTGYT	28	32	Herpes DNA polymerase	5'→3'	125
DFASLYA	GAYTTYGCNAGYYTNTAYCC	20	512	Herpes DNA polymerase	5'→3'	126
FDIEC1B	CACCCATRCAYTCDATRTCRAA	22	48	Herpes DNA polymerase	3'→5'	127
DIECA	TACAACGTCCTCTCCTTYGAYA THGARTG	29	24	Herpes DNA polymerase	5'→3'	128
CVN1A	GTCTGCGTGAAYGTNTTYGGN CA	23	64	Herpes DNA polymerase	5'→3'	129
CVNVA	GACGACCGCAGCGTGTGCGTG AAYGTNTTYGGNCA	35	64	Herpes DNA polymerase	5'→3'	130
CVNVSQA	ACGACCGCAGCGTGTGCGTG	20	1	Herpes DNA polymerase	5'→3'	131
CVNVB	TAAAAGTACAGCTCCTGCCCG AANACRTTNACRCA	35	64	Herpes DNA polymerase	3'→5'	132
CVNVSQB	TAAAAGTACAGCTCCTGCCCG AA	23	1	Herpes DNA polymerase	3'→5'	133
SLYP1A	TTTGACTTTGCCAGCCTGTAYC CNAGYATNAT	32	256	Herpes DNA polymerase	5'→3'	134
SLYP2A	TTTGACTTTGCCAGCCTGTAYC CNTCNATNAT	32	128	Herpes DNA polymerase	5'→3'	135
SLYPSQA	TTTGACTTTGCCAGCCTGTA	20	1	Herpes DNA polymerase	5'→3'	136
GDTD2B	CGGCATGCGACAAACACGGAG TCCGTRTCNCCRTADAT	38	48	Herpes DNA polymerase	3'→5'	137
YFDKB	TTAGCTACTCCGTGGAGCAGY TTRTCRAARTA	32	16	Herpes DNA polymerase (especially gamma)	3'→5'	138

PCR amplification was conducted as follows: 100 ng of DNA from each sample was first amplified in 50 μ L total reaction buffer under the following conditions: 1 x PCR buffer (67 mM Tris buffer pH 8.8, 16 mM (NH₄)₂SO₄, 10 mM β -mercaptoethanol, 0.1 mg/mL bovine serum albumin), 2 mM MgCl₂, 50 pmol of each oligonucleotide CVN1A and FDIEC1B, 100 μ M (each) dATP, dCTP, dGTP, dTTP, 1.25 units *Taq* DNA polymerase (AMPLITAQ™, Perkin-Elmer Cetus). Amplification was conducted through 45 cycles of

95°C for 30 sec; 50°C for 30 sec, and 72°C for 30 sec. PCR products were electrophoresed on a 2% agarose gel and visualized by ethidium bromide staining.

PCR products were purified using QIAQUICK SPIN™ PCR purification kit (Qiagen, Chatsworth CA). Products were cloned into PT7BLUE® Vectors (Novagen, Madison WI). Plasmids were purified using QUIAGEN SPIN™ plasmid miniprep kit. Purified plasmids were sequenced using ABI automated sequencing methodology, using M13 forward and reverse primers. Five clones were sequenced from each of K-12 and K-15.

Two body cavity lymphoma cell lines, designated BC-1 and BC-2, were used as DNA sources for determination of downstream sequence. 5×10^5 cells from each line were washed in PBS and pelleted separately. Proteinase-K buffer was added to each pellet and incubated at 65°C for 1 h. DNA was extracted twice with 1:1 (vol:vol) phenol:chloroform, precipitated and washed in ethanol, and resuspended in 10 mM Tris buffer pH 8.0.

Approximately 0.5 µg total genomic DNA from BC-1 and BC-2 cell lines was used with 25 pmol of oligonucleotide primers CVNVA and EARFB, 2.5 units *Taq* DNA polymerase (Boehringer-Mannheim), 250 µM dNTP, and 4 mM MgCl₂ in a total volume of 100 µL of 1 x PCR buffer. PCR amplification was conducted using a "hot start" at 70°C for 1 min prior to adding the *Taq* polymerase, and conducted through 35 cycles of 94°C for 45 sec; 60 °C for 45 sec, and 72 °C for 90 sec. PCR products were electrophoresed on a 2% agarose gel and visualized by ethidium bromide staining.

PCR products were purified and cloned into PT7BLUE® vectors as before. Purified plasmids were sequenced using ABI automated sequencing methodology using KSHV sequence specific primers RDSWA, FDCSA, YSTLB, and DYETB. DNA sequences were analyzed using the GenePro algorithm for single alignments open reading frames. The ClustalW algorithm was used for determining consensus sequences for multiple alignments.

The nucleotide sequence obtained is shown in Figure 13 (SEQ. ID NO:116) along with the encoded amino acid sequence (SEQ. ID NO:117). In total, 2511 nucleotides are shown, of which the first 35 correspond to the CVNVA primer, and the last 12 correspond to the YFDKB primer. Bases 36 to 2499 of SEQ. ID NO:116, corresponding to amino acids 13 to 833 of SEQ. ID NO:117, represent the KSHV DNA polymerase sequence.

Alignment of part of the KSHV DNA polymerase amino acid sequence with other herpes viruses is shown in Figure 14. Residues marked with an asterisk (*) are identical amongst all the sequences shown. Residues marked with a bullet (•) represent conservative amino acid substitutions. Residues marked with an arrow (↑) are of interest, because they are conserved between other herpes viruses but are different in KSHV. One of these is a histidine in KSHV in the position of an aspartic acid in other viruses, which is a non-conservative difference. Residues marked with an arrow may be suitable targets for antibodies or drugs that are specific for KSHV or for the RFHV/KSHV subfamily.

Amongst four KSHV DNA polymerase nucleotide sequences obtained, variations were noted in four positions. These are believed to represent naturally occurring allelic variants. At about nucleotide 319, the sequence TTCTCG was alternatively found as TTTTCG, which is a silent variation (not affecting the encoded protein sequence). At about nucleotide 348, the sequence AACCCG was alternatively found as AATCCG, which is also a silent mutation. At about nucleotide 1795, the sequence CCAGTA was

alternatively found to be CCAATA, which represents a change of the encoded peptide from -Pro-Val- to -Pro-Ile. At about nucleotide 1822, the sequence TTCAAG was alternatively found to be TTCAGG, which represents a change of the encoded peptide from -Phe-Lys- to -Phe-Arg-. Alignment of the KSHV amino acid sequence variants with DNA polymerase sequences of other herpes viruses is shown in Figure 15.

- 5 Comparison of the KSHV DNA polymerase nucleotide sequence with that of other herpes viruses led to design of additional Type 3 (virus-specific) oligonucleotides, listed in Table 11:

TABLE 11: Additional Type 3 Oligonucleotides Specific for Polynucleotides Encoding DNA Polymerase from KSHV						
Designation	Sequence (5' to 3')	Length	No. of forms	Target:	Orientation	SEQ ID:
SIIQB	TTGTGCGCTTGGATGATACT G	21	1	KSHV DNA polymerase	3'→5'	139
HVLQB	GAGGGCCTGCTGGAGGACG TG	21	1		3'→5'	140
SCGFB	CGGTGGAGAAGCCGCAGGA TG	21	1		3'→5'	141
LPHLA	ACCTCCCGCACCTGACCGTG T	21	1		5'→3'	142
QARQA	AAGCTAGACAGGAGGAGCTT C	21	1		5'→3'	143
KIIQB	ACTTGAATTATCTTGACGAAC	21	1		3'→5'	144
KVLMA	ACGACAAGGTTCTGATGAAG G	21	1		5'→3'	145
RDSWA	AGAGACTCTTGGACGGAAC G	21	1	KSHV DNA polymerase	5'→3'	146
FDCSA	AGTTTGACTGCAGCTGGGAG G	21	1		5'→3'	147
YSTLB	CGGGTATCAGTGTGGAGTAG C	21	1		3'→5'	148
DYETB	GAGGACAAAGGTTTCGTAGT C	21	1		3'→5'	149

- 10 Based upon other gamma herpes viruses, the KSHV DNA polymerase sequence is predicted to comprise a total of about 3000 base pairs, with additional nucleotides in both the 5' and 3' direction of the sequence shown. The remaining sequence may be determined by conducting the approach described on samples of affected tissue, using Type 1 oligonucleotides to sequence in from genes flanking the DNA polymerase in both the upstream and downstream direction.

- 15 Alternatively, complete DNA polymerase sequences may be obtained by generating DNA libraries from affected tissue. For the RFHV sequence, libraries are prepared from macaque monkey PBMC known from the amplification assay of Example 5 to contain RFHV DNA. For the KSHV sequence, libraries are prepared from Kaposi's sarcoma lesions or B cell body cavity lymphoma.

The DNA lysate is digested with proteinase K, and DNA is extracted using phenol-chloroform. After extensive dialysis, the preparation is partially digested with the Sau3A I restriction endonuclease. The

digest is centrifuged on a sucrose gradient, and fragments of about 10-23 kilobases are recovered. The lambda DASH-2™ vector phage (Stratagene) is prepared by cutting with BamHI. The size-selected fragments are then mixed with the vector and ligated using DNA ligase.

5 The ligated vector is prepared with the packaging extract from Stratagene according to manufacturer's directions. It is used to infect XL1-BLUE™ MRA bacteria. About 200,000 of the phage-infected bacteria are plated onto agar at a density of about 20,000 per plate. After culturing, the plates are overlaid with nitrocellulose, and the nitrocellulose is cut into fragments. Phage are eluted from the fragments and their DNA are subjected to an amplification reaction using appropriate virus-specific primers. The reaction products are run on an agarose gel, and stained with ethidium bromide. Phage are
10 recovered from regions of the plate giving amplified DNA of the expected size. The recovered phage are used to infect new XL1 bacteria and re-plated in fresh cultures. The process is repeated until single clones are obtained at limiting dilution.

Each clone selected by this procedure is then mapped using restriction nucleases to ascertain the size of the fragment incorporated. Inserts sufficiently large to incorporate the entire DNA polymerase
15 sequence are sequenced at both ends using vector-specific primers. Sequences are compared with the known polynucleotide sequence of the entire EBV genome to determine whether the fragment spans the intact DNA polymerase sequence. DNA is obtained from suitable clones, sheared, and sequenced by shot-gun cloning according to standard techniques.

20 **Example 10: Identifying immunogenic sites**

To identify what antibodies may be generated during the natural course of infection with RFHV, serial serum samples are obtained from 10-20 macaque monkeys giving a positive result in an RFHV DNA polymerase amplification test with PBMC, as in Example 5. To test for antibodies against KSHV, serum
25 samples are obtained from 10-20 AIDS subjects with Kaposi's Sarcoma lesions, from 10-20 HIV-positive symptom-negative subjects, and 10-20 HIV-negative controls. In initial studies, sera in each population are pooled for antibody analysis.

Peptides 12 residues long are synthesized according to the RFHV or KSHV sequence, as appropriate. Sequential peptides are prepared covering the entire sequence, and overlapping by 8
30 residues. The peptides are prepared on a nylon membrane support by standard F-Moc chemistry, using a SPOTS™ kit from Genosys according to manufacturer's directions. Prepared membranes are overlaid with the serum, washed, and overlaid with beta-galactose conjugated anti-monkey IgG or anti-human IgG, as appropriate. The test is developed by adding the substrate X-gal. Positive staining indicates IgG antibody reactivity in the serum against the corresponding peptide.

35

Example 11: Obtaining other DNA polymerase sequences of the RFHV/KSHV subfamily

A DNA polymerase encoding sequence from a third member of the RFHV/KSHV herpes virus subfamily was obtained as follows.

40 DNA was extracted from two frozen tissue samples from a *Macaca mulatta* monkey with retroperitoneal fibromatosis. Extraction was conducted according to Example 1. The extracted DNA was

precipitated with ethanol in the presence of 40 µg glycogen as carrier, washed in 70% ethanol, and resuspended in 10 mM Tris buffer, pH 8.0.

A 151 base pair fragment of a DNA polymerase encoding sequence was amplified using a triple-nested PCR: 100 ng of DNA from each sample was first amplified in 100 µL total reaction buffer under the following conditions: 1 x PCR buffer (67 mM Tris buffer pH 8.8, 16 mM (NH₄)₂SO₄, 10 mM β-mercaptoethanol, 0.1 mg/mL bovine serum albumin), 4mM MgCl₂, 25 pmol of each oligonucleotide VYGA and VYGCA, and 50 pmol of oligonucleotide GDTD1B, 25 µM (each) dATP, dCTP, dGTP, dTTP, 2.5 units *Taq* DNA polymerase (Boehringer-Mannheim). Amplification was conducted using a "hot start" at 70°C for 1 min prior to adding the *Taq* polymerase, and conducted through 42 cycles of 94°C for 30 sec; 60 °C for 30 sec, and 72 °C for 30 sec. A second amplification used 2 µL of the primary PCR product as template in 50 µL reaction volume as before, except that 25 pmol of each oligonucleotide PCLNA and GDTDSQB and 1.25 units *Taq* polymerase were used. Amplification was conducted using a "hot start" and 35 cycles of the same conditions as before. A third amplification used 2 µL of the secondary PCR product as template in 50 µL reaction volume as before, except that 25 pmol of each oligonucleotide KMLEA and GDTDSQB and 1.25 units *Taq* polymerase were used. Amplification was conducted using a "hot start" and 35 cycles of 94°C for 30 sec; 65 °C for 30 sec, and 72 °C for 30 sec.

The final PCR product was electrophoresed on a 3% agarose gel, and visualized by ethidium bromide staining. PCR products were purified using QIAQUICK SPIN™ PCR purification kit (Qiagen, Chatsworth CA). Products were cloned into PC7BLUE® vectors (Novagen, Madison WI). Plasmids were purified using QUIAGEN SPIN™ plasmid miniprep kit. Purified plasmids were sequenced using M13 forward and reverse primers with the USB Sequenase 7-deaza-dGTP kit.

Based on the sequence of the 151 base pair fragment, two sequence-specific (Type 3) oligonucleotides were designed, designated KVIYB and ASPDB. These were used in a nested PCR amplification with the Type 1 oligonucleotide QAHNA to obtain a 468 base pair fragment. The first amplification was conducted by using ~1 µg of each DNA sample in 100 µL PCR mixture as before, except that 50 pmol of each of QAHNA and KVIYB were used as primers. Amplification was conducted using a "hot start" and 35 cycles of 94°C for 30 sec; 55 °C for 60 sec, and 72 °C for 60 sec. The second amplification was conducted using 3 µL primary PCR product as template in 100 µL reaction volume and 50 pmol of QAHNA and ASPDB as primers. Amplification was conducted using a "hot start" and 40 cycles of 94°C for 30 sec; 60 °C for 60 sec, and 72 °C for 60 sec. PCR products were then electrophoresed on a 2.5% agarose gel, and visualized by ethidium bromide staining. PCR products were cloned into PC7BLUE® vectors and sequenced as before.

The nucleotide sequence obtained is shown in Figure 16, shown with the designation "RFMm" (SEQ. ID NO:118). This corresponds to a DNA polymerase encoding sequence referred to elsewhere in this application as "RFHVMm" or "RFHV2". The encoded protein sequence is shown in Figure 17 (SEQ. ID NO:119).

Identity analysis with DNA polymerase sequences of RFHVMm with other herpes viruses is shown in Table 12:

TABLE 12: Sequence Identities Between RFHV2 and other herpes viruses				
Viral DNA Polymerase Sequence	SEQ. ID NO:	Identity to RFHV 2 fragment (SEQ. ID NO:118) Bases 1-454	Identity to RFHV fragment (SEQ. ID NO:1) Bases 48-501	Identity to KSHV fragment (SEQ. ID NO:3) Bases 48-501
RFHV/KSHV subfamily:				
RFHV2 (RFHVMm)	118	—	83% (90%)	71% (84%)
RFHV1 (RFHVMn)	1	83% (90%)	—	69% (81%)
KSHV	3	69% (81%)	71% (84%)	—
gamma herpes				
eHV2	23	63% (66%)	68% (68%)	68% (73%)
sHV1	24	60% (64%)	59% (64%)	62% (68%)
EBV	25	57% (62%)	54% (63%)	62% (68%)
alpha herpes				
HSV1	36	52% (43%)	53% (46%)	53% (46%)
HSV2	37	53% (44%)	53% (46%)	53% (46%)
VZV	35	42% (41%)	45% (43%)	48% (45%)
beta herpes				
hCMV	33	45% (38%)	53% (41%)	49% (40%)
hHV6	42	44% (38%)	46% (41%)	48% (41%)
Percent identity shown at the polynucleotide level and the (amino acid level)				

Phylogenetic studies were performed using distance matrices, neighbor joining and bootstrap analysis, as implemented in the PHYLIP analysis package. Figure 18 shows the results of the bootstrap analysis, with the numbers indicated being the score out of 100 supporting the branch points shown. This analysis strongly supports a branch point that separates the RFHV/KSHV subfamily from other gamma herpes viruses. RFHVMm and RFHVMn are more closely related to each other than either are to KSHV.

Sequences were also analyzed for G+C content. Results are shown in Table 13. The percentage of G+C across the region corresponding to the 454 bp of RFHVMm is shown, as calculated using GenePro software (Riverside Scientific). Values in parenthesis are G+C content calculated for the entire DNA polymerase sequence, where known. Also shown are CpG ratios, which is the ratio of observed:expected frequencies of CpG, taking into consideration the mononucleotide composition.

TABLE 13: G+C mononucleotide and CpG dinucleotide frequencies in the DNA polymerase genes of different herpesviruses			
Herpes Virus	Subfamily	G + C	CpG ratio
RFHVMn	RFHV/KSHV (gamma)	55.9%	0.96
RFHVMm		51.1%	1.13
KSHV		54.4%	0.91
eHV2	other gamma	64.8% (63.6%)	0.71 (0.75)
sHV1		39.9% (34.9%)	0.28 (0.33)
EBV		64.4% (61.8%)	0.73 (0.70)
HSV1	alpha	67.6% (65.8%)	0.99 (1.06)
VZV		41.5% (42.2%)	1.37 (1.15)
hCMV	beta	60.2% (59.9%)	1.27 (1.23)
hHV6		46.0% (40.9%)	1.00 (1.12)

The G+C frequencies of the KS and RF sequences are quite similar to each other, falling midway between the high G-C content of EBV and eHV2 and the low G+C content of sHV1. The CpG dinucleotide frequencies of KS and RF are quite similar, close to the expected value (1.00) based on their mononucleotide compositions. These values are closer to those for alpha and beta herpes viruses, than for gamma herpes viruses outside the RFHV/KSHV subfamily. The CpG data suggest that RFHVMn, RFHVMm and KSHV genomes remain latent in non-dividing cells, in contrast to sHV1 and EBV which are latent in proliferating lymphoblastoid cells.

The phylogenetic analysis, the CpG analysis, and the similarity between symptoms caused by the three viruses support the use of the monkey viruses as models for KSHV, and other members of the RFHV/KSHV subfamily that may infect humans.

Examples of RFHVMm-specific Type 3 oligonucleotides is shown in Table 14:

TABLE 14: Type 3 Oligonucleotides Specific for Polynucleotides Encoding DNA Polymerase from RFHV2						
Designation	Sequence (5' to 3')	Length	No. of forms	Target:	Orientation	SEQ ID:
LCYSA	CTATGTTACTCTACCCTGATT	21	1	RFHVMm DNA Polymerase	5'→3'	150
KVIYB	GTATATCTCTTTAAACCTGGC	21	1		3'→5'	151
ASPDB	AACCTGGCGTCCGGGGAAGCG	21	1		3'→5'	152

Figure 19 is a map showing the approximate relative positions for hybridization of certain oligonucleotides of this invention along the DNA polymerase encoding sequence. Numbering of nucleotide residues is approximate, and based on a starting position in the Glycoprotein B encoding region, which flanks the DNA polymerase encoding region in the upstream direction. Following each oligonucleotide designation is an abbreviation in lower case which indicates the type of oligonucleotide: h

= all herpes viruses (Type 1); sq = additional sequencing tail available; g = gamma herpes viruses (Type 1); f = RFHV/KSHV subfamily herpes viruses (Type 2); m = RFHVMm specific (Type 3); n = RFHVMn specific (Type 3); ks = KSHV specific (Type 3).

The phylogenetic analysis, the CpG analysis, and the similarity between symptoms caused by the three viruses support the use of the monkey viruses as models for KSHV, and other members of the RFHV/KSHV subfamily that may infect humans.

Oligonucleotide primers were used in a screening assay to detect the presence of DNA polymerase encoding sequences in various biological samples. The results are shown in Figure 20. Results of RF samples of *M. nemestrina* monkeys #2, #3, #4, #7, #1 and #5 are shown in lanes A-D, I, and J respectively. Results from RF samples from a *M. mulatta* monkey is shown in lanes G & H. Results from peripheral blood lymphocytes of unaffected SRV2-negative *M. nemestrina* monkeys are shown in lanes E & F. Samples were assayed using nested PCR as follows: for the *M. nemestrina* samples, outer primers were VASGA and PEARB; inner primers were PEARB and PIEAB. For the *M. mulatta* samples, outer primers were FVEGA and KVIYB; inner primers were SPKDA and ASPDB. In this and other experiment, we found that the presence of amplification product correlates with the source of the samples in two ways: First, amplification was virus-specific (the RFHVMn specific oligonucleotides failed to amplify sequence from the *M. mulatta* RF lesion, but the RFHVMm specific oligonucleotides did. Second, *M. nemestrina* samples absent of RF-related symptoms did not yield reaction product, even when other viruses were present. A variety of tissues, including thymus, bone marrow, spleen, salivary gland, liver, mesenteric lymph node, ileocecal junction, duodenum, kidney and gonads naturally infected with SRV-2 were negative for the presence of RFHVMn sequences.

Example 12: Other human-infecting gamma herpes DNA polymerase sequences of the RFHV/KSHV subfamily

Human tissue samples suspected of containing a previously undescribed gamma herpes virus, particularly fibroproliferative conditions, lymphocyte malignancies, and conditions associated with immunodeficiency and immunosuppression, such as acute respiratory disease syndrome (ARDS), are preserved by freezing, and the DNA is extracted as in Example 2. Two rounds of PCR amplification are conducted using the three herpes virus oligonucleotide primers, DFASA, VYGA and GDTD1B, according to Example 3. Alternatively, subfamily-specific (Type 2) primers may be used as described earlier in this example in the discovery of RFHV2.

The amplified polynucleotide is electrophoresed in agarose and blotted onto a nylon membrane. The blot is hybridized with a probe comprising the polynucleotide fragment obtained from the RFHV polynucleotide encoding DNA polymerase (residues 330-501 of Figure 1), labeled with ³²P. The hybridization reaction is done under conditions that will permit a stable complex forming between the probe and DNA polymerase from a herpes virus, but not between the probe and endogenous eukaryotic DNA polymerase. The conditions will require approximately 60% identity between hybridizing segments of the probe and the target for a stable complex to form. These conditions are calculated using the formula given earlier, depending on the length and sequence of the probe and the corresponding sequence of the target. The conditions are estimated to be: a) allowing the probe to hybridize with the target in 6 x SSC (0.15 M

NaCl, 15 mM sodium citrate buffer) at room temperature in the absence of formamide; and b) washing newly formed duplexes for a brief period (5-10 min) in 2 x SSC at room temperature.

- 5 Amplified polynucleotides that hybridize to the labeled probe under these conditions are selected for further characterization. The expected size is 236 base pairs for the amplified inner fragment including the primer-binding regions, for a virus that has no insertions or deletions relative to RFHV or KSHV, and has been amplified using VYGA and GD TD1B as inner primers. The sequence of the fragment is determined as in Example 4. Samples containing fragments different from RFHV or KSHV are selected for determination of the entire DNA polymerase gene sequence by a method similar to that in Example 9.

REFERENCES

- Altschul et al. (1986). *Bull. Math. Bio.* 48:603-616.
- Ambroziuk et al. (1995). *Science* 268:582-583.
- 5 Basco et al. (1992). *J. Biol. Chem.* 267:19427-19434.
- Basco et al. (1993). *Chromosoma* 102:32-38.
- Berel V. et al. (1990). *Lancet* 335:123-128.
- Bernard et al. (1989). *Cell* 59:219-228.
- Bernard et al. (1990). *Proc. Natl. Acad. Sci. USA* 87:4610-4614.
- 10 Beaucage et al. (1981). *Tetra. Lett.* 22:1859-1862.
- Cesarman E. et al. (1995). *New Engl. J. Med.* 332:1186-1191.
- Chang Y. et al. (1994). *Science* 266:1865-1869.
- Derbyshire et al. (1991). *EMBO J.*, 10:17-24.
- Digard P. et al. (1995). *Proc. Natl. Acad. Sci. USA* 92:1456-1460.
- 15 Dorsky D.I. et al. (1990). *J. Virol.* 64:1394-1397.
- Dorsky D.I. et al. (1988). *J. Virol.* 62:3224-3232.
- Emery V.C. et al. (1992). pp. 257-277 in *Molecular and Cell Biology of Opportunistic Infections in AIDS*; S. Myint & A. Cann, eds, Chapman & Hall.
- Erickson et al. (1990). *Science* 249:527-533.
- 20 Fields B.N. & Knipe D.M., eds. (1991). *Fundamental Virology*, 2nd Edition, Raven Press.
- Firesmith T.H. et al. (1994). *Int. J. Dermatol.* 33:755-762.
- Gibbs J.S. et al. (1988a). *Proc. Natl. Acad. Sci. USA* 85:6672-6676.
- Gibbs J.S. et al. (1988b). *Proc. Natl. Acad. Sci. USA* 85:7969-7973.
- Giddens W.E. Jr. et al. (1983). pp. 249-253 in *Viral and Immunological Diseases in Nonhuman Primates*;
- 25 Alan R. Liss Inc.
- Glorioso J.C. et al. (1994). *Dev. Biol. Stand* 82:79-87.
- Haffey M.L. et al. (1988). *J. Virol.* 62:4493-4498.
- Hall J.D. et al. (1989). *Nucl. Acids Res.* 17:9231-9244.
- Henikoff et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10915-10919.
- 30 Hirose et al. (1978). *Tetra. Lett* (1978) 19:2449-2452.
- Hodgson (1991). *Bio/Technology* 9:19-21.
- Hopp T.P. et al. (1981). *Proc. Natl. Acad. Sci. USA* 78:3824-3828.
- Johnson P.A. et al. (1994). *Methods Cell Biol.* 43A: 191-210.
- Karlin S. et al. (1994). *J. Virol.* 68:1886-1902.
- 35 Knopf C.W. et al. (1988). *Biochim. Biophys. Acta* 951:298-314.
- Kumar et al. (1984). *J. Org. Chem.* 49:4905-4912.
- Larder B.A. et al. (1987). *EMBO J.* 6:169-175.
- Latchman D.S. et al. (1994). *Molec. Biotechnol.* 2:179-195.
- Lin L.S. et al. (1995). *J. Med. Virol.* 45:99-105.
- 40 Lisitsyn N. et al. (1993). *Science* 259:946-.

- Liu M.Y. et al. (1989). J. Med Virol. 28:101-105.
 Marcy A.I. et al. (1990). J. Virol. 64:5883-5890.
 Martin R.W. et al. (1993). Medicine 72:245-26.
 Meier J.L. et al. (1993). J. Virol. 67:7573-7581.
 5 Meinkoth J. et al. (1984). Anal. Biochem. 138:267-.
 Miles S.A. (1994). Curr. Opin. Oncol. 6:497-502.
 Mitsuyasu R.T. (1993). Curr. Opin. Oncol. 5:835-844.
 Moore P.S. et al. (1995). New Engl. J. Med. 332:1181-1185.
 Northfelt. D.W. (1994). Drugs (New Zealand) 48:569-582.
 10 O'Donnell M.E. et al. (1987). J Biol. Chem. 262:4252-4259.
 Reardon J.E. et al. (1989). J. Biol. Chem. 264:7405-7411.
 Simon et al. (1991). EMBO J. 10:2165-2171.
 Soengas et al. (1992). EMBO J. 11:4227-4237.
 Stow N.D. (1993). Nucl. Acids Res. 21:87-92.
 15 Tsai C.-C. et al. (1986). Lab. Animal Sci. 36:119-124.
 VanDevanter et al. (1996). J. Clin. Microbiol. 34:1666-1671.
 Wang T. S.-F. et al. (1989). FASEB J. 3:14-21.
 Ward P.L. et al. (1994). Trends Genet. 10:267-274.
 Yeung K.C. et al. (1991). Curr. Eye Res. 10 (Suppl.) 31-37.

20

Patents and Patent Applications:

	US 4415732	Caruthers M.H. et al.	(polynucleotide synthesis)
	US 4444887	Hoffman M.K.	(mAb method)
25	US 4472500	Milstein C. et al.	(mAb cell)
	US 4683195	Mullis K.B.	(PCR)
	US 4683202	Mullis K.B. et al.	(PCR)
	US 4642333	Person S.	(HSV Gb expression)
	US 5120639	Haffey M.L. et al.	(Ab vs POL in drug screening)
30	US 5124246	Urdea M.S. et al.	(branched DNA)
	US 5171568	Burke R.L. et al.	(HSV Gb/Gd vaccine)
	US 5176995	Sninsky J.J. et al.	(PCR method for viruses)
	US 5223391	Coen D.M. et al.	(UL42 peptides as POL inhibitors)
	US 5244792	Burke R.L. et al.	(HSV Gb expression)
35	US 5350671	Houghton M. et al.	(HCV diagnostics)
	US 5354653	Matsumoto T. et al.	(HSV strain probe assay)
	US 5399346	Anderson W.F. et al.	(gene therapy)
	EP 0337441	Haffey M.L.	(expression of HSV1 POL in yeast)
	WO 8904964	Feitelson M. et al.	(anti-HBV DNA POL in diagnosis)
40	JP 5309000	Iatron Lab Inc.	(PCR assay for EBV POL)

SEQUENCE LISTINGS:

SEQ. ID	Designation	Description	Type	Source
1	RFHV	DNA polymerase PCR segment	DNA	This invention
2	RFHV	DNA polymerase PCR segment	Protein	This invention
3	KSHV	DNA polymerase PCR segment	DNA	This invention
4	KSHV	DNA polymerase PCR segment	Protein	This invention
5-12		Herpes virus oligonucleotides	DNA	This invention
13-16		RFHV specific oligonucleotide	DNA	This invention
17-20		KSHV specific oligonucleotide	DNA	This invention
21-22		RFHV/KSHV subfamily oligonucleotide	DNA	This invention
23	eHV2	DNA polymerase	DNA	Genbank locus EHVU20824
24	sHV1	DNA polymerase	DNA	Genbank locus HSVSPOLGBP
25	EBV	DNA polymerase	DNA	Genbank locus EBV
26	hCMV	DNA polymerase	DNA	Genbank locus HS5POL
27	hHV6	DNA polymerase	DNA	Genbank locus HH6DNAPOL
28	hVZV	DNA polymerase	DNA	Genbank locus HEVZVXX
29	hHSV1	DNA polymerase	DNA	Genbank locus HEHSV1DP
30	eHV2	DNA polymerase	Protein	Genbank locus EHVU20824
31	sHV1	DNA polymerase	Protein	Genbank locus HSVSPOLGBP
32	EBV	DNA polymerase	Protein	Genbank locus EBV
33	hCMV	DNA polymerase	Protein	Genbank locus HS5POL
34	hHV6	DNA polymerase	Protein	Genbank locus HH6DNAPOL
35	hVZV	DNA polymerase	Protein	Genbank locus HEVZVXX
36	hHSV1	DNA polymerase	Protein	Genbank locus HEHSV1DP
37	hHSV2	DNA polymerase	Protein	PIR locus DJBE21
38	eHV1	DNA polymerase	Protein	PIR locus DJBEC3
39	mCMV	DNA polymerase	Protein	PIR locus DJBEMC
40	gpCMV	DNA polymerase	Protein	PIR locus L25706-B
41	iHV1	DNA polymerase	Protein	PIR locus DJBEI1
42	hHV6	DNA polymerase segment	DNA	Figure 3
43	hCMV	DNA polymerase segment	DNA	Figure 3
44	gpCMV	DNA polymerase segment	DNA	Figure 3
45	mCMV	DNA polymerase segment	DNA	Figure 3
46	hHSV1	DNA polymerase segment	DNA	Figure 3

SEQ. ID	Designation	Description	Type	Source
47	hHSV2	DNA polymerase segment	DNA	Figure 3
48	hVZV	DNA polymerase segment	DNA	Figure 3
49	eHV2	DNA polymerase segment	DNA	Figure 3
50	hEBV	DNA polymerase segment	DNA	Figure 3
51	sHV1	DNA polymerase segment	DNA	Figure 3
52	iHV1	DNA polymerase segment	DNA	Figure 3
53	hHV6	DNA polymerase segment	DNA	Figure 4
54	hCMV	DNA polymerase segment	DNA	Figure 4
55	gpCMV	DNA polymerase segment	DNA	Figure 4
56	mCMV	DNA polymerase segment	DNA	Figure 4
57	hHSV1	DNA polymerase segment	DNA	Figure 4
58	hVZV	DNA polymerase segment	DNA	Figure 4
59	eHV2	DNA polymerase segment	DNA	Figure 4
60	hEBV	DNA polymerase segment	DNA	Figure 4
61	sHV1	DNA polymerase segment	DNA	Figure 4
62	iHV1	DNA polymerase segment	DNA	Figure 4
63	hHV6	DNA polymerase segment	DNA	Figure 5
64	hCMV	DNA polymerase segment	DNA	Figure 5
65	gpCMV	DNA polymerase segment	DNA	Figure 5
66	mCMV	DNA polymerase segment	DNA	Figure 5
67	hHSV1	DNA polymerase segment	DNA	Figure 5
68	hVZV	DNA polymerase segment	DNA	Figure 5
69	eHV2	DNA polymerase segment	DNA	Figure 5
70	sHV1	DNA polymerase segment	DNA	Figure 5
71	hEBV	DNA polymerase segment	DNA	Figure 5
72	iHV1	DNA polymerase segment	DNA	Figure 5
73	IAETVTL	gamma-herpes antigen	Protein	This invention
74-79		RFHV/KSHV subfamily antigens	Protein	This invention
80-103		RFHV or KSHV specific antigens	Protein	This invention
104	SIIQB	KSHV specific oligonucleotide	DNA	This invention
105	QAHNA	Gamma herpesoligonucleotide	DNA	This invention
106	QAHNB	Gamma herpesoligonucleotide	DNA	This invention
107-109		RFHV/KSHV subfamily specific oligonucleotides	DNA	This invention
110	RFHV fragment	Shared polynucleotide sequence	DNA	This invention

SEQ. ID	Designation	Description	Type	Source
111	RFHV fragment	Shared polynucleotide sequence	DNA	This invention
112	RFHV fragment	Shared polypeptide sequence	Protein	This invention
113	KSHV fragment	Shared polypeptide sequence	Protein	This invention
114	KSHV fragment	KSHV fragment	DNA	This invention
115	KSHV fragment	KSHV fragment	Protein	This invention
116	KSHV	DNA polymerase segment	DNA	This invention
117	KSHV	DNA polymerase segment	Protein	This invention
118	RFHV2	DNA polymerase PCR segment	DNA	This invention
119	RFHV2	DNA polymerase PCR segment	Protein	This invention
120	KSHV	DNA polymerase variant	Protein	This invention
121	KSHV	DNA polymerase variant	Protein	This invention
122	KSHV	DNA polymerase variant	Protein	This invention
123	KSHV	DNA polymerase variant	Protein	This invention
124-138		Herpes virus (Type 1) oligonucleotides	DNA	This invention, Table 10
139-149		KSHV specific oligonucleotides	DNA	This invention, Table 11
150-152		RFHV2 specific oligonucleotides	DNA	This invention, Table 14

SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTGTTGACT TTGCTAGTCT TTACCCAGC ATCATGCAGG CACACAACCT CTGTTATTCT 60
 ACCCTGATTA CAGGAAGCGC CCTACACGGG CACCCCGAAC TGACCCCGA CGACTACGAA 120
 5 ACCTTCCACC TGAGCGGGGG AACGGTACAC TTTGTAAAA AGCACGTCCG CGAGTCACTA 180
 CTGTCCAAAC TGCTCACAAC ATGGCTGGCC AAGAGGAAAG AGATCCGCAA AAATTTAGCC 240
 TCGTGACAG ACCCCACCAT GCGCACCATA CTGGATAAAC AACAGCTGGC CATCAAGGTC 300
 ACATGTAACG CGGTGTACGG GTTCACCGGC GTCGCTTCG GCATCCTACC GTGCCTGAAC 360
 ATCGCAGAGA CGGTGACCCT CCAGGGCAGG AAAATGCTGG AAACGTCTCA GCGTTCGTA 420
 10 GAGGGAATCT CGCCAACGGC ACTGGCAGAC CTACTGCAGC GACCGATCGA GCGTCTCCG 480
 GAAGCCAGGT TTAAAGTGAT ATACGGCGAC ACCGACTCCG TGTTGTGCG ATGCCG 536

SEQUENCE DESCRIPTION: SEQ ID NO:2:

15 Val Phe Asp Phe Ala Ser Leu Tyr Pro Ser Ile Met Gln Ala His Asn
 Leu Cys Tyr Ser Thr Leu Ile Thr Gly Ser Ala Leu His Gly His Pro
 Glu Leu Thr Pro Asp Asp Tyr Glu Thr Phe His Leu Ser Gly Gly Thr
 Val His Phe Val Lys Lys His Val Arg Glu Ser Leu Leu Ser Lys Leu
 Leu Thr Thr Trp Leu Ala Lys Arg Lys Glu Ile Arg Lys Asn Leu Ala
 20 Ser Cys Thr Asp Pro Thr Met Arg Thr Ile Leu Asp Lys Gln Gln Leu
 Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala
 Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gln
 Gly Arg Lys Met Leu Glu Thr Ser Gln Ala Phe Val Glu Gly Ile Ser

Pro Thr Ala Leu Ala Asp Leu Leu Gln Arg Pro Ile Glu Ala Ser Pro
 Glu Ala Arg Phe Lys Val Ile Tyr Gly Asp Thr Asp Ser Val Phe Val
 Ala Cys

5	SEQUENCE DESCRIPTION: SEQ ID NO:3:	
	GTGTTGACT TTGCTAGCCT CTACCCAGT ATCATCCAAG CGCACAACTT GTGCTACTCC	60
	ACACTGATAC CCGGCGATTG GCTCCACCTG CACCCACACC TCTCCCGGA CGACTACGAA	120
	ACCTTTGTCC TCAGCGGAGG TCCGGTCCAC TTTGTAAAAA AACACAAAAG GGAGTCCCTT	180
10	CTTACCAAGC TTCTGACGGT ATGGCTCGCG AAGAGAAAAG AAATAAGAAA GACCCTGGCA	240
	TCATGCACGG ACCCGCACT GAAAACTATT CTAGACAAAC AACAACTGGC CATCAAGGTT	300
	ACCTGCAACG CGGTTTACGG CTTACGGGC GTTGCTCTG GCATACTGCC TTGCCTAAAC	360
	ATAGCGGAGA CCGTGACACT ACAAGGGCGA AAGATGCTGG AGAGATCTCA GGCCTTTGTA	420
	GAGGCCATCT CGCCGGAACG CCTAGCGGGT CTCCTGCGGA GGCCAATAGA CGTCTCACCC	480
15	GACGCCCGAT TCAAGGTCAT ATACGGCGAC ACCGACTCCG TGTTTGTGCG ATGCCG	536
	SEQUENCE DESCRIPTION: SEQ ID NO:4:	
	Val Phe Asp Phe Ala Ser Leu Tyr Pro Ser Ile Ile Gln Ala His Asn	
20	Leu Cys Tyr Ser Thr Leu Ile Pro Gly Asp Ser Leu His Leu His Pro	
	His Leu Ser Pro Asp Asp Tyr Glu Thr Phe Val Leu Ser Gly Gly Pro	
	Val His Phe Val Lys Lys His Lys Arg Glu Ser Leu Leu Thr Lys Leu	
	Leu Thr Val Trp Leu Ala Lys Arg Lys Glu Ile Arg Lys Thr Leu Ala	
	Ser Cys Thr Asp Pro Ala Leu Lys Thr Ile Leu Asp Lys Gln Gln Leu	
25	Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala	
	Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gln	
	Gly Arg Lys Met Leu Glu Arg Ser Gln Ala Phe Val Glu Ala Ile Ser	
	Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Ile Asp Val Ser Pro	
	Asp Ala Arg Phe Lys Val Ile Tyr Gly Asp Thr Asp Ser Val Phe Val	
30	Ala Cys	
	SEQUENCE DESCRIPTION: SEQ ID NO:5:	
	GTGTTGACT TYGCNAGYYT NTAYCC	26
35	SEQUENCE DESCRIPTION: SEQ ID NO:6:	
	GTGTTGACT TYCARAGYYT NTAYCC	26
	SEQUENCE DESCRIPTION: SEQ ID NO:7:	
40	ACGTGCAACG CGGTGTAYGG NKTNACNGG	29
	SEQUENCE DESCRIPTION: SEQ ID NO:8:	
	ACGTGCAACG CGGTGTACGG SGTSACSGG	29
	SEQUENCE DESCRIPTION: SEQ ID NO:9:	
45	ACGTGCAACG CGGTGTA	17
	SEQUENCE DESCRIPTION: SEQ ID NO:10:	
	TAYGGNGAYA CNGACTCCGT GTTTGTCGCA TGCCG	35
50	SEQUENCE DESCRIPTION: SEQ ID NO:11:	
	CGGCATGCGA CAAACACGGA GTCNGTRTCN CCRTA	35
	SEQUENCE DESCRIPTION: SEQ ID NO:12:	
55	CGGCATGCGA CAAACACGGA	20
	SEQUENCE DESCRIPTION: SEQ ID NO:13:	
	CGTCGCTTCC GGCATCCTAC C	21
60	SEQUENCE DESCRIPTION: SEQ ID NO:14:	
	GGCATCCTAC CGTGCCTGAA C	21
	SEQUENCE DESCRIPTION: SEQ ID NO:15:	
	CCGGAGACGC CTCGATCGGT C	21

	SEQUENCE DESCRIPTION: SEQ ID NO:16: AACCTGGCTT CCGGAGACGC C	21
5	SEQUENCE DESCRIPTION: SEQ ID NO:17: GCGTTGCCTC TGGCATACTG	20
	SEQUENCE DESCRIPTION: SEQ ID NO:18: CTGCCTTGCC TAAACATAGC G	21
10	SEQUENCE DESCRIPTION: SEQ ID NO:19: GGTGAGACGT CTATTGGCCT	20
	SEQUENCE DESCRIPTION: SEQ ID NO:20: AATCGGGCGT CGGGTGAGAC G	21
15	SEQUENCE DESCRIPTION: SEQ ID NO:21: GTCGCCTCTG GCATCCTNCC NTGYCTNAA	29
20	SEQUENCE DESCRIPTION: SEQ ID NO:22: CAGGGCCGGA AGATGCTGGA RACRTCNCAR GC	32
	SEQUENCE DESCRIPTION: SEQ ID NO:23: ATGAGTTTCT ACAACCCCTA CTTGGTCAAG AGGACCTTTC TTAAAAAGGC CGCCCCCTCG	60
	CGGCCGACCA AGGAATATAC CAGGATAATT CCAAAATGCT TCAAGACCCC AGGCGCCGCG	120
25	GGGGTGGTGC CCCACACCAG CACCCTGGAC CCGGTGTGCT TCGTGGGGGA CAAGGAGACC	180
	CCCATCCTGT ACGGGGACGG GAGCAGGAGC CTGTGGAGCG CGGGTGGGCG GGGCGGGCCG	240
	GGGACGGGCG CGGGCCAGGG CCACACGCCT GTGGCCCTGA CCTTCCACGT CTATGACATA	300
	ATAGAGACGG TGTACGGCCA GGACAGGTGC GACCACGTGC CCTTTCAGTT TCAGACGGAC	360
	ATCATCCCCA GCGGGACGGT CCTCAAGCTG CTGGGTGCGA CCTCGGACGA CCGCAGCGTG	420
30	TGCGTGAACG TGTTCAAGCA GGAGCTGTAC TTTTACGTGC GCGTGCCCGA GGGGCTCAAG	480
	CTGGACTTTC TCATCCAGCA GTGCTCGCGG GAGAACTTTA ACTTTAGCCA GGGCCGGTAC	540
	CGATATGAGA AAACAAGCAA GCGCGTGTG GCGGAGTACT GCGTCGAGGC GCGGGAGGTG	600
	TACCGGGTGT TCGCGTCGAG CCAGGGGTTC GTGGACCTCC TGGCCGGGGG GCTCACGGCC	660
	GCGGGGTGCG AGGTCTTCGA GACAAACGTG GACGCGGCCA GGCGTTTCAT CATAGACAAC	720
35	GGGTTCTCCA CCTTCGGGTG GTACTCGTGC GCGGCGGCCG TCCCGCGCCA GGGGGGCGCG	780
	GCCAGGGACT CCTGGACGGA GTTGGAGTAC GACTGCGCCG CGGGGACCT GGAGTTTCAC	840
	GCGGGGCGGG CGGACTGGCC GGGCTACAAC GTCCTCTCCT TCGATATAGA GTGCCTGGGG	900
	GAGAACGGGT TCCCCAACGC GAGCAGGGAC GAGGACATGA TCCTGCAGAT CTCCTGCGTG	960
	ATCTGGAAGG CGGGGTGCGG GGAGGCGCCC AGGAGCGTGC TCCTGAACCT GGGCACGTGC	1020
40	GAGGAGATAG AGGGGGTGA GGTGTACCAG TGCCCCTCGG AGCTGGACCT GCTCTACCTC	1080
	TTTTTCACCA TGATCAGGGA CGCGGACGTG GAGTTTGTGA CGGGCTACAA CATCTCCAAC	1140
	TTTGACTTCC CCTACGTGAT AGACAGGGCC ACGCAGGTGT ACAACCTGAA CCTGAAAGAG	1200
	TTCACCCGGG TCGCTCCTC GTCCATCTTC GAGGTGCACA AGCCCAAGAA CAGCTCAGCG	1260
	GGCTTCATGC GCGCGGTGTC CAAGGTCAAG GTGGCCGGGG TGGTGCCCAT AGACATGTAC	1320
45	CAGGTGTGCA GGGACAAGCT GAGCCTGTCC AACTACAAGC TGGACACGGT GGCCGGGGAG	1380
	TGCGTGGGCG CCAAGAAGGA GGACGTCTCC TACAAGGAGA TCCCCACCT GTTCAGGCAG	1440
	GGACCGGGGG GCAGGGCCAG GCTGGGGCTG TACTGCGTCA AGGATTCCGC CCTGGTGCTG	1500
	GACCTGCTGA GGTACTTTAT GACGCACGTG GAGATCTCTG AGATAGCCAA GATAGCCAAG	1560
	ATCCCCACGC GGCGGGTGCT CACGGACGGG CAGCAGATCA GGGTCTTCTC CTGCCTGCTG	1620
50	GACGTGGCCG GCGGGGAGGG CTACATCCTG CCAGTGGACA GGCACGCGGA CGCGGAGGGC	1680
	TACCAGGGGG CCACGGTCAT AGACCCCTCG CCCGGTTCT ACAACACCCC GGTGCTGGTG	1740
	GTGGACTTTG CCAGCCTGTA CCCCACCATC ATCCAGGCCC ACAACCTCTG CTACTCCACC	1800
	ATGATCCCCG GAGACAGGCT GTGCCTGCAC CCGACCTCG GGCCGGGCGA CTACGAGACC	1860
	TTTGAGCTCG CGAGCGGGCC GGTGCACTTT GTCAAGAAGC ACAAGGCGGT CTCGCTGCTG	1920
55	GCCACGCTGC TGAACGTGTG GCTGGCCAAG AGGAAGGCCA TCAGGCGCGA GCTGGCCACG	1980
	GTCTCGGACG AGGCCGTCAG GACCATCCTG GACAAGCAGC AGCTGGCCAT CAAGGTCACC	2040
	TGCAACGCGG TGTACGGGT CACGGGCGTG GCCTCGGGCA TCCTGCCCTG TCTCAAGATA	2100
	GCCGAGACGG TCACCTTCCA GGGCAGGCGC ATGCTGGAGA ACTCCAAGCG CTACATAGAG	2160
	GGGGTGACCC CCGAGGGGCT GGCAGACATA TTGGGCAGGC GGGTGGAGTG CGCCCCGAT	2220
60	GCCAGTTTTA AGGTCATCTA CGGGGACACG GACTCCCTGT TTATCCACTG CCGGGGCTAC	2280
	CGCCAGAGC AGGTCACGGG GTTCTGCGAC GAGCTGGCCG CTCACATGAC CCGAACCTG	2340
	TTCGTGGACC CCATCAAGCT GGAGGCCGAA AAGACCTTCA AGTGCCTGAT CTTACTGACC	2400
	AAAAAGAGGT ACATAGGCAT GATGACCACC GACAGGCTGC TCATGAAGGG GGTGGACCTG	2460
	GTGCGCAAGA CGGCGTGCAG GTTCGTGCAG GAGACCACCA AGGCCATCCT GGACCTGGTG	2520

	ATGGGGGACG AGGCGGTGCG GGCGGCGGCC GAGCGCCTGT GCGCCATGAG GGTGGAGGAG	2580
	GTGTGCGCGC GGGGGCCCC CGTCGGGTTC CTCAAGGTGG TGGACATCCT CAACGACAGC	2640
	TACAGGAAAC TAAGGCTCAA CCGGGTGCCC GTGGGCCAGC TGTCCTTCTC CACCGAGCTG	2700
5	AGCAGGCCCA TCTCTATTA CAAGACCCTG ACCCTGCCCC ACCTGGTGGT GTACCACAAG	2760
	ATCATGCAGA GGAACGAGGA GCTCCCCCAG ATCCACGATA GGATAGCCTA CGTGTTTGTG	2820
	CAGTCCCCCA AGGGGAAGCT GAGGTCCGAG ATGGCCGAGG ACCCGCCTA CGCGGCCAG	2880
	CACAACATCC CCCC GGCCGT GGACCTGTAC TTTGACAAGG TCATACACGG GGCGGCCAAC	2940
	ATCCTGCAGT GCCTGTTTGA GAACGACAGC GATAAGGCCG CGAGGGTGCT GTACAACTTT	3000
10	GCGGACCTGC CCCC GACGA CCTGTGA	3027
SEQUENCE DESCRIPTION: SEQ ID NO:24:		
	ATGGATTTTT ACAACCCATA TCTAAGTAAA AAGCCAACAG ATACAAAGAC ACCTAAGCTT	60
	CATACAACTA GACAATCTAT ATGTAGGTTA GTCCCTAAAT GTTTTAGAAA TCCTACTGAA	120
15	AAAGGCGTAG TGTCTGTGTC TTCTTTTGCT CTTCCAACCT ACTTTTCAA AGGTAATGAG	180
	AATAAAGTAT ATCTTGAAAA TGGTAAGTCT ATGTGGCACT TAAGAAGACC GTGTAAGAAC	240
	GCGTTGCTAG AAGAACAATC TATTACGTTT CATATTTATG ACATAGTAGA AACTACTTAT	300
	TCAGAAGACA GATGTAACGA TATTCCTTTT AAGTTTCAA CAGACATAAT ACCTAATGGA	360
	ACAGTGTTGA AACTACTTGG AAGAACAATA GAGGGTGCGA GCGTATGTGT TAACGTGTTT	420
	GGACAAAGAA ATTATTTTGA TGTTAAAGTT CCGGAAGGTG GCAACATAAC CTATCTTATA	480
20	AAACAAGCTT TGAATGAAAA ATTTAGCCCA TCTTGTGCAT ACCAACTGA AGCAGTAAAG	540
	AAGAAGATAC TATCTAGATA TGATCCAGAA GAACATGATG TGTTTAAGGT GACAGTGTCT	600
	TCTTCCCTTT CTGTTTATAA GATATCAGAT TCTTTAGTGT CTAATGGTTG TGAAGTTTTT	660
	GAAACAAATG TAGATGCTAT AAGAAGATTT GTAATTGATA ATGACTTTTC TACATTTGGT	720
25	TGGTACACAT GTAAGTCTGC ATGTCCTCGA ATCACAATA GAGACTCTCA TACTGACATT	780
	GAGTTTGACT GCGGGTACTA TGACTTAGAA TTTATGCTG ATAGAACAGA ATGGCCACCT	840
	TACAACATAA TGTCTTTTGA TATAGAATGT ATAGGAGAAA AAGGATTTCC TTGTGCAAAA	900
	AATGAAGGAG ATTTAATAAT TCAGATTTCA TGTGTGTTTT GGCACGCTGG GGCGCTTGAT	960
	ACAAC TAGAA ATATGCTATT ATCTTTAGGA ACGTGCTCAG CTGTTGAAAA TACTGAAGTT	1020
	TATGAGTTCC CTAGTGAAAT AGACATGCTG CATGGGTTTT TTTCATTAAT TAGAGACTTT	1080
30	AATGTTGAAA TAATTACTGG TTATAATATT TCTAACTTTG ACTTACCTTA TCTAATTGAT	1140
	AGAGCTACTC AAATTTATAA TATAAAGCTA TCTGATTATT CAAGAGTTAA AACAGGGTCT	1200
	ATTTTTCAAG TTCATACACC AAAAGATACA GGAATGGGT TTATGAGATC TGTCTCTAAA	1260
	ATAAAAATTT CAGGAATTAT AGCAATTGAC ATGTACATTG TGTGCAAGA CAACTCAGT	1320
35	CTGTCTAATT ACAAGCTTGA TACAGTTGCT AATCACTGTA TTGGTGCAAA AAAGGAAGAT	1380
	GTGTCTTACA AAGATATTAT GCCTCTTTTT ATGTCGGGAC CAGAAGGCAG AGCTAAGATA	1440
	GGACTATACT GTGTAATAGA TTCTGTTCTT GTGATGAAAC TTTTGAAATT TTTTATGATT	1500
	CATGTTGAAA TTTCTGAGAT AGCAAAACTC GCTAAAATCC CCACAAGAAG AGTTCTTACA	1560
	GATGGGCAAC AAATAAGAGT TTTTCTTGT CTGCTTGCAAG CAGCTCGTGC AGAAAACTAT	1620
	ATACTGCCTG TGTCAAATGA TGTCAATGCG GATGGGTTTC AAGGAGCTAC CGTTATAAAT	1680
40	CCAATTCCTG GATTTTATAA CAATGCTGTA TTAGTAGTAG ACTTTGCTAG CCTGTATCCT	1740
	AGTATTATAC AAGCTCATAA TCTATGCTAC TCCACTCTTA TACCCACCA TGCTTTACAC	1800
	AACTACCCTC ACTTAAATC TAGTGACTAT GAGACTTTCA TGCTCAGTTC TGGACCTATA	1860
	CACTTTGTGA AAAAACACAT TCAGGCATCT CTTCTATCTA GGCTCTTAAC TGTGTGGCTT	1920
	TCTAAGAGAA AAGCTATTAG GCAAAAGCTT GCTGAATGTG AAGACCTAGA CACTAAACT	1980
45	ATTCTAGATA AACAGCAACT CGCTATTTAA GTAACCTGTA ATGCTGTGTA TGGGTTTACA	2040
	GGAGTTGCGT CAGGCTTGCT GCCATGCATA AGCATTGCAG AGACTGTTAC TCTCCAAGGC	2100
	CGGACGATGC TAGAAAAATC AAAAATATTC ATAGAAGCAA TGACACCTGA TACTCTCAA	2160
	GAAATTGTTT CTCTATATAGT GAAGCATGAA CCTGATGCGA AGTTCAGAGT CATATATGGA	2220
	GACACAGACT CTCTATTTGT AGAATGTGTT GGGTATTCTG TAGACACAGT TGTTAAATTT	2280
50	GGAGATTTCT TAGCTGCTTT TACTTCTGAA AAGCTCTTTA ATGCTCCTAT AAAGTTAGAG	2340
	TCAGAAAAAA CATTTAGTG TTTGCTATTG CTTGCTAAAA AAAGATACAT TGGAATACTG	2400
	TCAAATGACA AATTGCTTAT GAAAGGTGTT GACTTAGTGA GAAAAACTGC TTGTAAATTT	2460
	GTTCAAAATA CTAGCTCAAA AATTCTTAAT CTTATACTTA AAGACCCTGA GGTAAAAGCA	2520
	GCTGCTCAGC TTTTGTCAAC AAAAGATCCA GACTATGCTT TTAGAGAAGG GCTTCCTGAT	2580
55	GGGTTTTTGA AAGTGATAGA CATTTTAAAT GAAAGCCACA AAAACCTCAG AACTGGGCAA	2640
	GTGCCGGTAG AGGAATTAAC ATTTTCTACA GAATTGAGTA GACCTATTTT TTCTTACAAA	2700
	ACTGAAAACT TGCCTCATTT AACTGTTTAT AAAAAATTA TTACAAGGCA TGAAGAACCT	2760
	CCACAAGTTC ATGACAGAAT CCCATACGTT TTTGTAGGCA AGACTACATC ATGCATATCA	2820
	AACATGGCTG AAGACCCAAC ATACACGTT CAAAATAATA TTCCAATTGC AGTGGATCTA	2880
60	TATTTTGATA AACTTATTCA CGGGGTAGCT AACATAATAC AGTGTCTCTT TAAAGACAGC	2940
	AGTAAACTG TGTCTGTTTT GTATAATTTT GTATCAACTC CTGTTTTATT TTCTTACGAG	3000
	CTTCTAACTG ATCATTCTGT AAAAGCATAA	3030

SEQUENCE DESCRIPTION: SEQ ID NO:25:

	ATGTCTGGGG	GACTCTTCTA	TAACCCTTTC	CTAAGACCTA	ATAAAGGCCT	TCTGAAAAAG	60
	CCTGACAAGG	AGTACCTGCG	TCTCATTCCC	AAGTGTITTC	AGACACCAGG	CGCCGCAGGG	120
5	GTGGTGGATG	TGCGGGGGCC	TCAGCCCCCC	CTGTGCTTCT	ACCAAGACTC	CCTGACGGTG	180
	GTGGGGGGTG	ACGAGGATGG	AAAGGGCATG	TGGTGGCGCC	AGCGTGCCCA	AGAGGGCACG	240
	GCAAGGCCGG	AGGCAGACAC	CCACGGAAGC	CCTCTGGACT	TCCATGTCTA	CGACATACTC	300
	GAGACGGTGT	ACACGCACGA	GAAATGCGCC	GTCATTCCAT	CGGATAAACA	GGGGTATGTG	360
	GTGCCATGTG	GCATCGTCAT	CAAGCTACTG	GGCCGGCGCA	AGGCCGATGG	GGCCAGCGTG	420
10	TGTGTGAACG	TGTTTGGGCA	GCAGGCCTAC	TTCTACGCCA	GCGCGCCTCA	GGGTCTGGAC	480
	GTGGAGTTTG	CAGTCTCAG	CGCCCTCAAG	GCCAGCACCT	TCGACCGCAG	GACCCCTGC	540
	CGGGTCTCGG	TGGAGAAGGT	CACGCGCCGT	TCCATTATGG	GCTACGGCAA	CCATGCCGGC	600
	GACTACCACA	AGATCACCTC	CTCCCATCCC	AACAGTGTGT	GTCACGTGGC	CACGTGGCTG	660
	CAAGACAAGC	ACGGGTGTCG	GATCTTTGAG	GCCAACGTGG	ATGCCACGCG	CCGCTTTGTC	720
15	CTGGACAATG	ACTTTGTAC	CTTTGGCTGG	TACAGCTGCC	GCCGCGCCAT	CCCCCGCTC	780
	CAGCACCGGG	ACTCGTACGC	CGAGCTCGAG	TACGACTGTG	AGGTGGGCGA	CCTCTCGGTC	840
	CGGCGTGAAG	ACAGCTCCTG	GCCCTCCTAC	CAGGCCCTGG	CCTTCGATAT	CGAGTGTCTG	900
	GGGGAGGAGG	GCTTCCCCAC	GGCCACCAAC	GAGGCTGACC	TGATCCTGCA	GATATCCTGC	960
	GTCCTCTGGT	CGACAGGGGA	GGAGGCCGGG	CGCTATAGGC	GCATCCTGCT	GACGCTGGGC	1020
20	ACCTGCGAAG	ACATAGAGGG	GGTTGAGGTC	TACGAGTTCC	CATCGGAGCT	GGACATGCTC	1080
	TACGCCTTCT	TCCAGCTCAT	CAGAGACCTC	AGCGTGAGGA	TTGTGACCGG	CTACAACGTG	1140
	GCCAACTTTG	ACTGGCCCTA	CATTCTGGAC	AGAGCCAGGC	ACATCTACAG	CATCAACCCA	1200
	GCCTCTCTGG	GCAAAATTAG	GGCTGGGGGC	GTCTGCGAGG	TCAGGCGACC	CCATGATGCG	1260
	GGCAAGGGCT	TCTTGCGGGC	CAACACCAAG	GTCCGCATCA	CCGGCCTCAT	CCCCATCGAC	1320
25	ATGTACGCCG	TGTGCCGGGA	CAAGCTCAGC	CTCTCAGACT	ACAAGCTGGA	CACAGTAGCC	1380
	AGGCACCTAC	TGGGGGCCAA	GAAGGAGGAT	GTGCATTACA	AGGAGATTCC	TCGCCTCTTT	1440
	GCAGCGGGCC	CCGAGGGGCG	CAGGCGGCTC	GGCATGTACT	GCGTGACGGA	CTCGGCCCTG	1500
	GTCATGGATC	TGCTAAACCA	TTTCGTGATC	CACGTGGAGG	TGGCAGAGAT	TGCCAAGATC	1560
	GCTCACATCC	CCTGCAGGCG	GGTGCTGGAC	GATGGGCAGC	AGATCCGCGT	GTTCTCCTGC	1620
30	CTCCTGGCGG	CCGCCCAAAA	GGAAACTTTT	ATCCTGCCCA	TGCCCTCGGC	CTCTGACCGG	1680
	GACGGCTACC	AGGGGGCCAC	CGTCATCCAG	CCCCTGTCCG	GATTCTACAA	CTCCCCGGTT	1740
	CTGGTGGTGG	ACTTTGCCAG	CCTCTACCCG	AGCATCATTG	AGGCTCATAA	TCTCTGTTAT	1800
	TCTACCATGA	TAACGCCGGG	AGAAGAGCAC	AGGCTAGCCG	GCCTGCGCCC	GGGAGAAGAC	1860
	TATGAGTCCT	TCAGGCTCAC	GGGGGGCGTC	TACCACTTTG	TAAAGAAGCA	CGTGACAGAG	1920
35	TCCTTCTTGG	CTAGTCTGTT	GACCTCCTGG	CTGGCCAAGC	GCAAGGCCAT	CAAGAAGCTG	1980
	CTGGCGGCCT	GCGAGGATCC	GCGCCAAAGG	ACCATCCTCG	ACAAGCAGCA	GCTGGCCATC	2040
	AAGTGACAGT	GCAACGCCGT	CTACGGCTTC	ACCGGGGTGG	CCAACGGCCT	CTTTCCCTGC	2100
	CTCTCCATCG	CCGAGACGGT	GACGCTGCAG	GGCCGCACGA	TGTTGGAGCG	GGCCAAGGCC	2160
	TTCGTGGAGG	CCCTGAGCCC	CGCCAACCTG	CAGGCCCTGG	CCCCCTCCCC	GGACGCCTGG	2220
40	GCGCCCTCA	ACCCCGAGGG	CCAGCTTCGA	GTCATCTACG	GGGACACGGA	CTCGCTGTTT	2280
	ATCGAGTGCC	GGGGGTTTTT	AGAGAGCGAG	ACCCTGCGCT	TTGCCGATGC	CCTGGCCGCC	2340
	CACACCACCC	GGAGCCTGTT	TGTGGCCCCC	ATCTCCCTGG	AGGCCGAGAA	GACCTTCTCC	2400
	TGCCTGATGC	TGATTACAAA	GAAGAGATAT	GTGGGGGTGC	TGACGGACGG	CAAGACCCTG	2460
	ATGAAGGGGG	TGGAGCTCGT	CCGGAAGACG	GCCTGCAAGT	TTGTGCAGAC	ACGCTGCCGG	2520
45	CGCGTGCTCG	ACCTGGTGCT	GGCGGATGCC	CGGGTAAAGG	AGGCGGCCAG	CCTCCTCTCC	2580
	CACCGGCCCT	TCCAAGAGTC	ATTTACACAA	GGGCTACCTG	TGGGCTTTTT	GCCCCTCATT	2640
	GACATCCTAA	ACCAGGCCTA	CACAGACCTC	CGTGAAGGCA	GGGTCCCCAT	GGGGGAGCTC	2700
	TGCTTTTCAA	CGGAGCTCAG	CCGCAAGCTC	TCAGCCTACA	AGAGCACCCA	GATGCCTCAC	2760
	CTGGCCGTCT	ACCAGAAGTT	CGTCGAGCGC	AACGAGGAAC	TGCCCCAGAT	CCACGACCGC	2820
50	ATCCAGTACG	TCTTTGTGGA	GCCCAAGGGG	GGAGTGAAGG	GGGCGAGAAA	GACGGAGATG	2880
	GCCGAGGACC	CGGCCTACGC	CGAGCGGCAC	GGCGTTCCCG	TGGCCGTGGA	TCATTATTTT	2940
	GACAAGCTGC	TCCAAGGAGC	GGCCAACATC	CTCCAGTGCC	TCTTTGATAA	CAACTCCGGG	3000
	GCCGCCCTCT	CCGTCTCTCA	GAATTTTACA	GCCCGGCCAC	CATTCTAA		3048

SEQUENCE DESCRIPTION: SEQ ID NO:26:

55	ATGTTTTTCA	ACCCGTATCT	GAGCGGCGGC	GTGACCGGCG	GTGCGGTCGC	GGGTGGCCGG	60
	CGTCAGCGTT	CGCAGCCCGG	CTCCGCGCAG	GGCTCGGGCA	AGCGGCCGCC	ACAGAAACAG	120
	TTTTTGAGA	TCGTGCCGCG	AGGTGTCATG	TTCGACGGTC	AGACGGGGTT	GATCAAGCAT	180
	AAGACGGGAC	GGCTGCCTCT	CATGTTCTAT	CGAGAGATTA	AACATTTGTT	GAGTCATGAC	240
60	ATGGTTTGGC	CGTGTCTTGG	GCGCGAGACC	CTGGTGGGTC	GCGTGGTGGG	ACCTATTCGT	300
	TTTCACACCT	ACGATCAGAC	GGACGCCGTG	CTCTTCTTGG	ACTCGCCCGA	AAACGTGTGC	360
	CCGCGCTATC	GTCAGCATCT	GGTGCCTTCG	GGGAACGTGT	TGCGTTTCTT	CGGGGCCACA	420
	GAACACGGCT	ACAGTATCTG	CGTCAACGTT	TTCGGGCAGC	GCAGCTACTT	TACTGTGAG	480
	TACAGCGACA	CCGATAGGCT	GCGTGAGGTC	ATTGCCAGCG	TGGCGAACT	AGTGCCCGAA	540

	CCGCGGACGC	CATACGCCGT	GTCTGTCACG	CCGGCCACCA	AGACCTCCAT	CTATGGGTAC	600
	GGGACGCGAC	CCGTGCCCCA	TTTGCACTGT	GTGTCTATCA	GCAACTGGAC	CATGGCCAGA	660
	AAAATCGGCG	AGTATCTGCT	GGAGCAGGGT	TTTCCCGTGT	ACGAGGTCCG	TGTGGATCCG	720
	CTGACGCGTT	TGGTCATCGA	TCGGCGGATC	ACCACGTTCT	GCTGGTGCTC	CGTGAATCGT	780
5	TACGACTGGC	GGCAGCAGGG	TCGCGCGTCG	ACTTGTGATA	TCGAGGTAGA	CTGCGATGTC	840
	TCTGACCTGG	TGGCTGTGCC	CGACGACAGC	TCGTGGCCGC	GCTATCGATG	CCTGTCCTTC	900
	GATATCGAGT	GCATGAGCGG	CGAGGGTGGT	TTTCCCTGCG	CCGAGAAGTC	CGATGACATT	960
	GTCATTGAGA	TCTCGTGCGT	GTGCTACGAG	ACGGGGGGAA	ACACCGCCGT	GGATCAGGGG	1020
	ATCCCAAACG	GGAACGATGG	TCGGGGCTGC	ACTTCGGAGG	GTGTGATCTT	TGGGCACTCG	1080
10	GGTCTTCATC	TCTTTACGAT	CGGCACCTGC	GGGCAGGTGG	GCCCAGACGT	GGACGTCTAC	1140
	GAGTTCCCTT	CCGAATACGA	GCTGCTGCTG	GGCTTTATGC	TTTTCTTTCA	ACGGTACGCG	1200
	CCGGCCTTTG	TGACCGTTA	CAACATCAAC	TCTTTTGACT	TGAAGTACAT	CCTCACGCGT	1260
	CTCGAGTACC	TGTATAAGGT	GGACTCGCAG	CGCTTCTGCA	AGTTGCCTAC	GGCGCAGGGC	1320
	GGCCGTTTCT	TTTTACACAG	CCCCGCCGTG	GGTTTTAAGC	GGCAGTACGC	CGCCGCTTTT	1380
15	CCCTCGGCTT	CTCACAACAA	TCCGGCCAGC	ACGGCCGCCA	CCAAGGTGTA	TATTGCGGGT	1440
	TCGGTGGTTA	TCGACATGTA	CCCTGTATGC	ATGGCCAAGA	CTAACTCGCC	CAACTATAAG	1500
	CTCAACACTA	TGGCCGAGCT	TTACCTGCGG	CAACGCAAGG	ATGACCTGTC	TTACAAGGAC	1560
	ATCCCGCGTT	GTTTCGTGGC	TAATGCCGAG	GGCCGCGCCC	AGGTAGGCCG	TTACTGTCTG	1620
	CAGGACGCCG	TATTGGTGCG	CGATCTGTTC	AACACCATTA	ATTTTCACTA	CGAGGCCGGG	1680
20	GCCATCGCGC	GGCTGGCTAA	AATCCGTTG	CGGCGTGTC	TCTTTGACGG	ACAGCAGATC	1740
	CGTATCTACA	CCTCGCTGCT	GGACGAGTGC	GCCTGCCGCG	ATTTTATCCT	GCCCAACCAC	1800
	TACAGCAAAG	GTACGACGGT	GCCCGAAACG	AATAGCGTTG	CTGTGTCACC	TAACGCTGCT	1860
	ATCATCTCTA	CCGCCGCTGT	GCCCGGCGAC	GCGGGTTCTG	TGGCGGCTAT	GTTTCAGATG	1920
	TCGCCGCCCT	TGCAATCTGC	GCCGTCCAGT	CAGGACGGCG	TTTACCCGG	CTCCGGCAGT	1980
25	AACAGTAGTA	GCAGCGTCGG	CGTTTTACGC	GTCGGCTCCG	GCAGTAGTGG	CGGCGTCGGC	2040
	GTTTCCAACG	ACAATCACGG	CGCCGGCGGT	ACTGCGGCGG	TTTCGTACCA	GGGCGCCACG	2100
	GTGTTTGAGC	CCGAGGTGGG	TTACTACAAC	GACCCCGTGG	CCGTGTTTCA	CTTTGCCAGC	2160
	CTCTACCTTT	CCATCATCAT	GGCCCAACAAC	CTCTGCTACT	CCACCCTGCT	GGTGCCGGGT	2220
	GGCGAGTACC	CTGTGGACCC	CGCCGACGTA	TACAGCGTCA	CGCTAGAGAA	CGGCGTGACC	2280
30	CACCGCTTTG	TGCGTGCTTC	GGTGC GCGTC	TCGGTGCTCT	CGGAAGTCT	CAACAAGTGG	2340
	GTTTCGACG	GGCGTGCCGT	GCGCGAATGC	ATGCGCGAGT	GTCAAGACCC	TGTGCGCCGT	2400
	ATGCTGCTCG	ACAAGGAACA	GATGGCGCTC	AAAGTAACGT	GCAACGCTTT	CTACGTTTTT	2460
	ACCGGCGTGG	TCAACGGTAT	GATGCCGTGT	CTGCCCATCG	CCGCCAGCAT	CACGCGCATC	2520
	GGTCGCGACA	TGCTAGAGCG	CACGGCGCGG	TTTCATCAAG	ACAACTTTTC	AGAGCCGTGT	2580
35	TTTTTGCACA	ATTTTTTTAA	TCAGGAAGAC	TATGTAGTGG	GAACGCGGGA	GGGGGATTCT	2640
	GAGGAGAGCA	GCGCGTTACC	GGAGGGGCTC	GAAACATCGT	CAGGGGGCTC	GAACGAACGG	2700
	CGGGTGGAGG	CGCGGGTCAT	CTACGGGGAC	ACGGACAGCG	TGTTTGTCGG	CTTTCTGTGC	2760
	CTGACGCCGC	AGGCTCTGGT	GGCGCGTGGG	CCCAGCCTGG	CGCACTACGT	GACGGCCTGT	2820
	CTTTTTGTGG	AGCCCGTCAA	GCTGGAGTTT	GAAAAGGTCT	TCGTCTCTCT	TATGATGATC	2880
40	TGCAAGAAAC	GTTACATCGG	CAAAGTGGAG	GGCGCCTCGG	GTCTGAGCAT	GAAGGGCGTG	2940
	GATCTGGTGC	GCAAGACGGC	CTGCGAGTTC	GTCAAGGGCG	TCACGCGTGA	CGTCCTCTCG	3000
	CTGCTCTTTG	AGGATCGCGA	GGTCTCGGAA	GCAGCCGTGC	GCCTGTCGCG	CCTCTCACTC	3060
	GATGAAGTCA	AGAAGTACGG	CGTGCCACGC	GGTTTCTGGC	GTATCTTACG	CCGCTTGCTG	3120
	CAGGCCCGCG	ACGATCTGTA	CCTGCACCGT	GTGCGTGTCG	AGGACCTGGT	GCTTTCGTCG	3180
45	GTGCTCTCTA	AGGACATCTC	GCTGTACCGT	CAATCTAACC	TGCCGCACAT	TGCCGTCATT	3240
	AAGCGATTGG	CGGCCCGTTC	TGAGGAGCTA	CCCTCGGTCT	GGGATCGGGT	CTTTTACGTT	3300
	CTGACGGCGC	CCGGTGTCCG	GACGGCGCCG	CAGGGTTCTT	CCGACAACGG	TGATTCTGTA	3360
	ACCGCCGGCG	TGGTTTCCCG	GTCGGACGCG	ATTGATGGCA	CGGACGACGA	CGCTGACGGC	3420
	GGCGGGGTAG	AGGAGAGCAA	CAGGAGAGGA	GGAGAGCCGG	CAAAGAAGAG	GGCGCGGAAA	3480
50	CCACCGTCGG	CCGTGTGCAA	CTACGAGGTA	GCCGAAGATC	CGAGCTACGT	GCGCGAGCAC	3540
	GGCGTGCCCA	TTCACGCCGA	CAAGTACTTT	GAGCAGGTTT	TCAAGGCTGT	AACTAACGTG	3600
	CTGTGCGCCG	TCTTTCCCGG	CGGCGAAACC	GCGCGCAAGG	ACAAGTTTTT	GCACATGGTG	3660
	CTGCCGCGGC	GCTTGCACTT	GGAGCCGGCT	TTTCTGCCGT	ACAGTGTCAA	GGCGCACGAA	3720
	TGCTGTTGA						3729
55	SEQUENCE DESCRIPTION: SEQ ID NO:27:						
	ATGGATTCCG	TGTCGTTTTT	TAATCCATAT	TTGGAAGCGA	ATCGCTTAAA	GAAAAAAGC	60
	AGATCGAGTT	ACATTCGTAT	ACTTCCTCGC	GGTATAATGC	ATGATGGTGC	GGCGGGATTA	120
	ATAAAGGATG	TTTGTGACTC	TGAACCGCGT	ATGTTTTATC	GAGACCGACA	GTATTTACTG	180
60	AGCAAAGAAA	TGACCTGGCC	GAGTTTGGAC	ATAGCTCGGT	CCAAGGATTA	TGATCATATG	240
	AGGATGAAGT	TTCACATATA	TGATGCTGTA	GAAACGTTAA	TGTTTACGGA	TTCGATCGAG	300
	AATCTTCCTT	TTCAGTATAG	ACATTTTGTG	ATTCCTTCGG	GGACAGTGAT	TAGAATGTTT	360
	GGGAGAACTG	AGGACGGTGA	GAAGATCTGC	GTGAACGTGT	TTGGACAGGA	GCAATATTTT	420
	TACTGCGAAT	GCGTCGACGG	AAGAAGCCTG	AAGGCTACTA	TAAACAATTT	GATGTTAACC	480

	GGCGAGGTTA AAATGTCGTG TTCTTTTGTG ATTGAGCCGG CTGATAAGTT GTCGTTGTAT	540
	GGGTACAATG CCAACACTGT CGTTAATCTG TTTAAAGTGA GTTTTGGAAT TTTTATGTA	600
	TCTCAACGTA TTGGAAAGAT TCTGCAGAAAT GAGGGATTCTG TAGTTTATGA AATCGACGTA	660
	GATGTTTTGA CTCGTTTCTT CGTCGATAAT GGTTTTTTGA GTTTCGGATG GTATAATGTA	720
5	AAAAAATATA TTCCTCAAGA TATGGGAAAA GGGAGTAATC TTGAGGTGGA AATTAATTGT	780
	CATGTCTCTG ATTTAGTTTC TCTGGAAGAC GTTAATTGGC CTTTATATGG ATGCTGGTCT	840
	TTCGACATAG AGTGTTTGGG TCAAAATGGG AATTTCCCGG ATGCCGAAAA TTTAGGTGAT	900
	ATAGTTATTC AGATTTCTGT AATTAGTTTC GATACGGAAG GTGACCGTGA TGAGCGACAT	960
	CTGTTTACTC TGGGAACATG TGAAAAAATT GACGGCGTGC ATATATATGA ATTTGCGTCA	1020
10	GAGTTTGAAT TACTTTTGGG TTTTTCATA TTTTAAAGGA TTGAGTCTCC GGAGTTTATT	1080
	ACCGGTATA ATATTAATAA TTTTGATTTA AAATATTTGT GTATAAGGAT GGATAAGATT	1140
	TACCATTATG ATATTGGTTG TTTTTCGAAA CTGAAGAATG GAAAGATTGG AATCTCTGTC	1200
	CCTCACGAAC AGTACAGGAA GGGGTTCTT CAGGCGCAA CCAAGGTGTT TACTTCCGGA	1260
	GTGTTGTATC TGGATATGTA TCCCGTCTAT TCTAGTAAGA TAACGGCGCA GAATTACAAA	1320
15	CTGGATACTA TTGCTAAGAT CTGTCTCCAG CAAGAAAAGG AGCAGTTATC GTACAAGGAA	1380
	ATACCAAAGA AATTTATTAG TGGACCCAGT GGCAGGGCTG TTGTCGGTAA GTATTGTCTA	1440
	CAGGACTCTG TCTTAGTTGT GCGTCTCTTT AAACAGATTA ATTATCATTT TGAGGTTGCC	1500
	GAGGTCGCCA GATTGGCACA CGTCACGGCT AGATGTGTGG TGTCGAGGG TCAGCAGAAG	1560
	AAGATATTTT CCTGCATTCT TACGGAAGCA AAACGCCGTA ATATGATTCT TCCGAGTATG	1620
20	GTGTCTTCGC ACAATAGACA AGGGATAGGT TACAAAGGGG CTACCGTTTT GGAGCCTAAG	1680
	ACGGGTATT ATGCTGTGCC TACCGTGGTG TTTGATTTTC AAAGTTTGTA TCCGAGCATT	1740
	ATGATGGCGC ATAATCTGTG TTATAGTACT TTAGTTTTGG ATGAACGACA GATAGCTGGA	1800
	TTGTCAGAGA GTGACATCTT AACCGTGAAG TTGGGGGATG AGACTCATCG GTTTGTGAAG	1860
	CCTGTATCC GTGAGTCTGT GCTTGGGAGT CTAATAAAGG ACTGGCTGGC CAAGAGACGA	1920
25	GAAGTGAAGG CGGAGATGCA GAACTGTTCTG GATCCGATGA TGAAACTTCT TCTGGATAAA	1980
	AAGCAGCTCG CTCTGAAAAC AACATGTAAC TCGGTGTACG GTGTCACGGG AGCGGCGCAC	2040
	GGGTATTGCG CGTGTGTTGC GATTGCTGCT TCTGTAACGT GTCTTGGAAG AGAGATGCTT	2100
	TGTTCCACGG TGGATTATGT TAATTCCAAG ATGCAGTCCG AGCAATTTT TTGCGAGGAA	2160
	TTTGTTTTAA CGTCATCAGA TTTTACTGGT GATTTGGAAG TGGAGGTAAT TTATGGTGAT	2220
30	ACGGATAGCA TCTTTATGTC TGTCAGAAAT ATGGTTAATC AGTCTCTGCG AAGGATTGCG	2280
	CCGATGATCG CCAAACATAT CACAGATCGT CTGTTCAAGT CGCCTATCAA GCTCGAGTTT	2340
	GAAAAGATTT TATGTCCGCT AATTTTGATT TGTAACAAAA GATACATTGG TAGACAGGAT	2400
	GATTCGCTTT TAATTTTAA GGGGGTAGAT CTGGTGAGAA AGACTTCTTG CGATTTTGTG	2460
	AAGGGTGTGG TGAAAGATAT CGTGGACTTG TTGTTCTTTG ATGAAGAGGT TCAGACTGCT	2520
35	GCTGTGGAGT TTTCTCACAT GACACAGACA CAGTTGCGTG AACAAGGAGT GCCTGTGGGT	2580
	ATTCATAAAA TTTTGCCTCG TCTGTGCGAA GCGCGGGAGG AGCTTTTCA GAATCGGGCA	2640
	GACGTGAGAC ATTTAATGTT GTCCTCTGTG CTTTCCAAAG AAATGGCTGC ATATAAGCAA	2700
	CCGAATCTGG CTCACCTTAG CGTCATTAGA AGGTTGGCGC AGAGAAAGGA AGAAATCCG	2760
	AATGTAGGTG ACCGAATTAT GTACGTGTTA ATAGCACCAT CTATTGGCAA TAAACAGACG	2820
40	CATAACTATG AATTAGCAGA AGATCCCAAC TATGTGATAG AACACAAGAT TCCTATACAT	2880
	GCGGAGAAGT ATTTGATCA GATTATCAAG GCTGTGACTA ATGCGATCTC ACCCATTTTT	2940
	CCGAAAACCG ATATAAAAAA AGAGAAGTTA CTATTGTATT TACTTCCTAT GAAAGTGTAT	3000
	TTGGATGAAA CATTTTCTGC TATTGCAGAG GTAATGTGA	3039
45	SEQUENCE DESCRIPTION: SEQ ID NO:28:	
	ATGGCGATCA GAACGGGGTT TTGTAATCCC TTTTAAACCC AAGCATCAGG GATTAAATAT	60
	AACCCAAGAA CCGGGCGCGG TAGTAACAGA GAATTTCTTC ATAGTTACAA AACTACCATG	120
	TCATCGTTTC AATTTTGGC CCCTAAATGT TTAGATGAAG ATGTGCCCAT GGAAGAACGA	180
	AAGGGGGTTC ACGTCGGTAC ACTTAGTCGA CCGCCTAAAG TTTACTGTAA TGGAAAAGAA	240
50	GTTCCGATTC TGGATTTTCG TTGTTCCAGC CCCTGGCCTA GACGCGTGAA TATTTGGGGG	300
	GAAATCGACT TTCGTGGGGA TAAGTTTGAC CCGGCTTTA ACACATTCCA TGTATATGAT	360
	ATTGTCGAAA CAACAGAAGC CGCGTCTAAT GGAGATGTAT CCCGGTTTGC AACTGCAACA	420
	CGACCGCTTG GTACCGTTAT TACTTTACTT GGCATGTCCC GATGTGGAAT AAGGGTGGCA	480
	GTTTCATGAT ACGGCATCTG TCAATATTTT TATATAAACA AAGCCGAGGT GGATACCGCT	540
55	TGTGGCATA GTTCCGGTAG CGAGTTATCT GTATTACTTG CCGAGTGTTT ACGCAGTTCT	600
	ATGATAACAC AAAATGATGC AACGTTAAAT GGAGACAAGA ACGCTTTTCA TGGTACCTCG	660
	TTTAAAAGCG CATCTCCAGA AAGCTTTTCG GTTGAGGTTA TTGAGCGCAC AGATGTTTAT	720
	TACTACGATA CACAGCCATG TGCGTTTAC AGGGTGTATT CTCCCTCATC TAAATTTACA	780
	AATTATCTTT GTGATAACTT TCACCCGGAG TTGAAAAAGT ATGAAGGTCG GGTAGACGCT	840
60	ACCACTCGTT TTCTAATGGA TAATCCCGGC TTTGTTAGTT TTGGTTGGTA TCAACTAAAA	900
	CCTGGAGTTG ATGGGGAACG TGTTGAGTT CGACCGGCAA GTCGCCAATT AACGTTAAGC	960
	GACGTTGAAA TTGACTGCAT GTCGGATAAT CTGCAGGCTA TACCAAACGA TGAATCATGG	1020
	CCTGACTACA AGTTGTTATG TTTGATATT GAATGTAAAT CAGGAGGATC TAATGAGCTG	1080
	GCGTTTCCCG ATGCAACACA TCTGGAGGAT CTTGTAATCC AAATTTCTTG TCTATTATAT	1140

	TCAATCCCTC	GACAGTCTTT	AGAACACATT	TTACTGTTTT	CCCTTGGCTC	TTGTGACTTA	1200
	CCACAAAGGT	ATGTACAAGA	AATGAAGGAC	GCGGGGTAC	CGGAGCCGAC	TGTGCTGGAG	1260
	TTTGATAGTG	AATTCGAGCT	ATTAATTGCA	TTTATGACCC	TCGTAAAACA	GTACGCTCCC	1320
	GAGTTTGCCA	CAGGTTATAA	CATTGTTAAT	TTTGATTGGG	CGTTTATTAT	GGAGAAACTT	1380
5	AATTCTATAT	ACAGTCTCAA	GCTTGATGGT	TATGGCAGTA	TAAACCGTGG	GGGTCTGTTT	1440
	AAGATATGGG	ATGTTGGCAA	ATCCGGATTT	CAGCGACGAA	GCAAGGTAAA	GATCAACGGT	1500
	CTCATATCTC	TGGATATGTA	TGCAATTGCA	ACTGAAAAAT	TAAACTCTC	GAGTTATAAA	1560
	TTAGATTCCG	TTGCACGTGA	AGCTCTAAAT	GAGTCCAAGA	GAGATTTGCC	CTACAAAGAC	1620
	ATTCCGGGAT	ATTACGCTAG	TGGACCGAAT	ACACGAGGAA	TTATTGGTGA	ATATTGTATA	1680
10	CAAGACTCGG	CTCTTGTTGG	GAAACTGTTT	TTTAAATATT	TACCACACCT	TGAGTTATCC	1740
	GCGGTTGCAA	GGCTAGCTAG	AATTACTTTA	ACCAAGGCTA	TTTACGACGG	ACAGCAGGTT	1800
	AGGATTTACA	CCTGTTTATT	AGGACTGGCT	TCGTCTCGAG	GATTTATTTT	ACCCGATGGG	1860
	GGATACCCAG	CTACTTTTGA	ATATAAGGAT	GTTATTCCCG	ATGTCGGGGA	TGTTGAGGAA	1920
	GAGATGGATG	AAGACGAGAG	CGTTTCTCCC	ACTGGTACGT	CAAGTGGGCG	AAATGTAGGA	1980
15	TATAAAGGAG	CCAGGGTTTT	TGACCCTGAT	ACGGGATTTT	ATATCGATCC	GGTGGTCGTA	2040
	TTGGATTTTG	CAAGTTTATA	TCCAAGTATA	ATTCAGGCC	ATAACTTATG	TTTTACCACG	2100
	CTAACGTTAA	ATTTTGAGAC	GGTTAAACGT	TTGAATCCAT	CCGATTATGC	CACCTTTACA	2160
	GTTGGAGGAA	AACGTCTTTT	TTTTGTGCGC	TCTAACGTTT	GAGAAAGTCT	GCTGGGTGTT	2220
	CTTTTAAAAG	ACTGGTTGGC	TATGCGCAAG	GCTATTAGAG	CGCGCATACC	CGGAAGTTCT	2280
20	TCAGATGAAG	CAGTGTTATT	AGACAAACAA	CAAGCCGCGA	TAAAAGTAGT	TTGTAATTCC	2340
	GTGTACGGTT	TTACTGGAGT	TGCGCAGGGA	TTTCTGCCAT	GTTTATACGT	AGCGGCCACT	2400
	GTCACTACAA	TTGGCCGTCA	AATGTTATTA	AGTACCAGAG	ATTATATTCA	TAATAACTGG	2460
	GCCGCATTTG	AACGTTTTAT	TACAGCGTTT	CCAGACATTG	AAAGTAGCGT	TCTCTCCCAA	2520
	AAAGCGTACG	AGGTAAAGGT	TATATATGGA	GATACGGATT	CTGTGTTTAT	CCGATTCAAG	2580
25	GGTGTTAGTG	TTGAGGGGAT	AGCTAAAATC	GGCGAGAAAA	TGGCACATAT	AATTTCAACG	2640
	GCTCTGTTTT	GTCCTCCTAT	AAAGTTGGAG	TGTGAAAAAA	CTTTTATAAA	ACTTTTGCTT	2700
	ATAACAAAGA	AAAAGTACAT	TGGGGTAATT	TACGGCGGAA	AGGTTTAAAT	GAAGGGAGTC	2760
	GACTTGTTTA	GAAAAAACAA	CTGTCAATTT	ATTAACGATT	ATGCCCGCAA	ACTTGTAGAA	2820
	CTGTTGTTAT	ATGACGACAC	CGTCTCGCGT	GCTGCGGCGG	AGGCGTCGTG	TGTTTCCATT	2880
30	GCTGAATGGA	ATAGACGGGC	CATGCCGTCT	GGGATGGCCG	GGTTTGGACG	CATAATTGCA	2940
	GATGCACATC	GCCAGATTAC	ATCACCCAAA	TTGGATATTA	ATAAGTTTGT	TATGACGGCC	3000
	GAGCTTAGTC	GTCCACCATC	CGCCTACATA	AACCGTCGCT	TGGCTCACTT	AACAGTATAT	3060
	TATAAATTAG	TAATGAGACA	GGGTCAAATC	CCAAACGTTT	GAGAACGCAT	CCCTTATGTT	3120
	ATTGTGGCCC	CCACAGACGA	AGTGGAGGCT	GATGCAAAAA	GTGTAGCTTT	GCTACGTGGA	3180
35	GATCCTTTAC	AGAATACCGC	AGGTAAACGG	TGTGGGGAAG	CAAAGCGTAA	GTTAATAATA	3240
	TCTGACTTAG	CGGAAGATCC	CATTACGTA	ACATCACACG	GGCTGTCTTT	AAACATTGAC	3300
	TATTATTTTT	CTCATCTCAT	TGGGACGGCG	AGTGTAACTT	TTAAGGCGTT	ATTTGGAAAC	3360
	GACACTAAAC	TCACAGAACG	GCTTTTAAAA	CGTTTTATTG	CAGAGACACG	AGTTGTAAAC	3420
	GTTAAAATGC	TAAACCGCTT	GCAGGCGGCA	GGCTTTGTTT	GTATACACGC	CCCGTGCTGG	3480
40	GATAATAAAA	TGAACACTGA	AGCTGAAATC	ACCGAGGAGG	AACAAAGTCA	TCAAATAATG	3540
	CGTAGAGTCT	TTTGATTATC	AAAAGCAATT	CTCCATCAAA	GTAA		3585

SEQUENCE DESCRIPTION: SEQ ID NO:29:

	ATGTTTTCCG	GTGGCGGCGG	CCCCTGTCC	CCCGGAGGAA	AGTCGGCGGC	CAGGGCGGCG	60
45	TCCGGGTTTT	TTGCGCCCGC	CGGCCCTCGC	GGAGCCGGCC	GGGGACCCCC	GCCTTGCTTG	120
	AGGCAAAACT	TTTACAACCC	CTACCTCGCC	CCAGTCGGGA	CGCAACAGAA	GCCGACCGGG	180
	CCAACCCAGC	GCCATACGTA	CTATAGCGAA	TGCGATGAAT	TTGATTTCAT	CGCCCCGCGG	240
	GTGCTGGACG	AGGATGCCCC	CCCGGAGAAG	CGCGCCGGGG	TGCACGACGG	TCACCTCAAG	300
	CGCGCCCCCA	AGGTGTACTG	CGGGGGGGAC	GAGCGCGACG	TCCTCCGCGT	CGGGTCGGGC	360
50	GGCTTCTGGC	CGCGGCGCTC	GCGCCTGTGG	GGCGGCGTGG	ACCACGCCCC	GGCGGGGTTT	420
	AACCCACCG	TCACCGTCTT	TCACGTGTAC	GACATCCTGG	AGAACGTGGA	GCACGCGTAC	480
	GGCATGCGCG	CGGCCAGTT	CCACGCGCGG	TTTATGGACG	CCATCACACC	GACGGGGACC	540
	GTCATCACGC	TCCTGGGCCT	GACTCCGGAA	GGCCACCGGG	TGGCCGTTCA	CGTTTACGGC	600
	ACGCGGCAGT	ACTTTTACAT	GAACAAGGAG	GAGGTCGACA	GGCACCTACA	ATGCCGCGCC	660
55	CCACGAGATC	TCTGCGAGCG	CATGGCCGCG	GCCCTGCGCG	AGTCCCCGGG	CGCGTCGTTT	720
	CGCGGCATTT	CCGCGGACCA	CTTCGAGGCG	GAGGTGGTGG	AGCGCACCGA	CGTGTACTAC	780
	TACGAGACGC	GCCCCGCTCT	GTTTTACCGC	GTCTACGTCC	GAAGCGGGCG	CGTGCTGTCG	840
	TACCTGTGCG	ACAACCTCTG	CCCGGCCATC	AAGAAGTACG	AGGGTGGGGT	CGACGCCACC	900
	ACCCGGTTCA	TCCTGGACAA	CCCCGGGTTT	GTCACCTTCG	GCTGGTACCG	TCTCAAACCG	960
60	GGCCGGAACA	ACACGCTAGC	CCAGCCGCGG	GCCCCGATGG	CCTTCGGGAC	ATCCAGCGAC	1020
	GTCGAGTTTA	ACTGTACGGC	GGACAACCTG	GCCATCGAGG	GGGGCATGAG	CGACCTACCG	1080
	GCATACAAGC	TCATGTGCTT	CGATATCGAA	TGCAAGGCGG	GGGGGGAGGA	CGAGCTGGCC	1140
	TTTCCGGTGG	CCGGGCACCC	GGAGGACCTG	GTCATCCAGA	TATCCTGTCT	GCTCTACGAC	1200
	CTGTCCACCA	CCGCCCTGGA	GCACGTCTCT	CTGTTTTTCG	TCGGTTCCTG	CGACCTCCCC	1260

	GAATCCCACC TGAACGAGCT GGCGGCCAGG GGCCTGCCCA CGCCCGTGGT TCTGGAATTC	1320
	GACAGCGAAT TCGAGATGCT GTTGGCCTTC ATGACCCTTG TGAAACAGTA CGGCCCCGAG	1380
	TTCGTGACCG GGTACAACAT CATCAACTTC GACTGGCCCT TCTTGCTGGC CAAGCTGACG	1440
	GACATTTACA AGGTCCCCCT GGACGGGTAC GGCCGCATGA ACGGCCGGGG CGTGTTTCGC	1500
5	GTGTGGGACA TAGGCCAGAG CCACTTCCAG AAGCGCAGCA AGATAAAGGT GAACGGCATG	1560
	GTGAGCATCG ACATGTACGG GATTATAACC GACAAGATCA AGCTCTCGAG CTACAAGCTC	1620
	AACGCCGTGG CCGAAGCCGT CCTGAAGGAC AAGAAGAAGG ACCTGAGCTA TCGCGACATC	1680
	CCCGCCTACT ACGCCGCCGG GCCCGCGCAA CGCGGGGTGA TCGCGAGTA CTGCATACAG	1740
	GATTCCCTGC TGGTGGGCCA GCTGTTTTTT AAGTTTTTGC CCCATCTGGA GCTCTCGGCC	1800
10	GTCGCGCGCT TGGCGGGTAT TAACATCACC CGCACCATCT ACGACGGCCA GCAGATCCGC	1860
	GTCTTTACGT GCCTGCTGCG CCTGGCCGAC CAGAAGGGCT TTATTCTGCC GGACACCCAG	1920
	GGGCGATTTA GGGGCGCCGG GGGGGAGGCG CCAAGCGTC CGGCCGCAGC CCGGGAGGAC	1980
	GAGGAGCGGC CAGAGGAGGA GGGGGAGGAC GAGGACGAAC GCGAGGAGGG CGGGGGCGAG	2040
	CGGGAGCCGG ACGGCGCGCG GGAGACCGCC GGCCGGCAGC TGGGGTACCA GGGGGCCAGG	2100
15	GTCCTTGACC CCACTTCCGG GTTTCACGTG AACCCCGTGG TGGTGTTCTGA CTTTGCCAGC	2160
	CTGTACCCCA GCATCATCCA GGCCACAAC CTGTGCTTCA GCACGCTCTC CCTGAGGGCC	2220
	GACGCAGTGG CGCACCTGGA GGCGGGCAAG GACTACCTGG AGATCGAGGT GGGGGGGCGA	2280
	CGGCTGTTCT TCGTCAAGGC TCACGTGCGA GAGAGCCTCC TCAGCATCCT CCTGCGGGAC	2340
	TGGCTCGCCA TCGAAAGCA GATCCGCTCG CGGATTCCCC AGAGCAGCCC CGAGGAGGCC	2400
20	GTGCTCCTGG ACAAGCAGCA GGCCGCCATC AAGGTCGTGT GTAACCTCGT GTACGGGTTT	2460
	ACGGGAGTGC AGCACGGACT CCTGCCGTGC CTGCACGTTG CCGCGACGGT GACGACCATC	2520
	GGCCGCGAGA TGCTGCTCGC GACCCGCGAG TACGTCCACG CGCGCTGGGC GGCCTTCGAA	2580
	CAGCTCCTGG CCGATTTCCT GGAGCGGGCC GACATGCGCG CCCCCGGGCC CTATTCCATG	2640
	CGCATCATCT ACGGGGACAC GGAATCCATA TTTGTGCTGT GCCGCGGCCT CACGGCCGCC	2700
25	GGGCTGACGG CCATGGGCGA CAAGATGGCG AGCCACATCT CGCGCGCGCT GTTCTGCCC	2760
	CCCATCAAAC TCGAGTGCGA AAAGACGTTT ACCAAGCTGC TGCTGATCGC CAAGAAAAAG	2820
	TACATCGGCG TCATCTACGG GGGTAAGATG CTCATCAAGG GCGTGGATCT GGTGCGCAAA	2880
	AACAAGTGC CGTTTATCAA CCGCACCTCC AGGGCCCTGG TCGACCTGCT GTTTTACGAC	2940
	GATACCGTCT CCGGAGCGGC CGCCGCGTTA GCCGAGCGCC CCGCAGAGGA GTGGCTGGCG	3000
30	CGACCCCTGC CCGAGGGACT GCAGGCGTTC GGGGCCGTCC TCGTAGACGC CCATCGGCGC	3060
	ATCACCGACC CGGAGAGGGA CATCCAGGAC TTTGTCTCTA CCGCCGAAT GAGCAGACAC	3120
	CCGCGCGCGT ACACCAACAA GCGCCTGGCC CACCTGACGG TGTATTACAA GCTCATGGCC	3180
	CGCCGCGCGC AGGTCCCGTC CATCAAGGAC CGGATCCCGT ACGTGATCGT GGCCAGACC	3240
	CGCGAGGTAG AGGAGACGGT CGCGCGGCTG GCCGCCCTCC GCGAGCTAGA CGCCGCCGCC	3300
35	CCAGGGGACG AGCCCGCCCC CCCC CGGCC CTGCCCTCCC CGGCCAAGCG CCCCCGGGAG	3360
	ACGCCGTGCG CTGCCGACCC CCGGGGAGGC GCGTCCAAGC CCGCAAGCT GCTGGTGTCC	3420
	GAGCTGGCCG AGGATCCCGC ATACGCCATT GCCCAGGCG TCGCCCTGAA CACGGACTAT	3480
	TACTTCTCCC ACCTGTTGGG GGCGGCGTGC GTGACATTCA AGGCCCTGTT TGGGAATAAC	3540
	GCCAAGATCA CCGAGAGTCT GTTAAAAAGG TTTATTCCCG AAGTGTGGCA CCCCCGGAC	3600
40	GACGTGACCG CGCGGCTCCG GGCCGAGGG TTCGGGGCGG TGGTGCCCG CGCTACGGCG	3660
	GAGGAACTC GTCGAATGTT GCATAGAGCC TTTGATACTC TAGCATGA	3708

SEQUENCE DESCRIPTION: SEQ ID NO:73:

Ile Ala Glu Thr Val Thr Leu

45

SEQUENCE DESCRIPTION: SEQ ID NO:74:

Val Ala Ser Gly Ile Leu Pro

SEQUENCE DESCRIPTION: SEQ ID NO:75:

50

Gly Ile Leu Pro Cys Leu Asn

SEQUENCE DESCRIPTION: SEQ ID NO:76:

Cys Leu Asn Ile Ala Glu Thr

55

SEQUENCE DESCRIPTION: SEQ ID NO:77:

Gln Gly Arg Lys Met Leu Glu

SEQUENCE DESCRIPTION: SEQ ID NO:78:

Ser Gln Ala Phe Val Glu

60

SEQUENCE DESCRIPTION: SEQ ID NO:79:

Ala Arg Phe Lys Val Ile

SEQUENCE DESCRIPTION: SEQ ID NO:80:

Leu Glu Thr Ser Gln Ala Phe

5 SEQUENCE DESCRIPTION: SEQ ID NO:81:
Leu Glu Arg Ser Gln Ala Phe

SEQUENCE DESCRIPTION: SEQ ID NO:82:
Glu Gly Ile Ser Pro Thr Ala

10 SEQUENCE DESCRIPTION: SEQ ID NO:83:
Glu Ala Ile Ser Pro Glu Arg

SEQUENCE DESCRIPTION: SEQ ID NO:84:
Ala Asp Leu Leu Gln Arg Pro

15 SEQUENCE DESCRIPTION: SEQ ID NO:85:
Ala Gly Leu Leu Arg Arg Pro

SEQUENCE DESCRIPTION: SEQ ID NO:86:
Gln Arg Pro Ile Glu Ala Ser

20 SEQUENCE DESCRIPTION: SEQ ID NO:87:
Arg Arg Pro Ile Asp Val Ser

SEQUENCE DESCRIPTION: SEQ ID NO:88:
Ile Glu Ala Ser Pro Glu Ala

25 SEQUENCE DESCRIPTION: SEQ ID NO:89:
Ile Asp Val Ser Pro Asp Ala

30 SEQUENCE DESCRIPTION: SEQ ID NO:90:
Pro Asp Asp Tyr Glu Thr Phe

SEQUENCE DESCRIPTION: SEQ ID NO:91:
Lys Arg Lys Glu Ile Arg Lys

35 SEQUENCE DESCRIPTION: SEQ ID NO:92:
Leu Ala Lys Arg Lys Glu Ile

SEQUENCE DESCRIPTION: SEQ ID NO:93:
Leu Ala Ser Cys Thr Asp Pro

40 SEQUENCE DESCRIPTION: SEQ ID NO:94:
Thr Gly Ser Ala Leu His Gly

45 SEQUENCE DESCRIPTION: SEQ ID NO:95:
Pro Gly Asp Ser Leu His Leu

SEQUENCE DESCRIPTION: SEQ ID NO:96:
Ser Ala Leu His Gly His Pro

50 SEQUENCE DESCRIPTION: SEQ ID NO:97:
Asp Ser Leu His Leu His Pro

SEQUENCE DESCRIPTION: SEQ ID NO:98:
Gly His Pro Glu Leu Thr Pro

55 SEQUENCE DESCRIPTION: SEQ ID NO:99:
Leu His Pro His Leu Gly Pro

60 SEQUENCE DESCRIPTION: SEQ ID NO:100:
His Leu Ser Gly Gly Thr Val

SEQUENCE DESCRIPTION: SEQ ID NO:101:
Val Leu Ser Gly Gly Leu Val

	SEQUENCE DESCRIPTION: SEQ ID NO:102: Thr Asp Pro Thr Met Arg Thr	
5	SEQUENCE DESCRIPTION: SEQ ID NO:103: Thr Asp Pro Ala Leu Lys Thr	
10	SEQUENCE DESCRIPTION: SEQ ID NO:104: CAGTATCATC CAAGCGCACA A	21
	SEQUENCE DESCRIPTION: SEQ ID NO:105: CCAAGTATCA THCARGCNCA YAA	23
15	SEQUENCE DESCRIPTION: SEQ ID NO:106: GGAGTAGCAC AARTTRTGNG CYTG	24
	SEQUENCE DESCRIPTION: SEQ ID NO:107: TACGAAACCT TTGACCTNAG YGGNGG	26
20	SEQUENCE DESCRIPTION: SEQ ID NO:108: CGCAAGAACC TGGCCTCNTG YACNGAYCC	29
25	SEQUENCE DESCRIPTION: SEQ ID NO:109: TCTCAGGCGT TCGTAGARGG NATHTCNCC	29
	SEQUENCE DESCRIPTION: SEQ ID NO:110: CAGCTGGCCA TCAAGGTCAC	20
30	SEQUENCE DESCRIPTION: SEQ ID NO:111: AACGCGGTGT ACGGGTTCAC	20
35	SEQUENCE DESCRIPTION: SEQ ID NO:112: Arg Thr Ile Leu Asp Lys Gln Gln Leu Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala Ser Gly Ile Leu Pro Cys Leu	
	SEQUENCE DESCRIPTION: SEQ ID NO:113: Ser Ile Ile Gln Ala His Asn Leu Cys Tyr Ser Thr Leu Ile Pro	
40	SEQUENCE DESCRIPTION: SEQ ID NO:114: CGTTGCCTCT GGCATACTGC CTTGCCTAAA CATAGCGGAG ACCGTGACAC TACAAGGGCG AAAGATGCTG GAGAGATCTC AGGCCTTTGT AGAGGCCATC TCGCCGGAAC GCCTAGCGGG TCTCCTGCGG AGGCCAATAG ACGTCTCACC CGACGCCCGA TTCAAGGTCA TA	60 120 172
45	SEQUENCE DESCRIPTION: SEQ ID NO:115: Val Ala Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gln Gly Arg Lys Met Leu Glu Arg Ser Gln Ala Phe Val Glu Ala Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Ile Asp Val Ser Pro Asp Ala Arg Phe Lys Val Ile	
50	SEQUENCE DESCRIPTION: SEQ ID NO:116: GAC GAC CGC AGC GTG TGC GTG AAY GTN TTY GGN CAG CGC TGC TAC TTC Asp Asp Arg Ser Val Cys Val Asn Val Phe Gly Gln Arg Cys Tyr Phe TAC ACA CTA GCA CCC CAG GGG GTA AAC CTG ACC CAC GTC CTC CAG CAG Tyr Thr Leu Ala Pro Gln Gly Val Asn Leu Thr His Val Leu Gln Gln GCC CTC CAG GCT GGC TTC GGT CGC GCA TCC TGC GGC TTC TCC ACC GAG Ala Leu Gln Ala Gly Phe Gly Arg Ala Ser Cys Gly Phe Ser Thr Glu CCG GTC AGA AAA AAA ATC TTG CGC GCG TAC GAC ACA CAA CAA TAT GCT Pro Val Arg Lys Lys Ile Leu Arg Ala Tyr Asp Thr Gln Gln Tyr Ala GTG CAA AAA ATA ACC CTG TCA TCC AGT CCG ATG ATG CGA ACG CTT AGC Val Gln Lys Ile Thr Leu Ser Ser Ser Pro Met Met Arg Thr Leu Ser GAC CGC CTA ACA ACC TGT GGG TGC GAG GTG TTT GAG TCC AAT GTG GAC Asp Arg Leu Thr Thr Cys Gly Cys Glu Val Phe Glu Ser Asn Val Asp GCC ATT AGG CGC TTC GTG CTG GAC CAC GGG TTC TCG ACA TTC GGG TGG Ala Ile Arg Arg Phe Val Leu Asp His Gly Phe Ser Thr Phe Gly Trp	48 96 144 192 240 288 336

	TAC GAG TGC AGC AAC CCG GCC CCC CGC ACC CAG GCC AGA GAC TCT TGG	384
	Tyr Glu Cys Ser Asn Pro Ala Pro Arg Thr Gln Ala Arg Asp Ser Trp	
	ACG GAA CTG GAG TTT GAC TGC AGC TGG GAG GAC CTA AAG TTT ATC CCG	432
	Thr Glu Leu Glu Phe Asp Cys Ser Trp Glu Asp Leu Lys Phe Ile Pro	
5	GAG AGG ACG GAG TGG CCC CCA TAC ACA ATC CTA TCC TTT GAT ATA GAA	480
	Glu Arg Thr Glu Trp Pro Pro Tyr Thr Ile Leu Ser Phe Asp Ile Glu	
	TGT ATG GGC GAG AAG GGT TTT CCC AAC GCG ACT CAA GAC GAG GAC ATG	528
	Cys Met Gly Glu Lys Gly Phe Pro Asn Ala Thr Gln Asp Glu Asp Met	
	ATT ATA CAA ATC TCG TGT GTT TTA CAC ACA GTC GGC AAC GAT AAA CCG	576
10	Ile Ile Gln Ile Ser Cys Val Leu His Thr Val Gly Asn Asp Lys Pro	
	TAC ACC CGC ATG CTA CTG GGC CTG GGG ACA TGC GAC CCC CTT CCT GGG	624
	Tyr Thr Arg Met Leu Leu Gly Leu Gly Thr Cys Asp Pro Leu Pro Gly	
	GTG GAG GTC TTT GAG TTT CCT TCG GAG TAC GAC ATG CTG GCC GCC TTC	672
	Val Glu Val Phe Glu Phe Pro Ser Glu Tyr Asp Met Leu Ala Ala Phe	
15	CTC AGC ATG CTC CGC GAT TAC AAT GTG GAG TTT ATA ACG GGG TAC AAC	720
	Leu Ser Met Leu Arg Asp Tyr Asn Val Glu Phe Ile Thr Gly Tyr Asn	
	ATA GCA AAC TTT GAC CTT CCA TAC ATC ATA GCC CGG GCA ACT CAG GTG	768
	Ile Ala Asn Phe Asp Leu Pro Tyr Ile Ile Ala Arg Ala Thr Gln Val	
	TAC GAC TTC AAG CTG CAG GAC TTC ACC AAA ATA AAA ACT GGG TCC GTG	816
20	Tyr Asp Phe Lys Leu Gln Asp Phe Thr Lys Ile Lys Thr Gly Ser Val	
	TTT GAG GTC CAC CAA CCC AGA GGC GGT TCC GAT GGG GGC AAC TTC ATG	864
	Phe Glu Val His Gln Pro Arg Gly Gly Ser Asp Gly Gly Asn Phe Met	
	AGG TCC CAG TCA AAG GTC AAA ATA TCG GGG ATC GTC CCC ATA GAC ATG	912
	Arg Ser Gln Ser Lys Val Lys Ile Ser Gly Ile Val Pro Ile Asp Met	
25	TAC CAG GTT TGC AGG GAA AAG CTG AGT CTG TCA GAC TAC AAG CTG GAC	960
	Tyr Gln Val Cys Arg Glu Lys Leu Ser Leu Ser Asp Tyr Lys Leu Asp	
	ACA GTG GCT AAG CAA TGC CTC GGT CGA CAA AAA GAT GAC ATC TCA TAC	1008
	Thr Val Ala Lys Gln Cys Leu Gly Arg Gln Lys Asp Asp Ile Ser Tyr	
	AAG GAC ATA CCC CCG CTT TTT AAA TCT GGG CCT GAT GGT CGC GCA AAG	1056
30	Lys Asp Ile Pro Pro Leu Phe Lys Ser Gly Pro Asp Gly Arg Ala Lys	
	GTG GGA AAC TAC TGT GTT ATT GAC TCG GTC CTG GTT ATG GAT CTT CTG	1104
	Val Gly Asn Tyr Cys Val Ile Asp Ser Val Leu Val Met Asp Leu Leu	
	CTA CGG TTT CAG ACC CAT GTT GAG ATC TCG GAA ATA GCC AAG CTG GCC	1152
	Leu Arg Phe Gln Thr His Val Glu Ile Ser Glu Ile Ala Lys Leu Ala	
35	AAG ATC CCC ACC CGT AGG GTA CTG ACG GAC GGC CAA CAG ATC AGG GTA	1200
	Lys Ile Pro Thr Arg Arg Val Leu Thr Asp Gly Gln Gln Ile Arg Val	
	TTT TCC TGC CTC TTG GAG GCT GCT GCC ACG GAA GGT TAC ATT CTC CCC	1248
	Phe Ser Cys Leu Leu Glu Ala Ala Ala Thr Glu Gly Tyr Ile Leu Pro	
	GTC CCA AAA GGA GAC GCG GTT AGC GGG TAT CAG GGG GCC ACT GTA ATA	1296
40	Val Pro Lys Gly Asp Ala Val Ser Gly Tyr Gln Gly Ala Thr Val Ile	
	AGC CCC TCT CCG GGA TTC TAT GAC GAC CCC GTA CTC GTG GTG GAT TTT	1344
	Ser Pro Ser Pro Gly Phe Tyr Asp Asp Pro Val Leu Val Val Asp Phe	
	GCC AGC TTG TAC CCC AGT ATC ATC CAA GCG CAC AAC TTG TGC TAC TCC	1392
	Ala Ser Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Tyr Ser	
45	ACA CTG ATA CCC GGC GAT TCG CTC CAC CTG CAC CCA CAC CTC TCC CCG	1440
	Thr Leu Ile Pro Gly Asp Ser Leu His Leu His Pro His Leu Ser Pro	
	GAC GAC TAC GAA ACC TTT GTC CTC AGC GGA GGT CCG GTC CAC TTT GTA	1488
	Asp Asp Tyr Glu Thr Phe Val Leu Ser Gly Gly Pro Val His Phe Val	
	AAA AAA CAC AAA AGG GAG TCC CTT CTT GCC AAG CTT CTG ACG GTA TGG	1536
50	Lys Lys His Lys Arg Glu Ser Leu Leu Ala Lys Leu Leu Thr Val Trp	
	CTC GCG AAG AGA AAA GAA ATA AGA AAG ACC CTG GCA TCA TGC ACG GAC	1584
	Leu Ala Lys Arg Lys Glu Ile Arg Lys Thr Leu Ala Ser Cys Thr Asp	
	CCC GCA CTG AAA ACT ATT CTA GAC AAA CAA CAA CTG GCC ATC AAG GTT	1632
	Pro Ala Leu Lys Thr Ile Leu Asp Lys Gln Gln Leu Ala Ile Lys Val	
55	ACC TGC AAC GCC GTT TAC GGC TTC ACG GGC GTT GCC TCT GGC ATA CTG	1680
	Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala Ser Gly Ile Leu	
	CCT TGC CTA AAC ATA GCG GAG ACC GTG ACA CTA CAA GGG CGA AAG ATG	1728
	Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gln Gly Arg Lys Met	
	CTG GAG AGA TCT CAG GCC TTT GTA GAG GCC ATC TCG CCG GAA CGC CTA	1776
60	Leu Glu Arg Ser Gln Ala Phe Val Glu Ala Ile Ser Pro Glu Arg Leu	
	GCG GGT CTC CTG CGG AGG CCA GTA GAC GTC TCA CCC GAC GCC CGA TTC	1824
	Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Ala Arg Phe	
	AAG GTC ATA TAC GGC GAC ACT GAC TCT CTT TTC ATA TGC TGC ATG GGT	1872
	Lys Val Ile Tyr Gly Asp Thr Asp Ser Leu Phe Ile Cys Cys Met Gly	

	TTC AAC ATG GAC AGC GTG TCA GAC TTC GCG GAG GAG CTA GCG TCA ATC	1920
	Phe Asn Met Asp Ser Val Ser Asp Phe Ala Glu Glu Leu Ala Ser Ile	
	ACC ACC AAC ACG CTG TTT CGT AGC CCC ATC AAG CTG GAG GCT GAA AAG	1968
	Thr Thr Asn Thr Leu Phe Arg Ser Pro Ile Lys Leu Glu Ala Glu Lys	
5	ATC TTC AAG TGC CTT CTG CTC CTG ACT AAA AAG AGA TAC GTG GGG GTA	2016
	Ile Phe Lys Cys Leu Leu Leu Leu Thr Lys Lys Arg Tyr Val Gly Val	
	CTC AGT GAC GAC AAG GTT CTG ATG AAG GGC GTA GAC CTC ATT AGG AAA	2064
	Leu Ser Asp Asp Lys Val Leu Met Lys Gly Val Asp Leu Ile Arg Lys	
	ACA GCC TGT CGT TTT GTC CAG GAA AAG AGC AGT CAG GTC CTG GAC CTC	2112
10	Thr Ala Cys Arg Phe Val Gln Glu Lys Ser Ser Gln Val Leu Asp Leu	
	ATA CTG CGG GAG CCG AGC GTC AAG GCC GCG GCC AAG CTT ATT TCG GGG	2160
	Ile Leu Arg Glu Pro Ser Val Lys Ala Ala Ala Lys Leu Ile Ser Gly	
	CAG GCG ACA GAC TGG GTG TAC AGG GAA GGG CTC CCA GAG GGG TTC GTC	2208
	Gln Ala Thr Asp Trp Val Tyr Arg Glu Gly Leu Pro Glu Gly Phe Val	
15	AAG ATA ATT CAA GTG CTC AAC GCG AGC CAC CGG GAA CTG TGC GAA CGC	2256
	Lys Ile Ile Gln Val Leu Asn Ala Ser His Arg Glu Leu Cys Glu Arg	
	AGC GTA CCA GTA GAC AAA CTG ACG TTT ACC ACC GAG CTA AGC CGC CCG	2304
	Ser Val Pro Val Asp Lys Leu Thr Phe Thr Thr Glu Leu Ser Arg Pro	
	CTG GCG GAC TAC AAG ACG CAA AAC CTC CCG CAC CTG ACC GTG TAC CAA	2352
20	Leu Ala Asp Tyr Lys Thr Gln Asn Leu Pro His Leu Thr Val Tyr Gln	
	AAG CTA CAA GCT AGA CAG GAG GAG CTT CCA CAG ATA CAC GAC AGA ATC	2400
	Lys Leu Gln Ala Arg Gln Glu Glu Leu Pro Gln Ile His Asp Arg Ile	
	CCC TAC GTG TTC GTC GAC GCC CCA GGT AGC CTG CGC TCC GAG CTG GCA	2448
	Pro Tyr Val Phe Val Asp Ala Pro Gly Ser Leu Arg Ser Glu Leu Ala	
25	GAG CAC CCC GAG TAC GTT AAG CAG CAC GGA CTG CGC GTG GCG GTG GAC	2496
	Glu His Pro Glu Tyr Val Lys Gln His Gly Leu Arg Val Ala Val Asp	
	CTG TAT TTC GAC AAG	2511
	Leu Tyr Phe Asp Lys	
30	SEQUENCE DESCRIPTION: SEQ ID NO:117:	
	Asp Asp Arg Ser Val Cys Val Asn Val Phe Gly Gln Arg Cys Tyr Phe	
	Tyr Thr Leu Ala Pro Gln Gly Val Asn Leu Thr His Val Leu Gln Gln	
	Ala Leu Gln Ala Gly Phe Gly Arg Ala Ser Cys Gly Phe Ser Thr Glu	
	Pro Val Arg Lys Lys Ile Leu Arg Ala Tyr Asp Thr Gln Gln Tyr Ala	
35	Val Gln Lys Ile Thr Leu Ser Ser Ser Pro Met Met Arg Thr Leu Ser	
	Asp Arg Leu Thr Thr Cys Gly Cys Glu Val Phe Glu Ser Asn Val Asp	
	Ala Ile Arg Arg Phe Val Leu Asp His Gly Phe Ser Thr Phe Gly Trp	
	Tyr Glu Cys Ser Asn Pro Ala Pro Arg Thr Gln Ala Arg Asp Ser Trp	
	Thr Glu Leu Glu Phe Asp Cys Ser Trp Glu Asp Leu Lys Phe Ile Pro	
40	Glu Arg Thr Glu Trp Pro Pro Tyr Thr Ile Leu Ser Phe Asp Ile Glu	
	Cys Met Gly Glu Lys Gly Phe Pro Asn Ala Thr Gln Asp Glu Asp Met	
	Ile Ile Gln Ile Ser Cys Val Leu His Thr Val Gly Asn Asp Lys Pro	
	Tyr Thr Arg Met Leu Leu Gly Leu Gly Thr Cys Asp Pro Leu Pro Gly	
	Val Glu Val Phe Glu Phe Pro Ser Glu Tyr Asp Met Leu Ala Ala Phe	
45	Leu Ser Met Leu Arg Asp Tyr Asn Val Glu Phe Ile Thr Gly Tyr Asn	
	Ile Ala Asn Phe Asp Leu Pro Tyr Ile Ile Ala Arg Ala Thr Gln Val	
	Tyr Asp Phe Lys Leu Gln Asp Phe Thr Lys Ile Lys Thr Gly Ser Val	
	Phe Glu Val His Gln Pro Arg Gly Gly Ser Asp Gly Gly Asn Phe Met	
	Arg Ser Gln Ser Lys Val Lys Ile Ser Gly Ile Val Pro Ile Asp Met	
50	Tyr Gln Val Cys Arg Glu Lys Leu Ser Leu Ser Asp Tyr Lys Leu Asp	
	Thr Val Ala Lys Gln Cys Leu Gly Arg Gln Lys Asp Asp Ile Ser Tyr	
	Lys Asp Ile Pro Pro Leu Phe Lys Ser Gly Pro Asp Gly Arg Ala Lys	
	Val Gly Asn Tyr Cys Val Ile Asp Ser Val Leu Val Met Asp Leu Leu	
	Leu Arg Phe Gln Thr His Val Glu Ile Ser Glu Ile Ala Lys Leu Ala	
55	Lys Ile Pro Thr Arg Arg Val Leu Thr Asp Gly Gln Gln Ile Arg Val	
	Phe Ser Cys Leu Leu Glu Ala Ala Ala Thr Glu Gly Tyr Ile Leu Pro	
	Val Pro Lys Gly Asp Ala Val Ser Gly Tyr Gln Gly Ala Thr Val Ile	
	Ser Pro Ser Pro Gly Phe Tyr Asp Asp Pro Val Leu Val Val Asp Phe	
	Ala Ser Leu Tyr Pro Ser Ile Ile Gln Ala His Asn Leu Cys Tyr Ser	
60	Thr Leu Ile Pro Gly Asp Ser Leu His Leu His Pro His Leu Ser Pro	
	Asp Asp Tyr Glu Thr Phe Val Leu Ser Gly Gly Pro Val His Phe Val	
	Lys Lys His Lys Arg Glu Ser Leu Leu Ala Lys Leu Leu Thr Val Trp	
	Leu Ala Lys Arg Lys Glu Ile Arg Lys Thr Leu Ala Ser Cys Thr Asp	
	Pro Ala Leu Lys Thr Ile Leu Asp Lys Gln Gln Leu Ala Ile Lys Val	

Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala Ser Gly Ile Leu
 Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gln Gly Arg Lys Met
 Leu Glu Arg Ser Gln Ala Phe Val Glu Ala Ile Ser Pro Glu Arg Leu
 Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Ala Arg Phe
 5 Lys Val Ile Tyr Gly Asp Thr Asp Ser Leu Phe Ile Cys Cys Met Gly
 Phe Asn Met Asp Ser Val Ser Asp Phe Ala Glu Glu Leu Ala Ser Ile
 Thr Thr Asn Thr Leu Phe Arg Ser Pro Ile Lys Leu Glu Ala Glu Lys
 Ile Phe Lys Cys Leu Leu Leu Leu Thr Lys Lys Arg Tyr Val Gly Val
 Leu Ser Asp Asp Lys Val Leu Met Lys Gly Val Asp Leu Ile Arg Lys
 10 Thr Ala Cys Arg Phe Val Gln Glu Lys Ser Ser Gln Val Leu Asp Leu
 Ile Leu Arg Glu Pro Ser Val Lys Ala Ala Ala Lys Leu Ile Ser Gly
 Gln Ala Thr Asp Trp Val Tyr Arg Glu Gly Leu Pro Glu Gly Phe Val
 Lys Ile Ile Gln Val Leu Asn Ala Ser His Arg Glu Leu Cys Glu Arg
 Ser Val Pro Val Asp Lys Leu Thr Phe Thr Thr Glu Leu Ser Arg Pro
 15 Leu Ala Asp Tyr Lys Thr Gln Asn Leu Pro His Leu Thr Val Tyr Gln
 Lys Leu Gln Ala Arg Gln Glu Glu Leu Pro Gln Ile His Asp Arg Ile
 Pro Tyr Val Phe Val Asp Ala Pro Gly Ser Leu Arg Ser Glu Leu Ala
 Glu His Pro Glu Tyr Val Lys Gln His Gly Leu Arg Val Ala Val Asp
 Leu Tyr Phe Asp Lys

20

SEQUENCE DESCRIPTION: SEQ ID NO:118:

C CTA TGT TAC TCT ACC CTG ATT CAG GGG AAC GCC ATT CTC TCG CAC 46
 Leu Cys Tyr Ser Thr Leu Ile Gln Gly Asn Ala Ile Leu Ser His
 CCC GAG TTG ACC CCG AAC GAC TAC GAA ACA TTC CAC CTA AGC GGA GGA 94
 25 Pro Glu Leu Thr Pro Asn Asp Tyr Glu Thr Phe His Leu Ser Gly Gly
 CCG GTG CAC TTC GTA AAA AAA CAC GTA CGA GAG TCA TTA CTG TCA AAA 142
 Pro Val His Phe Val Lys Lys His Val Arg Glu Ser Leu Leu Ser Lys
 CTT CTG ACG ACT TGG CTA ACA AAA AGA AAA GAG ATC CGC AAA AAT CTC 190
 Leu Leu Thr Thr Trp Leu Thr Lys Arg Lys Glu Ile Arg Lys Asn Leu
 30 GCC TCG TGC GGA GAC CCA ACC ATG CGA ACC ATC CTT GAT AAG CAG CAG 238
 Ala Ser Cys Gly Asp Pro Thr Met Arg Thr Ile Leu Asp Lys Gln Gln
 CTG GCC ATC AAG GTC ACA TGT AAT GCG GTG TAC GGG TTT ACC GGC GTC 286
 Leu Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val
 GCC TCC GGT ATT CTA CCG TGC CTG AAT ATT GCA GAA ACA GTC ACC CTC 334
 35 Ala Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu
 CAG GGC AGA AAA ATG CTA GAA ACG TCC CAG GCG TTT GTA GAG GGC ATA 382
 Gln Gly Arg Lys Met Leu Glu Thr Ser Gln Ala Phe Val Glu Gly Ile
 TCG CCA AAA GAC CTG TCA GAC CTG ATA CAA CGT CCG ATC GAC GCT TCC 430
 Ser Pro Lys Asp Leu Ser Asp Leu Ile Gln Arg Pro Ile Asp Ala Ser
 40 CCG GAC GCC AGG TTT AAA GTG ATA 454
 Pro Asp Ala Arg Phe Lys Val Ile

SEQUENCE DESCRIPTION: SEQ ID NO:119:

Leu Cys Tyr Ser Thr Leu Ile Gln Gly Asn Ala Ile Leu Ser His Pro
 45 Glu Leu Thr Pro Asn Asp Tyr Glu Thr Phe His Leu Ser Gly Gly Pro
 Val His Phe Val Lys Lys His Val Arg Glu Ser Leu Leu Ser Lys Leu
 Leu Thr Thr Trp Leu Thr Lys Arg Lys Glu Ile Arg Lys Asn Leu Ala
 Ser Cys Gly Asp Pro Thr Met Arg Thr Ile Leu Asp Lys Gln Gln Leu
 Ala Ile Lys Val Thr Cys Asn Ala Val Tyr Gly Phe Thr Gly Val Ala
 50 Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr Leu Gln
 Gly Arg Lys Met Leu Glu Thr Ser Gln Ala Phe Val Glu Gly Ile Ser
 Pro Lys Asp Leu Ser Asp Leu Ile Gln Arg Pro Ile Asp Ala Ser Pro
 Asp Ala Arg Phe Lys Val Ile

55 SEQUENCE DESCRIPTION: SEQ ID NO:120:

Val Ala Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr
 Leu Gln Gly Arg Lys Met Leu Glu Arg Ser Gln Ala Phe Val Glu Ala
 Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Val Asp Val
 Ser Pro Asp Ala Arg Phe Arg Val Ile

60

SEQUENCE DESCRIPTION: SEQ ID NO:121:

Val Ala Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr
 Leu Gln Gly Arg Lys Met Leu Glu Arg Ser Gln Ala Phe Val Glu Ala
 Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Ile Asp Val

Ser Pro Asp Ala Arg Phe Lys Val Ile

5	SEQUENCE DESCRIPTION: SEQ ID NO:122:	
	Val Ala Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr	
	Leu Gln Gly Arg Lys Met Leu Glu Arg Ser Gln Ala Phe Val Glu Ala	
	Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Ala Arg Phe Lys Val Ile	
10	SEQUENCE DESCRIPTION: SEQ ID NO:123:	
	Val Ala Ser Gly Ile Leu Pro Cys Leu Asn Ile Ala Glu Thr Val Thr	
	Leu Gln Gly Arg Lys Met Leu Glu Arg Ser Gln Ala Phe Val Glu Ala	
	Ile Ser Pro Glu Arg Leu Ala Gly Leu Leu Arg Arg Pro Val Asp Val Ser Pro Asp Ala Arg Phe Arg Val Ile	
15	SEQUENCE DESCRIPTION: SEQ ID NO:124:	
	AACACAGAGT CNGTRTCNCC RTA	23
20	SEQUENCE DESCRIPTION: SEQ ID NO:125:	
	AGCATCATCA TGGCCCA YAA YCTNTGYT	28
	SEQUENCE DESCRIPTION: SEQ ID NO:126:	
	GAYTTYGCNA GYYTNTAYCC	20
25	SEQUENCE DESCRIPTION: SEQ ID NO:127:	
	CACCCATRCA YTCDATRTCR AA	22
	SEQUENCE DESCRIPTION: SEQ ID NO:128:	
	TACAACGTCC TCTCCTTYGA YATHGARTG	29
30	SEQUENCE DESCRIPTION: SEQ ID NO:129:	
	GTCTGCGTGA AYGNTNTTYGG NCA	23
35	SEQUENCE DESCRIPTION: SEQ ID NO:130:	
	GACGACCGCA GCGTGTCGT GAAYGTNTTY GGNCA	35
	SEQUENCE DESCRIPTION: SEQ ID NO:131:	
	ACGACCGCAG CGTGTCGTG	20
40	SEQUENCE DESCRIPTION: SEQ ID NO:132:	
	TAAAAGTACA GCTCCTGCCC GAANACRTTN ACRC A	35
	SEQUENCE DESCRIPTION: SEQ ID NO:133:	
	TAAAAGTACA GCTCCTGCCC GAA	23
45	SEQUENCE DESCRIPTION: SEQ ID NO:134:	
	TTTGACTTTG CCAGCCTGTA YCCNAGYATN AT	32
50	SEQUENCE DESCRIPTION: SEQ ID NO:135:	
	TTTGACTTTG CCAGCCTGTA YCCNTCNATN AT	32
	SEQUENCE DESCRIPTION: SEQ ID NO:136:	
	TTTGACTTTG CCAGCCTGTA	20
55	SEQUENCE DESCRIPTION: SEQ ID NO:137:	
	CGGCATGCGA CAAACACGGA GTCCGTRTCN CCRTADAT	38
	SEQUENCE DESCRIPTION: SEQ ID NO:138:	
	TTAGCTACTC CGTGGAGCAG YTTRTCRAAR TA	32
60	SEQUENCE DESCRIPTION: SEQ ID NO:139:	
	TTGTGCGCTT GGATGATACT G	21
	SEQUENCE DESCRIPTION: SEQ ID NO:140:	
	GAGGGCCTGC TGGAGGACGT G	21

	SEQUENCE DESCRIPTION: SEQ ID NO:141: CGGTGGAGAA GCCGCAGGAT G	21
5	SEQUENCE DESCRIPTION: SEQ ID NO:142: ACCTCCCGCA CCTGACCGTG T	21
	SEQUENCE DESCRIPTION: SEQ ID NO:143: AAGCTAGACA GGAGGAGCTT C	21
10	SEQUENCE DESCRIPTION: SEQ ID NO:144: ACTTGAATTA TCTTGACGAA C	21
	SEQUENCE DESCRIPTION: SEQ ID NO:145: ACGACAAGGT TCTGATGAAG G	21
	SEQUENCE DESCRIPTION: SEQ ID NO:146: AGAGACTCTT GGACGGAAC T	21
20	SEQUENCE DESCRIPTION: SEQ ID NO:147: AGTTTGACTG CAGCTGGGAG G	21
	SEQUENCE DESCRIPTION: SEQ ID NO:148: CGGGTATCAG TGTGGAGTAG C	21
25	SEQUENCE DESCRIPTION: SEQ ID NO:149: GAGGACAAAG GTTTCGTAGT C	21
	SEQUENCE DESCRIPTION: SEQ ID NO:150: CTATGTTACT CTACCCTGAT T	21
30	SEQUENCE DESCRIPTION: SEQ ID NO:151: GTATATCTCT TTAAACCTGG C	21
	SEQUENCE DESCRIPTION: SEQ ID NO:152: AACCTGGCGT CCGGGGAAGC G	21
35		

CLAIMS

We claim:

- 5 1. An isolated polynucleotide with a region encoding a DNA polymerase of a herpes virus, the polynucleotide comprising a sequence of nucleotides at least 69% identical to nucleotides 27 to 501 of a sequence selected from the group consisting of SEQ. ID NO:1 and SEQ. ID NO:3.
- 10 2. An isolated polynucleotide comprising a fragment of at least 18 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of claim 1, wherein the sequence of said fragment is not contained in SEQ. ID NOS:110 or 111.
- 15 3. An isolated polynucleotide comprising a fragment of at least 50 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of claim 1.
4. The isolated polynucleotide of claim 2, which encodes a polypeptide with nucleic acid binding activity, nucleotide binding activity, or DNA polymerase activity.
- 20 5. An isolated polynucleotide with a region encoding a DNA polymerase of a herpes virus, the polynucleotide comprising a sequence of 26 nucleotides at least 80% identical to oligonucleotide LSGGA (SEQ. ID NO:107), or a sequence of 29 nucleotides at least 69% identical to oligonucleotide CTDPA (SEQ. ID NO:108) or a sequence of 32 nucleotides at least 80% identical to oligonucleotide KMLEA (SEQ. ID NO:22), or a sequence of 29 nucleotides at least 69% identical to oligonucleotide GISPA (SEQ. ID NO:109).
- 25 6. An isolated polynucleotide comprising a fragment of at least 18 consecutive nucleotides of the DNA polymerase encoding region of the polynucleotide of claim 5, wherein the sequence of said fragment is not contained in SEQ. ID NOS:110 or 111.
- 30 7. The polynucleotide of claim 1 or claim 2, wherein said herpes virus is capable of infecting primates.
8. The polynucleotide of claim 1 or claim 2, wherein said herpes virus is RFHV, RFHV2, or KSHV.
- 35 9. An isolated polynucleotide comprising a linear sequence of at least 18 nucleotides identical to a linear sequence between nucleotides 27 to 501 inclusive of SEQ. ID NO:1, or between nucleotides 27 to 501 inclusive of SEQ. ID NO:3, or between nucleotides 36 to 2499 inclusive of SEQ. ID NO:116, or between nucleotides 1 to 454 inclusive of SEQ. ID NO:118, but not to a linear sequence within either SEQ. ID NO:110 or SEQ. ID NO:111.
- 40

10. The isolated polynucleotide of claim 9, comprising a linear sequence essentially identical to nucleotides 27 to 501 of SEQ. ID NO:1, or to nucleotides 27 to 501 of SEQ. ID NO:3, or to nucleotides 36 to 2499 of SEQ. ID NO:116, or to nucleotides 1 to 454 of SEQ. ID NO:118.
- 5 11. An isolated polypeptide encoded by the polynucleotide of claim 3.
12. An isolated polypeptide, comprising a linear sequence of at least 12 amino acids essentially identical to a sequence between amino acids 10 to 167 inclusive of SEQ. ID NO:2 or between amino acids 10 to 167 inclusive of SEQ. ID NO:4 or between amino acids 13 to 833 inclusive of
10 SEQ. ID NO:117, or in any of SEQ. ID NOS:119-123, but which is not contained in SEQ. ID NOS:112 or in SEQ. ID NO:113.
13. The isolated polypeptide of claim 12, which has nucleic acid binding activity, nucleotide binding activity, or DNA polymerase activity.
- 15 14. A fusion polypeptide comprising the amino acid sequence of an isolated peptide of claim 12, joined to a second amino acid sequence.
15. An isolated polypeptide, comprising a linear sequence of amino acids identical to a sequence
20 selected from the group consisting of SEQ. ID NOS:80, 82, 84, 86, 88, and 90 to 103.
16. An isolated or non-naturally occurring polynucleotide encoding the polypeptide of claim 12.
17. A polynucleotide encoding a fusion polypeptide, comprising the polynucleotide of claim 2 joined
25 directly to a second polynucleotide encoding a polypeptide.
18. A recombinant cloning vector comprising a polynucleotide sequence encoding a polypeptide of at least 12 consecutive amino acids identical to that of a polypeptide according to claim 12.
- 30 19. A recombinant expression vector comprising a polynucleotide sequence encoding a polypeptide of at least 12 consecutive amino acids identical to that of a polypeptide according to claim 12.
20. A recombinant cloning vector comprising a linear sequence encoding a DNA polymerase of a
35 herpes virus, the sequence being at least 18 nucleotides long and identical to a linear sequence within SEQ. ID NOS:1, 3, 116, or 118, but not in SEQ. ID NOS:110 or 111.
21. A host cell genetically altered by the polynucleotide of claim 16, or by the vector of claim 18, claim 19, or claim 20.
- 40

22. A monoclonal or isolated polyclonal antibody specific for a DNA polymerase encoded in said encoding region of the polynucleotide of claim 1.
23. A monoclonal or isolated polyclonal antibody specific for the polypeptide of claim 12.
24. The antibody of claim 22, which is a monoclonal antibody.
25. The antibody of claim 22, which is an isolated polyclonal antibody.
26. An oligonucleotide essentially identical to an oligonucleotide selected from the group consisting of SEQ. ID NOS:5 to 16, 21, 22, 104-109, and 124-152.
27. A method of obtaining an amplified copy of a polynucleotide encoding a DNA polymerase, comprising the steps of:
- a) contacting the polynucleotide with the oligonucleotide of claim 26; and
- b) elongating oligonucleotide that has formed a duplex with the polynucleotide.
28. The method of claim 27, comprising performing a polymerase chain reaction (PCR).
29. The method of claim 28, wherein said PCR comprises repeated cycles of annealing and elongating, wherein the annealing is conducted at a temperature of at least 60°C.
30. The method of claim 28, wherein said PCR is conducted in a buffer containing 10-30 mM $(\text{NH}_4)_2\text{SO}_4$ and 1-10 mM MgCl_2 .
31. The method of claim 27, wherein the polynucleotide which is amplified is first obtained from a biological sample taken from an individual affected with a disease featuring fibroblast proliferation and collagen deposition.
32. A method of detecting viral DNA or RNA in a sample of primate origin, comprising the steps of:
- a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of claim 2 under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:24 to 29; and
- b) detecting the presence of said stable duplex formed in step a), if any.
33. The method of claim 32 further comprising conducting an amplification reaction on the DNA or RNA of the sample prior to being contacted with the probe.

34. The method of claim 33, wherein the amplification reaction is conducted using an oligonucleotide primer comprising a sequence according to claim 26.
35. A method of detecting viral DNA or RNA in a sample of primate origin, comprising the steps of:
- 5 a) contacting the DNA or RNA in the sample with an oligonucleotide probe comprising a sequence shown in SEQ. ID NOS: 21, 22, 107, 108, or 109, under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:24 to 29; and
- 10 b) detecting the presence of said stable duplex formed in step a), if any.
36. A method of detecting viral DNA or RNA in a sample, comprising the steps of:
- 15 a) contacting the DNA or RNA in the sample with an oligonucleotide probe comprising a sequence shown in SEQ. ID NOS:22, 107, 108 or 109 under conditions that would permit the probe to form a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:23 to 29; and
- b) detecting the presence of said stable duplex formed in step a), if any.
- 20 37. A method of detecting viral DNA or RNA in a sample, comprising the steps of:
- a) conducting an amplification reaction on a polynucleotide in the sample using the oligonucleotide of claim 26 as a primer in the reaction; and
- b) detecting the presence of amplified copies of the polynucleotide, if any.
- 25 38. An isolated polynucleotide capable of forming a stable duplex with an oligonucleotide comprising a sequence selected from the group consisting of SEQ. ID NO:107, SEQ. ID NO:108, and their respective complementary sequences, under conditions wherein the oligonucleotide is capable of forming a stable duplex with a polynucleotide having the sequence shown in SEQ. ID NO:1, and with a polynucleotide having the sequence shown in
- 30 SEQ. ID NO:3, but not with a polynucleotide having a sequence of any of SEQ. ID NOS:23 to 29.
39. An isolated polypeptide comprising a linear sequence of 12 amino acids encoded within the polynucleotide of claim 38.
- 35 40. A method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of claim 32

41. A method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of:
- 5 a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of claim 2 under conditions that would permit the probe to form a stable duplex with a polynucleotide having at least one sequence selected from the group consisting of SEQ. ID NOS:1, 3, 116, or 118, but not with polynucleotides having a sequence of any of SEQ. ID NOS:24 to 29; and
- 10 b) detecting the presence of said stable duplex formed in step a), if any.
42. A method for detecting infection of an individual by a herpes virus, comprising detecting viral DNA or RNA in a biological sample obtained from the individual, wherein the detecting of viral DNA or RNA is by the method of:
- 15 a) contacting the DNA or RNA in the sample with a probe comprising the polynucleotide of claim 2 under conditions that would permit the probe to form a stable duplex with a polynucleotide having a sequence shown in SEQ. ID NO:116, but not with polynucleotides having a sequence of any of SEQ. ID NOS:24 to 29; and
- 20 b) detecting the presence of said stable duplex formed in step a), if any.
43. A diagnostic kit for detecting a herpes virus polynucleotide in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the polynucleotide of claim 2.
44. A diagnostic kit for detecting a herpes virus polynucleotide in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the oligonucleotide of claim 26.
- 25 45. A method of detecting infection of an individual by a herpes virus, comprising the steps of:
- 30 a) contacting antibody from a sample obtained from the individual with the polypeptide of claim 11 or claim 12 under conditions that permit the formation of a stable antigen-antibody complex; and
- b) detecting said stable complexes formed in step a), if any.
46. A diagnostic kit for detecting an anti-herpesvirus antibody present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the polypeptide of claim 11 or claim 12.
- 35 47. A method of detecting infection of an individual by a herpes virus, comprising the steps of:
- 40 a) contacting a polypeptide from a sample obtained from the individual with the antibody of claim 22 or claim 23 under conditions that permit the formation of a stable antigen-antibody complex; and
- b) detecting said stable complexes formed in step a), if any.

- 5
48. A diagnostic kit for detecting a herpes virus polypeptide present in a biological sample, comprising a reagent in suitable packaging, wherein the reagent comprises the antibody of claim 22 or claim 23.
49. A composition for use in the treatment of herpes virus infection, comprising the polynucleotide of claim 2 and a compatible pharmaceutical excipient.
- 10
50. A method of determining whether a pharmaceutical candidate is useful for treating gamma herpes infection, comprising the steps of:
- a) contacting the polypeptide of claim 11 with the pharmaceutical candidate; and
 - b) determining whether a biochemical function of the polypeptide is altered by the pharmaceutical candidate.
- 15
51. The method of claim 50, wherein the biochemical function of the polypeptide determined in step b) is the binding of the polypeptide to a nucleic acid.
52. The method of claim 50, wherein the biochemical function of the polypeptide determined in step b) is DNA polymerase activity.
- 20
53. A method of determining whether a pharmaceutical candidate is useful for treating gamma herpes infection, comprising the steps of:
- a) genetically altering a cell with the polynucleotide of claim 2; and
 - b) determining the effect of the pharmaceutical candidate on the cell in comparison with a cell not genetically altered with the polynucleotide.
- 25
54. A method of obtaining a compound for use in treating an individual infected with herpes virus, comprising the steps of:
- a) creating a compound capable of binding a region of the polypeptide of claim 11 or claim 12 involved in interacting with a nucleic acid; and
 - b) determining whether the compound interferes with a biochemical function of the polypeptide.
- 30

Figure 1(A)

1/28

KSHV GTGTTGACTTTGCTAGCCTCTACCCCAGTATCATCCAAGCGCACAACTTGTGCTACTCC 60
V F D F A S L Y P S I I Q A H N L C Y S
(DFASA>) gtgttcgacttygcnagyytntaycc

KSHV ACACTGATACCCGGCGATTGCTCCACCTGCACCCACACCTCTCCCCGGACGACTACGAA 120
T L I P G D S L H L H P H L S P D D Y E

KSHV ACCTTTGTCCTCAGCGGAGGTCCGGTCCACTTTGTAAAAAACACAAAAGGGAGTCCCTT 180
T F V L S G G P V H F V K K H K R E S L

KSHV CTTACCAAGCTTCTGACGGTATGGCTCGCGAAGAGAAAAGAAATAAGAAAGACCCTGGCA 240
L T K L L T V W L A K R K E I R K T L A

KSHV TCATGCACGGACCCCGCACTGAAACTATTCTAGACAAACAACAACTGGCCATCAAGGTT 300
S C T D P A L K T I L D K Q Q L A I K V

(PCLNA>) gtcgcctctggcatcctnccntgyctnaa
(ILPCA>) ggcacccctaccgtgcctgaac
(VASGA>) cgctgcctccggcatcctacc

RFHV T C N A V Y G F T G V A S G I L P C L N 360
ACGTGCAACGCGGTGTACGGGTTTACGGGCGTCGCTTCCGGCATCTACCGTGCCTGAAC
** ***** ** ***** ** ** ***** ** ** ***** **

KSHV ACCTGCAACGCGGTGTACGGGTTTACGGGCGTTCGCTCTGGCATACTGCCTTGCCTAAAC 360
T C N A V Y G F T G V A S G I L P C L N
(VYGA>) acgtgcaacgcggtgtayggnktnacngg (CLNIA>) ctgccttgccctaaac-
(SGILA>) gcgttgccctctggcatactg

(GISPA>) tctcaggcgcttcgta-
(KMLEA>) cagggccggaagatgctggaracrtncargc

RFHV I A E T V T L Q G R K M L E I S Q A F V 420
ATCGCAGAGACGGTGACCCTCCAGGGCAGGAAAATGCTGGAAACGTCTCAGGCGTTCGTA
** ** ***** ** ** ** * ** ***** * ***** ** **

KSHV ATAGCGGAGACCGTGACACTACAAGGGCGAAAGATGCTGGAGAGATCTCAGGCCTTTGTA 420
I A E T V T L Q G R K M L E R S Q A F V
-atagcg (CLNIA>)

Figure 1(B)

2/28

(<PEARB) ccgcagagggc-
-garggnathtcncc (GISPA> (<PIEAB) ctggctagctccgcagagggc-
E G I S P I A L A D L L Q R P I E A S P
RFHV GAGGGAATCTCGCCAACGGCACTGGCAGACCTACTGCAGCGACCGATCGAGGCGTCTCCG 480
**** ***** ** ** * ** ***** * * ** ** * ** **
KSHV GAGGCCATCTCGCCGGAACGCCTAGCGGGTCTCCTGCGGAGGCCAATAGACGTCTCACCC 480
E A I S P E B L A G L L R R P I D V S P
(<IEASB) tccggttatctgcagagtgg
(<EARFB) gcagagtggg-

-cttcggtccaa (<PEARB)
-c (<PIEAB)
E A R F K V I Y G D T D S V F V A C
RFHV GAAGCCAGGTTTAAAGTGATATACGGCGACACCGACTCCGTGTTTGTGCATGCCG 536
** *** * ** ** ** *****
KSHV GACGCCGATTCAAGGTCATATACGGCGACACCGACTCCGTGTTTGTGCATGCCG 536
D A R F K V I Y G D T D S V F V A C
(<GDTD1B) atrccnctrtnctgaggcacaacagcgtacggc
-ctgcgggctaa (<EARFB)

3/28

Figure 2 (1)

hHV6	V-----MDSV-SFFNPYLEA-----NRLKK
hHSV1	MFSGG---GGPLSPGGKSAARAASGFFAPAGPRGAGR-GPPPCLRQNFYNPYLAPVGTQQ
hHSV2	MFCAA---GGPASPGGKSAARAASGFFAPHNPRGATQTAPPPCRRQNFYNPHLAQTGTQP
hVZV	M-----AIR-----TGFCNPFLTQASGI-----KYNPRTGRGSN--
eHV1	M-----AAREQANSVRR--SGFFNPFIGKRP-----FFRPGSGQTAETE
hEBV	M-----SGGL--FYNPFL-----RPNKGLLKPD--
sHV1	M-----D-----FYNPYL-----SKKPTDTKTPKLH
mCMV	M-----DTCVETFFNPYL-----RRK----PRRDWRR---CED----
gpCMV	M-----SAPV--FFNPYLCGGAARRNG-CSTVDSRR---VNGPTKK
hCMV	M-----FFNPYLSGGVTGGAVA-GGRRQRSQPGSAQGSQGR
iHV1	MDRNAVLYGVLEHRLPKWVELSDDTDLEPFFFSVRYITAGS-----EDAIMIQA
hHV6	KSRS-----SYIRILPRGIMHDGAA----GLIKDVCDSEPRMFYRDRQYLLSK
hHSV1	KPTGPTQRHTYYSECDEFRIAPRVLDEDAPPEKRAGVHDGHLKRAPKVYCGGDERDV-L
hHSV2	KAPGPAQRHTYYSECDEFRIAPRSLDEDAPAEQRTGVHDGRLRRAPKVYCGGDERDV-L
hVZV	--REF--LHSYKTTMSSFQFLAPKCLDEDVPMEEKGVHVGTLRPPKVYCNGKEVPI-L
eHV1	RPRPP--QHSYCTEVGSFKFIAPRCLDEEAPADQRRGVHVGTLRPPKVYCDGSEYDV-L
hEBV	--KE-----YL-RLIPKCFQTPGAA----GVVDVRGPQPPLCFYQDSLTVVGG
sHV1	TTRQ-----SICRLVPKCFRNPTEK----GVVSVSSFALPTYFFKGNNKVYL
mCMV	N-NK-----NFLQVVRGVLYDGAT----GLIKVQSGMEPRMFYAEKEYVLNP
gpCMV	G-KK-----SFLQVVRGVLYDGAT----GLIKVQSGMEPRMFYAEKEYVLNP
hCMV	PPQK-----QFLQIVPRGVMFQDGT----GLIKHKTGRLPLMFYREIKHLLSH
iHV1	LNLNTDEIVVFLVTNLNFMALIPTVYIENPGIRQLIASTPISYRSPITVFNGD-----
hHV6	EMTWPSL--DIARSKDY-----DHM-RMK-FHIYDAVETL--MFTDSIENLPFQYRHFV
hHSV1	RVGSGGFWRPRRSLWGGVDHAPAGFNPTVTVFHVYDILENVEHAYGMRAAQFHARFMDAI
hHSV2	RVGPEGFWPRRLRLWGGADHAPEGFDPTVTVFHVYDILEHVEHAYSMRAAQLHERFMDAI
hVZV	DFRCSSPWPRRVNIWGEIDFRGDKFDPRFNTFHVYDIVETTEAA----SNGDVS RFATAT
eHV1	NFASGGCWPRRIRVWNGQDFRGDGFNPRFERFHVYDIVETSESA----SHDDPSRFAELS
hEBV	DEDGKGMWWRQRAQEGTARPEADTHGSPLD-FHVYDILETV--YTHEKCAVIPSDKQGYV
sHV1	-ENGKSMWHLRRPCKNALLEEQ-----SIT-FHIYDIVETT--YSEDRCNDIPFKFQTDI
mCMV	DKPWP-----TLRTRGWCRGPYSDD---VR-FHTYDQVVNL--VLADSDEQISPRWNSHV
gpCMV	QMSWP-----TLPCRETCRVGCGREQ-PLR-FHTFDQIDST--VYADSVEQIFLGYYRRHV
hCMV	DMVWPCPWRETLVGRV-----VG-PIR-FHTYDQTDV--LFFDSPENVSPRYRQHL
iHV1	-----LKKWMDCDLFVFGTMAAQKAF-----IKAGNSVLGSLGGNVYTYGDHV
hHV6	IPSGTVIRMFGR-TEDGE----KICVNVFGQEYFY-----CECVDGRSLKATINN
hHSV1	TPTGTVITLLGL-TPEGH----RVAVHVGTRQYFYMNKEEVDRHLQCRAPRDL CERMAA
hHSV2	TPAGTVITLLGL-TPEGH----RVAVHVGTRQYFYMNKAEDVDRHLQCRAPRDL CERLAA
hVZV	RPLGTVITLLGM-SRCGK----RVAVHVGICQYFYINKAEVDTACGIRSGSELSVLLAE
eHV1	RPSGSVVTLLGM-SECGK----RVAVHVGVRHYFYMAKAEVDSACGITTEAELVRAMVD
hEBV	VPCGIVIKLLGRRKADGA----SVCVNVFGQQAYFY-----ASAPQGLDVEFAVLS
sHV1	IPNGTVLKLGR-TLEGA----SVCVNVFGQRNYFY-----VKVPEGGNITYLIKQ
mCMV	VPAGNVIRMFGA-TDEGV----SVCVNVFGQKAYFY-----CERMQSEDLKNTVYD
gpCMV	VPCGNVIRMFGR-TCDGS----SVCVNVFGQPSYFY-----CEYDGSEGYLDNYLS
hCMV	VPSGNVLRFFGA-TEHGY----SICVNVFGQRSYFY-----CEYSDTDRLREVIAS
iHV1	SNFDGNTPVLQNNLMCSHVYYTRYKTDVYAPWEFYDQKRDQGYL-----MSLPAIIPR

4/28

Figure 2 (2)

hHV6 LMLTGE----VK-----MSCSFVIEPADKLSLYGYNANTVVN
hHSV1 ALRESP-----GASF-----RGISADHFEAEVVERTDVYYYETRPAL-
hHSV2 ALRESP-----GASF-----RGISADHFEAEVVERADVYYYETRPTL-
hVZV CLRSSM-ITQNDATLNGDKNAFHGTSF-----KSASPESFRVEVIERTDVYYYDTQPCA-
eHV1 CAHSSA-LSAALGNNGNGGKQSGGSGGGWWGG-KHVSADCFKVETVCHTTLYYFGSKPAL-
hEBV -ALKAS-TFDRR-----TPCRVSVEKVTRRSIMGYGNHA-GD
sHV1 -ALNEK--FS-----PSCAYQTEAVKKKILSRYDPEE-HD
mCMV IADKVP-EPCSP-----FSVSISPVTKSSFYGYGLGHIPN
gpCMV TVLKET-EDVTK-----IVFTLDAQRVHKYSLFGYNTKYIEN
hCMV VGELVP-EP RTP-----YAVSVTPATKTSIYGYGTRPVPD
iHV1 CKREGAFDIETIVHENAMDQDLNCQKFFKSEFRSMEE SQVLIQRFREAGVTGLPPSPFVG

hHV6 LFKVSFGNFYVSQRIGKILQN-EGFVVYEIDVDVLTFRFFVDN-GFLSFGWYNVKKYIPQD
hHSV1 FYRVYVRSGRVL SYLCDNFNCP--AIKKYEGGV DATTRFILDNPGFVTFGWYRLKPGRNNT
hHSV2 YYRVFVRSGRALAYLCDNFNCP--AIRKYEGGV DATTRFILDNPGFVTFGWYRLKPGRGNA
hVZV FYRVYSPSSKFTNYLCDNFNHP--ELKKYEGRVDATTRFLMDNPGFVSFGWYQLKPGVDGE
eHV1 YYRVSASSSRLGGFICDNFHP--EITKFEGSVDVTTRLLLDNENFTSFGWYRLRPGTHGE
hEBV YHKITLSHPNSVCHVATWLQDKHGCRIFEANVDATRRFVLDN-DFVTFGWYSCRRAIPRL
sHV1 VFKVTVSSSLSVYKISDSLVS-NGCEVFETNVDAIRRFVIDN-DFSTFGWYTCKSACPRI
mCMV LYRLSFNNWNMCRKIGKRMLE-EGRKVYELGVDPLARFLIDR-KIPSFGWCLARRYSVRA
gpCMV LYRVTLNNWPVCKRLAQNLS-RGLRVYEAGVDPVARFCVDR-KIPSFGWCVIKRFYARS
hCMV LQCVSISNWTMARKIGEYLL-QGFPVYEV RVDPLTRLVIDR-RITTFGWCSVNRYDWRQ
iHV1 ITQKLHEIVSISLVVCNYHKTGPKKKEY-----YVYNTKK-----

EXO 1

hHV6 MGK-----GSNLEVEINCHVSDLVSL-EDVNWP LYGCWSFDIECLGQNGN---FPDAE
hHSV1 LAQPRAPMAFGTSSDVEFNCTADNLAIEGGMSDLPAYKLMCFDIECKAGGEDELAFFVAG
hHSV2 PAQPRPPTAFGTSSDVEFNCTADNLAIEGGMSDLPAYKLMCFDIECKAGGEDELAFFVAE
hVZV RVRVRPASRQLTSLDVEIDCMSDNLQAI PNDDSWPDYKLLCFDIECKSGGSNELAFFDAT
eHV1 RVQLRPVERHVTSSDVEINCTPDNLEPI PDEAAWPDYKLMCFDIECKAGTGNEMAFFVAT
hEBV QHR-----DSYAELEYDCEVGDL SVRREDSSWPSYQALAFDIECLGEEG----FPTAT
sHV1 TNR-----DSHTDIEFDCGYDLEFHADRTEWPPYNIMSF DIECIGEGK----FPCAK
mCMV AGY-----VSRAQLEIDCDVADILPIEEQSNWPFYRCLSF DIECMSGTGA---FPAAE
gpCMV SGL-----ASFCDIEIDCEIGDVEADDSMSWPEYRCASF DIECMSGGDR---FPDSS
hCMV QGR-----ASTCDIEVDCDVSDLVAVPDDSSWPRYRCLSF DIECMSGEGG---FPCAE
iHV1 ---MENPMEMIPVEHLHL DASRIKFEACKNE----FYMLLAF-INRLRKSVNVL-YVYNA

hHV6 NLGDIVIQISVISFDTEG-----DRDERHLFTLGTCEKID-
hHSV1 HPEDLVIQISCLLYDLST-TALEHVLLFSLG-SCDLPESHNLNLAARGL-----P
hHSV2 RPEDLVIQISCLLYDLST-TALEHILLFSLG-SCDLPESHLSDLASRGL-----P
hVZV HLEDLVIQISCLLYSIPR-QSLEHILLFSLG-SCDLPQRYVQEMKDAGL-----P
eHV1 NQEDLVIQISCLLYSLAT-QNHEHTLLFSLG-SCDIS EYSFACVQRGE-----P
hEBV NEADLILQISCVLWSTGEEAGRYRRI-----LLTLGTCE DIE-
sHV1 NEGDLIIQISCVFWHAGALDTT-RNM-----LLSLGTCSAVE-
mCMV NVDDIIIIQISCVCF-----GVGEMVHHAYDVHADLSTPAVPEN---HLFTIGPCAPI-P
gpCMV MVDDIVIQISVICY-----AVGRSGAESDGVSG--AEAAVREHQ--HLFTLGPCAPI-P
hCMV KSDDIVIQISCVCYETGGNTAVDQGI PNGNDGRGCTSEGVIFGHSGLHLFTIGTCGQVGP
iHV1 QFDIQVIQQRRLRYAFKQRAPR-----CCKGHDDIPHEW GKALMEKWEAFLSVKP

5/28

Figure 2 (3)

EXO 2

hHV6	GVHIYEFASEFELLGFFIFLRIESPEFI	EGYNINNFDLKYL	CIRMDKIYHYDIGCFSKL
hHSV1	TPVVLEFDSEFEMLLAFMTLVKQYGPEFVE	EGYNIINFDPFELLAKLTDIYKVPLDGYGRM	
hHSV2	APVVLEFDSEFEMLLAFMTFVKQYGPEFVE	EGYNIINFDPFVLTKLTEIYKVPLDGYGRM	
hVZV	EPTVLEFDSEFELLIAFMTLVKQYAPFA	EGYNIVNFDWAFIMEKLNSIYSLKLDGYGSI	
eHV1	RPTVLEFDSEYELLVAFLTFLKQYSPEFA	EGYNIVNFDWAFIVNKVTSVYNIKLDGYGKF	
hEBV	GVEVYEFPSIDMLYAFFQLIRDLSEIVE	EGYNVNFDPYITDRARHIYSINPASLGKI	
sHV1	NTEVYEFPSIDMLHGFFSLIRDFNVEI	EGYNISNFDLPYLIDRATQIYNIKLSYSRV	
mCMV	DVKIYTFPSEYEMLRGFFIFLSWYSPEFI	EGYNINGFDIKYILTRAEKLYKMDVGQFTKL	
gpCMV	GTHVYEFPSYELLGFFIFFKAYPPDIL	EGYNINLFDIKYLLORMEKIYHANVSEFTKL	
hCMV	DVDVYEFPSYELLGFMFFQRYAPAFV	EGYNINSEDLKYILTRLEYLYKVDSQRFCKL	
iHV1	QL----FKA--QILMG-QDILKANYLKL	EGIGSVLAQAKSTM	AKMCTI-KERIDSYRKM

hHV6	K---NGKIGIS-VPHEQYRKGFLQA-----	QTKVFTSGVLYLDMYPVYSSKI
hHSV1	N--GRGVFRVWDIGQSHFQK-----	RSKIKVNGMVNIDMYGIITDKI
hHSV2	N--GRGVFRVWDIGQSHFQK-----	RSKIKVNGMVNIDMYGIITDKV
hVZV	N--RGGLFKIWDVGKSGFQR-----	RSKVKINGLISLDMYAIATEKL
eHV1	N--KGGLFKVWDIATNHFQK-----	KSKVKINGLISLDMYSVATEKL
hEBV	RA--GGVCEVR-RPHDA-GKGFLRA-----	NTKVRITGLIPIDMYAVCRDKL
sHV1	KT--GSIFQVH-TPKDT-GNGFMRS-----	VSKIKISGIIAIDMYIVCKDKL
mCMV	RR--GGRMFVF-SPEKG-----	KAGFGTSNTVKVFWSGTVVLDMPVCTAKA
gpCMV	RF--GGRFSIY-VPVGT-----	KPRNASSASIKVHCTGTVVLDMPVCAKT
hCMV	PTAQGGRFFLH-SPAVGFKRQYAAAFPSASHNNPASTAATKVYIAGSVVIDMYPVCMMAKT	
iHV1	KDTVQN-FKSHGFGCDIIDMMYV-----	CKRKEFEAKDGSINTVAQLIIKKFKPHKATP

EXO 3

hHV6	TAQNYKLDITIAKICLQQEKEQLSYKEIPKKFISGPSGRAVVGKRYCLQDSVLV	WRLFKQIN
hHSV1	KLSSYKLNVAEAVLKDKKKDLSYRDIPAYYATGPAQRGVIGEXCIQDSLLVGQ	LFFKFL
hHSV2	KLSSYKLNVAEAVLKDKKKDLSYRDIPAYYASGPAQRGVIGEXCVQDSLLVGQ	LFFKFL
hVZV	KLSSYKLDVAREALNESKRDLPYKDIPGYASGPNTRGIIIGEXCIQDSALVGK	LFFKYL
eHV1	KLPSYKLDVAVGDLGEHKIDLPYKEIPSYAGGPDRRGVIGEXCIQDSRLVGK	LFFKYL
hEBV	SLSDYKLDTVARHLLGAKKEDVHYKEIPRLFAAGPEGRRLGMYCVQDSALVMDLLNHFV	
sHV1	SLSNYKLDTVANHCIGAKKEDVSYKDIMPLMSGPEGRAKIGLYCVIDSVLVMKLLKFFM	
mCMV	SSPNYKLDTMAEIIYLKKKKDDLKYKEIPVQFSAGDEGRAPGGKYCLQDAVLVRELFEMLA	
gpCMV	SAPNYKLETMAEMLNEHKDDLKYKEIPPTFLANDNGRAVVGRYCIKDALLVKRLFELN	
hCMV	NSPNYKLNMTMAELYLRQKDDLKYKDIPRCFVANAEGRAQVGRYCLQDAVLVRDLFNTIN	
iHV1	KI-----HKMDDITYDKLDGYRAGGT	KIAECLLYNLIDSLVIRIAKNLK

hHV6	YHFEVAEVARLAHVITARC	VVFEGQQKKIFPCILTEAKRRNMILPSMVS-----
hHSV1	PHLELSAVARLAGINITRTIYDGQQIRVFTCLLRLADQKGFILPDTQGRFRGAGGE----	
hHSV2	PHLELSAVARLAGINITRTIYDGQQIRVFTCLLRLAGQKGFILPDTQGRFRGLDKE----	
hVZV	PHLELSAVARLARITLT	KAIYDGQQVRIYTCLLGLASSRGFILPD-----
eHV1	PHLELSAVAKLARITL	TRVIFDGQQIRVYTCLLKLARENFILPDNRRRFRDSQADA----
hEBV	IHVEVAEIAKIAHIPCR	RVLDDGQQIRVFSCLLAAQKENFILPM-----
sHV1	IHVEISEIAKLAKIPT	RRVLTGQQIRVFSCLLAAARAENYILPV-----
mCMV	FHFEAAAIARLARIP	LRKVIFDGQQIRIYTCLLECSGRDMILPNMPSLG-----
gpCMV	YHYEAAASVARLARIP	LRSVIFEGQQIRIYSCILEEAGERNMILPSFLTAK-----
hCMV	FHYEAGAIARLAKIP	LRVIFDGQQIRIYTSLLDECACRDFILPNHYSKGTTPETNSVA
iHV1	-----PMEEYIY-----	RQLACYNIDTAAHT---RGVMNECGFIQSTKVVE

6/28

Figure 2 (4)

```

hHV6 -----
hHSV1 -----APKRPAAREDEERP-----EEEG-EDEDEREE
hHSV2 -----APKRPAVPRGEGERP GDGNGDEDK-DDDEDGDE
hVZV -----GGYPATFEYKDVIPDVGDVEEEMD
eHV1 -----ASETSELAMDSQSHAFDSTDEPDGVDGTPDAAG
hEBV -----
sHV1 -----
mCMV -----HGAAAAIEEAAAGG---EGD
gpCMV -----RPGELATESSPVASFEEDSE
hCMV VSPNAAIIISTAAVPGDAGSVAAMFQMSPLQSA PSSQDGVSPGSGSNSSSSVGVFSVSGS
iHV1 VSRNKARLDAGIVMATDYIRNSLF-----

```

REGION 2**(DFASA>)**

```

hHV6 -----SHNRQIGYKGATVLEPKTG-YYAVPTVVF----DFQSLYPSIMMAH
hHSV1 GGGEREPEGARETAGRH--VG YQGAKVLDPTSG-FHVN PVVF----DFASLYPSIIQAH
hHSV2 DGDERE-EVARETGGRH--VG YQGARVLDPTSG-FHVD PVVF----DFASLYPSIIQAH
hVZV EDESVSPTGTSSG--RN--VG YKGARVFDPTG-FYIDPVVVL----DFASLYPSIIQAH
eHV1 SGATSENGGGKPGVGRA--VG YQGAKVLDPVSG-FHVD PVVF----DFASLYPSIIQAH
hEBV -----PSASDRDGYQGATVIQPLSG-FYN SPVLV----DFASLYPSIIQAH
sHV1 -----SNDVNADGFQGATVINPIPG-FYN NAVLV----DFASLYPSIIQAH
mCMV ETSE---GENSNNSRT---VG YQGATVLEPECG-FHHVPVCVF----DFASLYPSIIMSN
gpCMV QTS DSSLGEVSSQGSSDGGVG YQGATVLEPDVG-FYDTPVAVF----DFASLYPSIIMRH
hCMV SSGGVGVSNDNHGAGGTA AVSYQGATVFEPEVG-YYNDPVAVF----DFASLYPSIIMAH
iHV1 -----TPETI HRRGGFVMAPLTGLEFARPTQCFELCLDFTSMYPSMCDL

```

2 cont.**REGION 4**

```

hHV6 NLCYSTLVLE--RQIAG-----LSES-DILTVKLGDETH-RFVKPCIRESVLGSL-
hHSV1 NLCFSTLSLRAD--AVAH-----LEAG-KDYLEIEVGGRRLFFVKAHVRESLLSIL-
hHSV2 NLCFSTLSLRPE--AVAH-----LEAD-RDYLEIEVGGRRLFFVKAHVRESLLSIL-
hVZV NLCFTTLTLNFE--TVKR-----LNPS--DYATFTVGGKRLFFVRSNVRESLLGVL-
eHV1 NLCFTTLALDEV--DLAG-----LQPS-VDYSTFEVGDQKLFFVHAHIRESLLGIL-
hEBV NLCYSTMITPGEHRLAG-----LRPG-EDYESFRLTGGVYHFVKKHVHESFLASL-
sHV1 NLCYSTLIPHHALHNYPH-----LKSS--DYETFMLSSGPIHFVKKHIQASLLSRL-
mCMV NLCYSTLLVEG--SPE-----VPEK-DVLRVEIGDQCH-RFVRENVHRSLLAEL-
gpCMV NLCYSTYLPLG--RDD-G-----LSDD-DVFLLEFDDGTRYGFVREHVRKSILGEL-
hCMV NLCYSTLLVPG--GEY-P-----VDPA-DVYSVTLENGVTHRFVRASVRVSVLSEL-
iHV1 NISPETIVDSDKTNRVGDYMGYDWSKIDQGF EKFTLVLRVDRTDPENPKLVRHISDTSLS

```

REGION 3**(VYGA>)****4 cont.**

```

hHV6 LKDWLAKRREVKAEMQNCSDPMMKLLIDKKQLALKTT CNSVYGV TGAAGLLPCVAIAAS
hHSV1 LRDWLAMRKQIRSRIPQ-SSPEEAVLLDKQQA AIKVVCNSVYGFTGVQHGLLPCLHVAAT
hHSV2 LRDWLAMRKQIRSRIPQ-SSPEEAVLLDKQQA AIKVVCNSVYGFTGVQHGLLPCLHVAAT
hVZV LKDWLAMRKAIRARIPG-SSSDEAVLLDKQQA AIKVVCNSVYGFTGV AQGFLPCLYVAAT
eHV1 LRDWLAMRKAVRARIPT-STPEEAVLLDKQQA AIKVVCNSVYGFTGV ANGLLPCLRIAAT
hEBV LTSWLAKRKA IKLLAACEDPRQRTI LDKQQLAIKVT CNVYGFTGV ANGLFPCLSLAET
sHV1 LTVWLSKRKAIRQKLAECEDLDTKT I LDKQQLAIKVT CNVYGFTGV ASGLLPCLISIAET
mCMV LVRWLTQRKLVREAMKQCTNEMQPMIMDKQQLALKVTCNAFYGFTGV AAGMLPCLPIAAS
gpCMV LARWLAKRKSVRKVLAECQDEVEKLI LDKYQLALKVTCNAFYGFTGV SSGMMPCLPIAAA
hCMV LNKWVSQRRAVRECMRECQDPVRRMLIDKEQMA LKVT CNVYGFTGV VNGMMPCLPIAAS
iHV1 LKRYLRLRTEHKRALKQSSGSVAEYH-NRLQNE MICTNTHYGVSEHTCSLM-----

```

7/28

Figure 2 (5)

REGION 3 cont.	
hHV6	VTCLGREMLCSTVDYVNSKMQSEQFFCEE-----GLTSSDFT
hHSV1	VTTIGREMLLATREYVHARWAAFEQLLADF-----PE-AADMRA PG--
hHSV2	VTTIGREMLLATRAYVHARWAEFDQLLADF-----PE-AAGMRA PG--
hVZV	VTTIGRQMLLSTRDYIHNNWAAFERFITAF-----PDISSVLSQK--
eHV1	VTTIGRDMMLKTRDYVHSRWATRELLEDNF-----PG-AIGFRNHK--
hEBV	VTLQGRTMLEERAKAFVEA-LSPANLQALAPSPDAWAPLNPEG-----
shV1	VTLQGRTMLEKSKIFIEA-MTPDTLQEIVPHI---VKHEPDA-----
mCMV	ITKIGRDMMLATAGHIEDRCNRPDFLRTVL-----GLPPEAID
gpCMV	ITRIGRDMMLMSVVDYVNTYMGHAEFWLRYL-----G--EEDLT
hCMV	ITRIGRDMMLERTARFIKDNFSEPCFLHNFFNQEDYVVG TREGDSEESSALPEGLETSSGG
iHV1	ITTQGOHKIKLVNEFIKTLNRTGHS LFPN-----
REGION 1 (<GDTD1B)	
hHV6	GD---LEVEVIYGD TDSIFMSVRNMVNQSLRRIAPMIAKHITDRLFKSPIKLEFEKILCP
hHSV1	----PYSMRIIYGD TDSIFVLCRGLTAAGLTAMGDKMASHISRALFLPPIKLECEKTF TK
hHSV2	----PYSMRIIYGD TDSIFVLCRGLTGEALVAMGDKMASHISRALFLPPIKLECEKTF TK
hVZV	----AYEVKVIYGD TDSVFIRFKGVSVVEGIAKIGEKMAHII STALFCPPIKLECEKTF IK
eHV1	----PYSVRVIYGD TDSVFIKFGVGLTYEGVSELGDAMSRQISADLFRAPIKLECEKTFQR
hEBV	-----QLRVIYGD TDSLFI ECRGFSESETLRFADALAAHTTRSLFVAPISLEAEKTFSC
shV1	-----KFRVIYGD TDSLFEVCVGSVDTVVKFGDFLAFTSEKLFNAPIKLESEKTFQC
mCMV	PEALRV--KIIYGD TDSVF AAFYGI DKEALLKAVGALAA NVTNALFKEPVRLEFEKMFVS
gpCMV	GDALNV--KVIYGD TDSVFVICGGVKCGSVLEHGEA IAGHITRALFREPIKLEFEKV FVN
hCMV	SNERRVEARVIYGD TDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEPVKLEFEKV FVS
iHV1	-----YGD T DSTMLYHPSDESETQLED MVTLEDEMRAEL-----
REGION 7 REGION 5	
hHV6	LILICKKRYIGR-QDDSL LIFKGV DLVRKTSQDFVKG VVKD IVDLLFFDEEVQTAAVEFS
hHSV1	LLLI AKKKYIGVIYGGKML- IKGVDLVRKNNCAF INRTSRALVDLLFYDDTVSGAAAALA
hHSV2	LLLI AKKKYIGVICGGKML- IKGVDLVRKNNCAF INRTSRALVDLLFYDDTVSGAAAALA
hVZV	LLLI TKKKYIGVIYGGKVL- MKGV DLVRKNNQOF INDIYARKLVELLLYDDTVSRAAAEAS
eHV1	LLLI TKKKYIGVINGGKML- MKGV DLVRKNNQSF INLYARHLVDLLYDEDVATAAAEVT
hEBV	LMLITKKRYVGVLTDGKTL- MKGV ELVRKTA CKFVQTRCRRVLDLVLADARVKEAASLLS
shV1	LLLI AKKRYIGILSNDKLL- MKGV DLVRKTA CKFVQNTSSKILNLILKDPEVKAAAQLLS
mCMV	LMMICKKRYIGKVHGSQNL SMKGVDLVRRTACGFVKAVVSDVLHMFNDET VSEGTMKLS
gpCMV	LMMICKKRYVGRIYGT KLSMKGIELVRKTACEYVKSTVRNV LNMIF FEDDVSAGAVELS
hCMV	LMMICKKRYIGKVEGASGL SMKGVDLVRKTACEFVKGVTRDVL SLLFEDREVSEAAVRLS
iHV1	-----REYMLKKLSAE- LVNRVKEKTKRTD- TFVQSFLSDV- ETVLFDDMVEK----LR
hHV6	HMTQTQLREQGVPVGIHKILRRLCEAREELFQNRADVRLMLSSVLSKEMAAYKQPNLAH
hHSV1	ERPAAEWLARPLPEGLQAFGAVLVD AHRRTDPERDIQDFVLTAE LSRHPRAYTNKRLAH
hHSV2	ERPAAEWLARPLPEGLQAFGAVLVD AHRRTDPERDIQDFVLTAE LSRHPRAYTNKRLAH
hVZV	CVSIAEWNRRAMP SGMAGFGRIIADAHRQITSPKLDINKFVMTAE LSRPPSAYINRRLAH
eHV1	DVPPAEWVGRPLPSGFDKFGRLVEAYNRITAPNL DVREFVMTAE LSRSPESYTNKRLPH
hEBV	HRPFQESFTQGLPVGFLPVIDILNQAYTDLREGRVPMGELCFSTELSRKLSAYKSTQMPH
shV1	TKDPDYAFREGLPDGFLKVIDILNESHKNLRTGQVPVEELTFSTELSRPISSYKTENLPH
mCMV	RMTFDDLKKN GIPCEFGPVVSRLCRARDDLHLKKVPVPELT LSSVLSQELSCYKQKNLPH
gpCMV	RMTMDDVKRHGVPSGFYRIVEALS NARDELYLNRVDVKKLVLSASLSQEV SAYKQQNLPH
hCMV	RLSLDEVKKYGVPRGFWRILRRLVQARDDL YLHRVRVEDLV LSSVLSKDISLYRQSNLPH
iHV1	LFSQGEVIEPFKDG GTWVVDPLTGIWMD-----CSTPFSSSELICK

8/28

Figure 2 (6)

```

hHV6      LSVIRRLAQRKEEIPNVGDRIMYVLIAPSI-----
hHSV1     LTVYYKLMARRAQVPSIKDRIPYVIVAQTREVEETVARLAALRELDAAAPGDEPAPPAAL
hHSV2     LTVYYKLMARRAQVPSIKDRIPYVIVAQTREVEETVARLAALRELDAAAPGDEPAPPAAL
hVZV      LTVYYKLVMRQGQIPNVREIRIPYVIVAPTDEVEADAKSVALLRG-----DPLQ
eHV1      LTVYFKLAMRNEELPSVKERIPYVIVAQTEAAEREAGVVNSMRG-----TAQN
hEBV      LAVYQKFVERNEELPQIHDRIQYVFVEP-----
sHV1      LTVYKKIITRHEEPPQVHDIRIPYVVFV-----
mCMV      LAVIRRLAARKEELPAVGDRVEYVLTLP-----D-GCKKN-----
gpCMV     LRVIQRLAARRPELPSVGDRVPYVLIAP-----PPGSSKN-----
hCMV      IAVIKRLAARSEELPSVGDRVFYVLTAPGVRTAPQGSSDNGDSVTAGVVSRSDAIDGTDD
iHV1      L-----

```

```

hHV6      -----GNKQTH-----NYELAEDPNYVIEHKIPIHAKEYFDQIIKA
hHSV1     PSPAKRPRETPSHADPPGG--ASKPRKLLVS-ELAEDPAYAIAHGVALNTDYYFSHLLGA
hHSV2     PSPAKRPRETPSHADPPGG--ASKPRKLLVS-ELAEDPGYAIARGVPLNTDYYFSHLLGA
hVZV      NTAGKRC-GEAK-----RKLIIS-DLAEDPIHVTSHGLSLNIDYYFSHLLGT
eHV1      PVVTKTARPQPK-----RKLLVS-DLAEDPTYVSENDVPLNTDYYFSHLLGT
hEBV      -----KGGVKGARKT-----EMAEDPAYAERHGVPAVDHYFDKLLQG
sHV1      -----GKTTSCIS-----NMAEDPTYTVQNNIPIAVDLYFDKLIHG
mCMV      -----VPNYEIAEDPRHVVEAKLSINAEKYEEQVVKA
gpCMV     -----VPNYEISEDPGYVIEHKLPVNGEKYFEHVVK
hCMV      DADGGGVEESNRRGGEPAKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKA
iHV1      -----EYENASSIGCHVAKKMVSIGSTYL-----

```

```

hHV6      VTNAISPIFPKTDI-KKEKLLLYLLPMKVYLDET-----F-----
hHSV1     ACVTFKALFGN-NAKITESLLKRFIPEV-WHPPDDVAARLRAAGF-----GAV
hHSV2     ACVTFKALFGN-NAKITESLLKRFIPEV-WHPPDDVAARLRAAGF-----GPA
hVZV      ASVTFKALFGN-DTKLTERLLKRFIPEV-RVNVKMLNRLQAAGFVCIHAPCWDNKMNTE
eHV1      ISVTFKALFGN-DVRTTENLLKRFIPEVPHKTPTKTQALLERAGF-----EKLTP-
hEBV      AANILQCLFDN-NSGAALSVLQNFRTARPPF-----
sHV1      VANIIQCLF-K-DSSKTVSVLYNFVSTPVLFSYE-----LL-----
mCMV      VTNTLMPVFPR-DMPKREKFFSLVVPQRIYIPDQ-----FL--HLCGNVNELARG
gpCMV     VTNVLGPPIPK-DCARKEKFLSYVLPQRVYVSRP-----FM--PYACAANELVVG
hCMV      VTNVLSPVFPGETARKDKFLHMLPRRLHLEPA-----FL--PYSVKAHE----
iHV1      -----FFKKIS-----LYHVRVWR-----MCADTDGSPSHLYFP

```

```

hHV6      -----SAIAEVM--
hHSV1     GAGATAEETRMLHRAFDL-----A
hHSV2     GAGATAEETRMLHRAFDL-----A
hVZV      AEITEEQSHQIMRRVFCIPKAILHQS
eHV1      --FTPEEESRRILHTVFCTLEAAPHQS
hEBV      -----
sHV1      -----TDHSVKA
mCMV      GDDSDGGDSEKENMDTERSSSHEAMET
gpCMV     -----V
hCMV      -----CC
iHV1      VSLSRTRAKQRGDH-----

```

Figure 3

9/28

hHV6 GTGGTGTTTGATTTTCAAAGTTTGTATCCGAGCATTATGATGGCGCATAATCTGTGTTATAGTACTTTAGTTTTGGAT
hCMV GCCGTGTTGACTTTGCCAGCCTCTACCCCTCCATCATCATGGCCCACAACCTCTGCTACTCCACCCTGCTGGTGCCG
gpCMV GCCGTCTTCGATTTGCCAGTCTGTATCCGTCTATCATTATGCGACACAACCTGTGTTACTCGACGTATCTCCGCTC
mCMV TGGGTGTTGATTTGCCAGTCTGTATCCGTCCATCATCATGTCCAACAATCTGTGCTACTCCACCCTCTTGGTGGAG

hHSV1 GTGGTGTTGACTTTGCCAGCCTGTACCCAGCATCATCCAGGCCACAACCTGTGCTTCAGCACGCTCTCCCTGAGG
hHSV2 GTGGTGTTTGACTTTGCCAGCCTGTACCCAGCATCATCCAGGCCACAACCTGTGCTTCAGTACGCTCTCCCTGCGG
hVZV GTCGTATTGGATTTTGCAAGTTTATATCCAAGTATAATTCAGGCCATAACTTATGTTTTACCACGCTAACGTTAAAT
eHV1 GTGGTGTTTGACTTCGCTAGCTTATACCCAAGCATTATCCAGGCCATAACCTCTGTTTCACCACCCTGGCGCTCGAT

hEBV CTGGTGGTGGACTTTGCCAGCCTCTACCCGAGCATCATTGAGGCTCATAATCTCTGTTATTCTACCATGATAACGCCG
sHV1 TTAGTAGTAGACTTTGCTAGCCTGTATCCTAGTATTATACAAGCTCATAATCTATGCTACTCCACTCTTATACCCAC

iHV1 CTGTGTCTGGACTTTACCAGCATGTACCCAGTATGATGTGCGATCTCAACATCTCTCTGAAACCATCGTGGACAGC

5'-gtgttcgacttygcnagyytntaycc-3'
DFASA 256-fold 26mer>

5'-gtgttcgacttycaragyytntaycc-3'
DFQSA 128-fold 26mer>

Figure 4

10/28

hHV6	GCTCTGAAAACAACATGTAAC TCGGTGTACGGTGTACGGGAGCGGCGCACGGG
hCMV	GCGCTCAAAGTAACGTGCAACGCTTTCTACGGTTTTACCGGCGTGGTCAACGGT
gpCMV	GCCCTCAAAGTGACGTGCAACGCGTTTTACGGTTTCACCGGGGTGAGCAGCGGC
mCMV	GCCCTCAAAGTAACGTGCAACGCTTTCTACGGTTTCACGGGGGTAGCGGCCGGG
hHSV1	GCCATCAAGGTCGTGTGTAAC TCGGTGTACGGGTTACGGGAGTGCAGCACGGA
hVZV	GCGATAAAAGTAGTTTGTAATTCCGTGTACGGTTTTACTGGAGTTGCGCAGGGA
eHV1	GCGATTAAGGTGATATGCAACTCGGTTTACGGATTACGGGGGTGGCAAACGGC
hEBV	GCCATCAAGTGACGTGCAACGCCGTCTACGGCTTCACCGGGGTGGCCAACGGC
sHV1	GCTATTAAAGTAACTTGTAATGCTGTGTATGGGTTTACAGGAGTTGCGTCAGGC
iHV1	GAAATGAAGATCTGTACAAACACCCACTACGGGGTCTCTGAGCACACGTGTTG

5' -acgtgcaacgcggtgtayggnktnacngg-3'
VYGA 256-fold 30mer>

5' -acgtgcaacgcggtgtacggsgetsacsgg-3'
VYGCA 8-fold GC-rich 30mer>

5' -acgtgcaacgcggtgta>-3'
VYGSQA 17mer>

Figure 5

11/28

hHV6	GTAATTTATGGTGATACGGATAGCATCTTTATGTCTGTCAGAAAT
hCMV	ATCATCTACGGGGACACGGACTCCATATTTGTGCTGTGCCGCGGC
gpCMV	GTGATATACGGGGACACGGACAGCGTCTTTGTCATATGCGGCGGT
mCMV	ATCATCTACGGCGACACCGACAGTGTGTTTGCGGCTTTCTACGGC
hHSV1	ATCATCTACGGGGACACGGACTCCATATTTGTGCTGTGCCGCGGC
hVZV	GTTATATATGGAGATACGGATTCTGTGTTTATCCGATTCAAGGGT
eHV1	GTTATCTACGGAGACACCGACTCCGTGTTTATCAAGTTTGTGGGC
shV1	GTCATATATGGAGACACAGACTCTCTATTTGTAGAATGTGTTGGG
hEBV	GTCATCTACGGGGACACGGACTCGCTGTTTATCGAGTGCCGGGGG
iHV1	CCCAATTATGGGGATACGGATAGTACGATGCTGTACCACCCATCG

5' - tayggngayacngactccgtgtttgtcgcacatgccg - 3'

3' - atrccnctrtnctgaggcacaacagcgtagggc - 5'
<GDTD1B 64-fold 35mer

3' - aggcacaacagcgtagggc - 5'
<GTDTSQB 20mer

12/28

Figure 6

RFHV CGTCGCTTCCGGCATCCTACCGTGCCTGAACATCGCAGAGACGGTGACCCTCCAGGGCAGGAAAAT
KSHV ...T..C..T.....A..G..T.....A.....A..G.....C.....A..A..A..GC..A..G..
eHV2 ...G..C..G.....G..C..T..C..G..A..C.....C...T.....CGC..
SHV1 A..T..G..A...T.G..G..A...A.A.G...T.....T..T..T.....A...C...CG..
EBV G..G..CAA....C..T.T..C.....CTC.....C.....G..G.....C.C.CG..

RFHV GCTGGAAACGTCTCAGGCGTTCTAGAGGGAATCTCGCCAACGGCACTGGCAGACCTACTGCAGCG
KSHVG.GA.....C..T.....CC.....GGAACGC..A..G.GT..C....G.A..
eHV2G.AC..CA..CGC.A.A.....GG.GA.C..CGA..GG.....A..T..GGCA..
SHV1 ...A....AA..AA.AATA...A....A.C...GA.A..TGATA...TCA...AA.TG.T.CT.A
EBV .T....GCG.G.CA....C.....G....CCC.GAGC..CG.CAAC...CAG.C...GGCC.CCTC

RFHV ACCGATCGAGGCGTCTCCG-----GAAGCCAGGTTTAAAGTGATA
KSHV G..A..A..C.TC..A..C-----..C...C.A..C..G..C..
eHV2 G.G.G.G...TGCG.C..C-----..T....T....G..C..C
SHV1 TATAG.GA..CATGAA..T-----..T..G.A...C.G...C..
EBV C...GA..CCTG.G.G..CCTCAACCCC..G.G.CA.C..CG...C..C

"." = identical residues
"-" = deletions

Figure 7

RFHV VASGILPCLNIAETVTLQGRKMLET SQAFVEGISPTALADLLQRP IEASP---EARFKVI
KSHVR.....A...ER..G..R...DV....-D.....
eHV2K.....F...R...N.KRYI..VT.EG...I.G.RV.CA.---D.S....
sHV1L...IS.....T...K.KI.I.AMT.DT.QEIVPHIVKHE.---D.K.R..
EBV ..N.LF...S.....T...RAK....AL..AN.QA.APS.DAWA.LNP.GQLR..

"." = identical residues
"-" = deletions

Class I: IAETVTL

Class II:

 CLNIAET SQAFVE
VASGILP QGRKMLE ARFKVI
 GILPCLN

Class III:

 LETSQAF ADLLQRP
 LERSQAF AGLLRRP
 EGISPTA QRPIEAS
 EAISPER RRPIDVS
 IEASP---EA
 IDVSP---DA

Figure 8

RFHV	VASGILPCLNIAETVTLQGRKMLET SQAFVEGISPTALADLLQRP-----	IEASPEARFKVI
KSHV	VASGILPCLNIAETVTLQGRKMLET SQAFVEAISPERLAGLLRRP-----	VDVSPDARFRVI
eHV2	VASGILPCLKIAETVTFQGRRMLENSKRYIEGVTPEGLADILGRR-----	VECAPDASFVKVI
sHV1	VASGLLPCISIAETVTLQGRTMLEKSKIFIEAMTPDTLQEIVPHI-----	VKHEPDAKFRVI
hEBV	VANGLFPCLSIAETVTLQGRTMLERAKAFVEALSPANLQALAPSP-----	DAWAPLNPEGQLRVI
hCMV	VVNGMMPCLPIAASITRIGRDMLERTARFIKDNFSEPCFLHNFFNQEDYVVGTR	EGDSEESSALPEGLETSSGGSNERRVEARVI
mCMV	VAAGMLPCLPIAASITKIGRDMLLATAGHIEDRCNRPDFLRTVLG-----	LPPEAIDPEALRVKII
gpCMV	VSSGMMPCLPIAAAITRIGRDMLMSVVDYVNTYMGHAEFWLRYLG-----	EEDLTGDALNVKVI
hHV6-A	AAHGLLPCVAIAASVTCLGREMLCSTVDYVNSKMQSEQFFCEEFG-----	LTSSDFTGDLEVEVI
hVZV	VAQGFLPCLYVAATVTTIGRQMLLSTRDYIHNNWAAFERFITAFP-----	DISSVLSQKAYYEVKVI
hHSV1	VQHGLLPCLHVAATVTTIGREMLLATREYVHARWAAFEQLLADFP-----	EAADMRA PGPYSMRII
hHSV2	VQHGLLPCLHVAATVTTIGREMLLATRAYVHARWAEFDQLLADFP-----	EAAGMRA PGPYSMRII
eHV1	VANGLLPCLRIAATVTTIGRDMLLKTRDYVHSRWATRELLEDNFP-----	GAIGFRNHKPYSVRVI
hPOLd	AQVGKLPCL EISQSVTGFGFRQMI EKTQQLVESKYTV-----	ENGYSTSAKVV
bPOLd	AQVGRLPCL EISQSVTGFGFRQMI EKTQQLVETKYTV-----	ENGYSTSAKVV


Figure 9

Figure 10

	G V A S G I L P C L N I A E T V T L Q G R K M
RFHV	GGCGTCGCTTCCGGCATCCTACCGTGCCTGAACATCGCAGAGACGGTGACCCTCCAGGGCAGGAAAATG
KSHV	GGCGTTGCCTCTGGCATACTGCCTTGCCTAAACATAGCGGAGACCGTGACACTACAAGGGCGAAAGATG
eHV2	GGCGTGGCCTCGGGCATCCTGCCCTGTCTCAAGATAGCCGAGACGGTCACCTTCCAGGGCAGGCGCATG
sHV1	GGAGTTGCGTCAGGCTTGCTGCCATGCATAAGCATTGCAGAGACTGTTACTCTCCAAGGCCGGACGATG
EBV	GGGGTGGCCAACGGCCTCTTCCCTGCCTCTCCATCGCCGAGACGGTGACGCTGCAGGGCCGCACGATG


5'-gtcgcctctggcatcctncntgyctnaa>-3'	5'-cagggccggaagatg
PCLNA 128-fold 29mer>	KMLEA 32-fold
	32mer>

	L E T S Q A F V E G I S P T A L A D L L Q R P
RFHV	CTGGAAACGTCTCAGGCGTTCGTAGAGGGAATCTCGCCAACGGCACTGGCAGACCTACTGCAGCGACCG
KSHV	CTGGAGAGATCTCAGGCCTTTGTAGAGGCCATCTCGCCGGAACGCCTAGCGGGTCTCCTGCGGAGGCCA
eHV2	CTGGAGAACTCCAAGCGCTACATAGAGGGGGTGACCCCGAGGGGCTGGCAGACATATTGGGCAGGCGG
sHV1	CTAGAAAAATCAAAAATATTCATAGAAGCAATGACACCTGATACACTTCAAGAAATTGTTCTCATATA
EBV	TTGGAGCGGGCCAAGGCCTTCGTGGAGGCCCTGAGCCCGCCAACCTGCAGGCCCTGGCCCCCTCCCCG

ctggaracrtncargc>-3'
(KMLEA cont'd>)

5'-tctcaggcgttcgtagarggnathtcncc-3'
GISPA 96-fold 29mer>

	I E A S P - - - E A R F K V I
RFHV	ATCGAGGCGTCTCCG-----GAAGCCAGGTTTAAAGTGATA
KSHV	GTAGACGTCTACCC-----GACGCCCGATTGAGGGTCATA
eHV2	GTGGAGTGCGCCCC-----GATGCCAGTTTTAAGGTCATC
sHV1	GTGAAGCATGAACCT-----GATGCGAAGTTCAGAGTCATA
EBV	GACGCCTGGGCGCCCCTCAACCCCGAGGGCCAGCTTCGAGTCATC

Figure 11

```

SIMQAHNLCY  STLITGSALH  GHPELTPDDY  ETFHLSGGTV  HFVKKHAVRES  LLSKLLTTWL
  ^^^  ^^^^^  ~~~~~  --  ^^^  ^^^  ~~~~~  ^^^^^

AKRKEIRKNL  ASCTDPTMRT  ILDKQQLAIK  VTCNAVYGFT  GVASGILPCL  NIAETVTLQG
^~~~~~


RKMLETSQAF  VEGISPTALA  DLLQRPIEAS  PEARFKVI
              ~~~~~

```

- - antigenic
 ^ - hydrophobic

Figure 12

18/28



```

SIIQAHNLCY  STLIPGDSLH  LPHLSRDDY  ETFVLGGGLV  HFVKKHKRES  LLTKLLTVWL      60
  ^^^  ^^^^^~
AKRKEIRKTL  ASCTDPALKT  ILDKQQLAIK  VTCNAVYGFT  GVASGILPCL  NIAETVTLQG     120
^~~~~~
RKMLERSQAF  VEAISPERLA  GLLRRPIDVS  PDARFKVI
~~~~~

```

~ - antigenic
^ - hydrophobic

Figure 13(A)

CVNVA>
gacgaccgcagcgtgtgcgtgaaygtnttyggnc
D D R S V C V N V F G Q R C Y F Y T L A 60
GACGACCGCAGCGTGTGCGTGAAYGTNTTYGGNCAGCGTGCTACTTCTACACACTAGCA

P Q G V N L T H V L Q Q A L Q A G F G R 120
CCCCAGGGGTAAACCTGACCCACGTCCTCCAGCAGGCCCTCCAGGCTGGCTTCGGTCGC

A S C G F S T E P V R K K I L R A Y D T 180
GCATCCTGCGGCTTCTCCACCGAGCCGGTCAGAAAAAATCTTGCGCGGTACGACACA

Q Q Y A V Q K I T L S S S P M M R T L S 240
CAACAATATGCTGTGCAAAAAATAACCCTGTCATCCAGTCCGATGATGCGAACGCTTAGC

D R L T T C G C E V F E S N V D A I R R 300
GACCGCCTAACAACTGTGGGTGCGAGGTGTTTGAGTCCAATGTGGACGCCATTAGGCGC

F V L D H G F S T F G W Y E C S N P A P 360
TTCGTGCTGGACCACGGGTTCTCGACATTCCGGTGGTACGAGTGCAGCAACCCGGCCCCC

R T Q A R D S W T E L E F D C S W E D L 420
CGCACCAGGCCAGAGACTCTTGACGGAACCTGGAGTTTGACTGCAGCTGGGAGGACCTA

K F I P E R T E W P P Y T I L S F D I E 480
AAGTTTATCCCGAGAGGACGGAGTGGCCCCATACACAATCCTATCCTTTGATATAGAA

C M G E K G F P N A T Q D E D M I I Q I 540
TGTATGGGCGAGAAGGGTTTTCCCAACGCGACTCAAGACGAGGACATGATTATACAAATC

S C V L H T V G N D K P Y T R M L L G L 600
TCGTGTGTTTTACACACAGTCGGCAACGATAAACCGTACACCCGCATGCTACTGGGCCTG

G T C D P L P G V E V F E F P S E Y D M 660
GGGACATGCGACCCCTTCTGGGGTGGAGGTCTTTGAGTTTCTTCGGAGTACGACATG

L A A F L S M L R D Y N V E F I T G Y N 720
CTGGCCGCCTTCTCAGCATGCTCCGCGATTACAATGTGGAGTTTATAACGGGGTACAAC

I A N F D L P Y I I A R A T Q V Y D F K 780
ATAGCAAACCTTGACCTTCCATACATCATAGCCGGGCAACTCAGGTGTACGACTTCAAG

L Q D F T K I K T G S V F E V H Q P R G 840
CTGCAGGACTTCACCAAAATAAAAAGTGGGTCCGTGTTTGAGGTCCACCAACCCAGAGGC

G S D G G N F M R S Q S K V K I S G I V 900
GGTTCCGATGGGGGCAACTTCATGAGGTCCAGTCAAAGGTCAAATATCGGGGATCGTC

P I D M Y Q V C R E K L S L S D Y K L D 960
CCCATAGACATGTACCAGGTTTGCAGGAAAAGCTGAGTCTGTCAGACTACAAGCTGGAC

Figure 13(B)

T V A K Q C L G R Q K D D I S Y K D I P
ACAGTGGCTAAGCAATGCCTCGGTCGACAAAAAGATGACATCTCATACAAGGACATACCC 1020

P L F K S G P D G R A K V G N Y C V I D
CCGCTTTTTAAATCTGGGCCTGATGGTCGCGCAAAGGTGGGAACTACTGTGTTATTGAC 1080

S V L V M D L L L R F Q T H V E I S E I
TCGGTCCTGGTTATGGATCTTCTGCTACGGTTTCAGACCCATGTTGAGATCTCGGAAATA 1140

A K L A K I P T R R V L T D G Q Q I R V
GCCAAGCTGGCCAAGATCCCCACCGTAGGGTACTGACGGACGGCCAACAGATCAGGGTA 1200

F S C L L E A A A T E G Y I L P V P K G
TTTTCTGCCTCTTGGAGGCTGCTGCCACGGAAGGTTACATTCTCCCCGTCCCAAAGGA 1260

D A V S G Y Q G A T V I S P S P G F Y D
GACGCGGTTAGCGGGTATCAGGGGGCCACTGTAATAAGCCCCCTCTCCGGGATTCTATGAC 1320

D P V L V V D F A S L Y P S I I Q A H N
GACCCCGTACTCGTGGTGGATTTGCCAGCTTGTACCCAGTATCATCCAAGCGCACAAC 1380

L C Y S T L I P G D S L H L H P H L S P
TTGTGCTACTCCACTGATACCCGGCGATTGCTCCACCTGCACCCACACCTCTCCCCG 1440

D D Y E T F V L S G G P V H F V K K H K
GACGACTACGAAACCTTTGTCCTCAGCGGAGGTCCGGTCCACTTTGTAAAAAACACAAA 1500

R E S L L A K L L T V W L A K R K E I R
AGGGAGTCCCTTCTTGCCAAGCTTCTGACGGTATGGCTCGCGAAGAGAAAAGAAATAAGA 1560

K T L A S C T D P A L K T I L D K Q Q L
AAGACCCTGGCATCATGCACGGACCCCGCACTGAAAACATTCTAGACAAACAACAACTG 1620

A I K V T C N A V Y G F T G V A S G I L
GCCATCAAGGTTACCTGCAACGCCGTTTACGGCTTCACGGGCGTTGCCTCTGGCATACTG 1680

P C L N I A E T V T L Q G R K M L E R S
CCTTGCCTAAACATAGCGGAGACCGTGACACTACAAGGGCGAAAGATGCTGGAGAGATCT 1740

Q A F V E A I S P E R L A G L L R R P V
CAGGCCTTTGTAGAGGCCATCTCGCCGGAACGCCTAGCGGGTCTCCTGCGGAGGCCAGTA 1800

D V S P D A R F K V I Y G D T D S L F I
GACGTCTACCCGACGCCCGATTCAAGGTCATATACGGCGACACTGACTCTTTTCATA 1860

C C M G F N M D S V S D F A E E L A S I
TGCTGCATGGGTTTCAACATGGACAGCGTGTGCACTTCGCGGAGGAGCTAGCGTCAATC 1920

T T N T L F R S P I K L E A E K I F K C
ACCACCAACACGCTGTTTCGTAGCCCCATCAAGCTGGAGGCTGAAAAGATCTTCAAGTGC 1980

Figure 13(C)

L L L L T K K R Y V G V L S D D K V L M
CTTCTGCTCCTGACTAAAAAGAGATACGTGGGGTACTCAGTGACGACAAGGTTCTGATG 2040

K G V D L I R K T A C R F V Q E K S S Q
AAGGGCGTAGACCTCATTAGGAAAACAGCCTGTCGTTTTGTCCAGGAAAAGAGCAGTCAG 2100

V L D L I L R E P S V K A A A K L I S G
GTCCTGGACCTCATACTGCGGGAGCCGAGCGTCAAGGCCGCGGCCAAGCTTATTTGCGGG 2160

Q A T D W V Y R E G L P E G F V K I I Q
CAGGCGACAGACTGGGTGTACAGGGAAGGGCTCCAGAGGGGTTCTGCAAGATAATTCAA 2220

V L N A S H R E L C E R S V P V D K L T
GTGCTCAACGCGAGCCACCGGGAAGTGTGCGAACGCAGCGTACCAGTAGACAAACTGACG 2280

F T T E L S R P L A D Y K T Q N L P H L
TTTACCACCGAGCTAAGCCGCCCGCTGGCGGACTACAAGACGAAAACCTCCCGCACCTG 2340

T V Y Q K L Q A R Q E E L P Q I H D R I
ACCGTGTACCAAAAGCTACAAGCTAGACAGGAGGAGCTTCCACAGATACACGACAGAATC 2400

P Y V F V D A P G S L R S E L A E H P E
CCCTACGTGTTCTGTCGACGCCCCAGGTAGCCTGCGCTCCGAGCTGGCAGAGCACCCGAG 2460

Y V K Q H G L R V A V D L Y F D K
TACGTTAAGCAGCACGGACTGCGCGTGGCGGTGGACCTGTATTTGACAAG 2511
atraarctrttygacgaggtgcctcatcgatt
(<YFDKB)

```

TR1910_KSH -----GSLRSELAEHPEYVKQHGLRVAVDLYFDK-----
TR2108_EBV -----VKGARKTEMAEDPAYAERHGVPAVDHYFDKLLQGAANILQCLFDNNSGAAL
TR2109_eHV -----GKLRSEMAEDPAYAAQHNIPPAVDLYFDKVIHGAANILQCLFENDSDKAA
TR2110_hHS G--GASKPRKLLVSELAEDPAYAIAHGVALNTDYYFSHLLGAACVTFKALFGNNAKITE
TR2111_hVZ ---CGEAKRKLIISDLAEDPIHVTSHGLSLNIDYYFSHLIGTASVTFKALFGNDTKLTE
TR2112_hHV -----THNYELAEDPNYVIEHKIPIHAEKYFDQIIKAVTNAISPIFPKTDIK-K
TR2113_hCM AKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKAVTNVLSPVFPGGETARK
TR2114_EBV -----VKGARKTEMAEDPAYAERHGVPAVDHYFDKLLQGAANILQCLFDNNSGAAL
TR2115_sHV -----TSCISNMAEDPTYTVQNNIPIAVDLYFDKLIHGVANIIQCLFK-DSSKTV

```

Figure 15

RFHVMn	VASGILPCLNIAETVTLOGRKMLET SQAFVEGISPTALADLLQRPIEASP---EARFKVI
RFHVMmKD.S..I....D....-D.....
KSHV-KS7R.....A...ER..G..R..VDV...-D...R..
KSHV-KSF2R.....A...ER..G..R...DV...-D.....
KSHVpath1R.....A...ER..G..R..VDV...-D.....
KSHVpath2R.....A...ER..G..R..VDV...-D...R..
eHV2K.....F...R...N.KRYI..VT.EG...I.G.RV.CA...-D.S....
sHV1L...IS.....T...K.KI.I.AMT.DT.QEIVPHIVKHE...-D.K.R..
EBV	..N.LF...S.....T...RAK....AL..AN.QA.APS.DAWA.LNP.GQLR..

Figure 16

(DFASA>)gtgttcgacttygcnagvytntaycc 1
RFMn (QAHNA>)ccaagtatcathcargcncayaaCCTCTGTTATTCTAC
RFMm ...A....C.....
KS .T.G..C..C..C..

20 40 60 80
RFMn CCTGATTACAGGAAGCGCCCTACACGGGCACCCCGAACTGACCCCGACGACTACGAAACCTTCCACCTG
RFMmCAG..G.A....A.T.T.TC.....GT.....GA.....A.....A
KS A.....AC.C..CGATT.G..C...CT.....AC.C..CT....G.....TGT...C

100 120 140
RFMn AGCGGGGGAACGGTACACTTTGTAAAAAGCACGTCCGCGAGTCACTACTGTCCAACTGCTCACAACAT
RFMmA...C....G.....C.....A....A..A.....T.....A.....T..G..G..T.
KSA..TC....C.....A...AAAA.G....C..T..TA....G..T..G..GGT..

160 180 200 220
RFMn GGCTGGCCAAGAGGAAAGAGATCCGCAAAAATTTAGCCTCGTGCACAGACCCCAACATGCGCACCATACT
RFMmAA.A..A..A.....C.C.....GG.....A.....A.....C..
KSC..G....A....A..AA.A..G.CCC.G..A..A.....G.....G.AC..AAA..T..T..

240 260 280
RFMn GGATAAACAACAGCTGGCCATCAAGGTCACATGTAACGCGGTGTACGGGTTACGGGCGTCGCTTCCGGC
RFMm T.....G..G.....T.....T..C.....C.....T
KS A..C.....A.....T..C..C.....T....C.....T..C..T...

300 320 340 360
RFMn ATCCTACCGTGCCTGAACATCGCAGAGACGGTGACCCTCCAGGGCAGGAAAATGCTGGAAACGTCTCAGG
RFMm ..T.....T..T....A..A..C.....A.....A.....C....
KS ..A..G..T....A....A..G....C....A..A..A..GC.A..G.....G.GA.....

380 400 420
RFMn CGTTCGTAGAGGGAATCTCGCCAACGGCACTGGCAGACCTACTGCAGCGACCGATCGAGGCGTCTCCGGA
RFMmT.....C..A.....AA.AC...T.....GA.A..A..T.....C..T..C...
KS .C..T.....CC.....GGAACGC..A..G.GT..C....G.A.G..A..A..C.TC..A..C..

440 454
RFMn AGCCAGGTTTAAAGTGATAtaygngayacngactccgtgtttgtcgcatgccg(<GDTDB complement)
RFMm C.....
KS C...C.A..C..G..C...

Figure 17

	20	40
RFHVMn	SIMQAHNLCYSTLITGSALHGHPELTPD-DYETFHLSGGTV	
RFHVMm	
KSHV	..I.....P.DS..L..H.S.-.....V....L.	
eHV2	T.I.....M.P.DR.CL..H.G.G-.....E.AS.P.	
sHV1	..I.....PHH...NY.H.KSS-.....M..S.PI	
EBV	..I.....M..PGEE.RLAG.R.GE...S.R.T..VY	

	60	80
RFHVMn	HFVKKHVRESLLSKLLTTWLAKRKEIRKNLASCTDPTMRTI	
RFHVMm	
KSHVK.....T....V.....T.....ALK..	
eHV2KAV...AT..NV.....A..RE..TVS.EAV...	
sHV1IQA....R...V..S...A..QK..E.E.LDTK..	
EBVH..F.AS...S.....A.K.L..A.E..RQ...	

	100	120
RFHVMn	LDKQQLAIKVTNAVYGFVGASGILPCLNIAETVTLQGRK	
RFHVMm	
KSHV	
eHV2K.....F...R	
sHV1L...IS.....T	
EBVC.....N.LF...S.....T	

	140
RFHVMn	MLETQAFVEGISPTALADLLQRPIEASP---EARFKVI
RFHVMmKD.S..I....D----D.....
KSHVA...ER..G..R...DV----D.....
eHV2	...N.KRYI..VT.EG...I.G.RV.CA---D.S....
sHV1	...K.KI.I.AMT.DT.QEIVPHIVKHE---D.K.R..
EBV	...RAK....AL..AN.QA.APS.DAWA.LNP.GQLR..








Figure 18

Figure 19**DEGENERATE OLIGONUCLEOTIDES
(GAMMA HERPESVIRUS)****SPECIFIC AND DEGENERATE OLIGONUCLEOTIDES
(RFHVM_m)****SPECIFIC AND DEGENERATE OLIGONUCLEOTIDES
(RFHVM_n)****SPECIFIC AND DEGENERATE OLIGONUCLEOTIDES
(KSHV)****DEGENERATE OLIGONUCLEOTIDES
(KSHV/RFHV SUBCLASS OF HERPESVIRUS)**

28/28

Figure 20

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/11688

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/54 C12N15/62 C12N9/12 C07K16/40 C12Q1/68
C12Q1/70 G01N33/571 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EMBL SEQUENCE DATA LIBRARY, HEIDELBERG, BRD, XP002021595 J.-C. ALBRECHT ET AL.: Accession no. P24907 & VIROLOGY, vol. 174, no. 2, February 1990, ACADEMIC PRESS, INC., NEW YORK, US, pages 533-542, XP000615610 J.-C. ALBRECHT AND B. FLECKENSTEIN: "Structural organization of the conserved gene block of Herpesvirus saimiri coding for DNA polymerase, glycoprotein B, and major DNA binding protein" see the whole document --- -/--</p>	12,13

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 December 1996

Date of mailing of the international search report

15.01.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/11688

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EMBL SEQUENCE DATA LIBRARY, HEIDELBERG, BRD, XP002021631 H. DANG AND S.R. ELLIS: "Structural and functional analysis of a yeast mitochondrial ribosomal protein homologous to ribosomal protein S15 of Escherichia coli" Accession no.S12797 & NUCLEIC ACIDS RESEARCH, IRL PRESS LIMITED,OXFORD,ENGLAND, see figure 5</p> <p>---</p>	15
X	<p>EMBL SEQUENCE DATA LIBRARY, HEIDELBERG, BRD, XP002021632 L. HILLIER ET AL.: "ya03b03.r2 Homo sapiens cDNA clone 60365 5'" Accession no. T39269</p> <p>---</p>	12
X	<p>EMBL SEQUENCE DATA LIBRARY, 4 May 1995, HEIDELBERG, BRD;;, XP002021596 E.A. TELFORD ET AL.: "Equine herpesvirus type 2" Accession no. U20824 & J. MOL. BIOL., vol. 249, no. 3, 9 June 1995, ACADEMIC PRESS,US, pages 520-528, XP000615359 E.A.R. TELFORD ET AL.: "The DNA sequence of equine herpesvirus 2" see the whole document</p> <p>---</p>	1
A	<p>PROC. NATL.ACAD SCI., vol. 92, February 1995, NATL. ACAD SCI.,WASHINGTON,DC,US;;, pages 1456-1460, XP002021599 P. DIGARD ET AL.: "Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface" cited in the application see the whole document</p> <p>---</p>	1-54
A	<p>THE NEW ENGLAND JOURNAL OF MEDCINE, vol. 332, no. 18, 4 May 1995, MA. MED. SOC., BOSTON, MA,US, pages 1227-1228, XP000615343 B. ROIZMAN : "New viral footprints in Kaposi's sarcoma" see the whole document</p> <p>---</p>	1-54

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/11688

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SCIENCE, vol. 266, 16 December 1994, AAAS, WASHINGTON, DC, US, pages 1865-1869, XP002021597 Y. CHANG ET AL.: "Identification of Herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma" cited in the application see the whole document ---</p>	1-54
A	<p>NATURE MEDICINE, vol. 1, no. 7, July 1995, NATURE PUBLISHING CO., NY, US, pages 707-708, XP002021598 M. SCHALLING ET AL.: "A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma" see the whole document ---</p>	1-54
A	<p>THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 332, no. 18, 4 May 1995, MA. MED. SOC., BOSTON, MA, US, pages 1181-1185, XP000615345 P.S. MOORE ET AL.: "Detection of Herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection" see the whole document ---</p>	1-54
A	<p>NEW ENGLAND JOURNAL OF MEDICINE 332 (18). 1995. 1186-1191. ISSN: 0028-4793, 4 May 1995, XP000615344 CESARMAN E ET AL: "Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas." see the whole document -----</p>	1-54